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Huntington’s disease 
Huntington’s disease (HD) is a progressive neurodegenerative disorder first 
described by George Huntington in his paper On Chorea1 in 1872. He described 
a form of chorea he called hereditary chorea, evident in some families living on 
Long Island, USA, which seemed different to the chorea occurring in children. As 
an acknowledgment of his accurate description, the disease was later named after 
him.
The observations by George Huntington still hold true to this day. Besides giving 
a detailed description of chorea, he also described the hereditary nature of the 
disease, a tendency towards insanity and suicide, and onset in adult life1. More 
recent clinical descriptions elaborate on the symptoms and signs describing motor-, 
cognitive-, and psychiatric disturbances, and also autonomic nervous system 
impairment, weight loss and sleep disturbances2;3. 
Motor symptoms are the most visibly explicit symptoms and consist of chorea, 
dystonia, loss of postural reflexes, bradykinesia and rigidity2. Cognitive decline is 
also evident with impairment in memory, psychomotor speed, negative emotion 
recognition and executive functioning4. Among the psychiatric symptoms a 
high risk of depression, suicide, obsessive compulsive disorders, irritability and 
aggression exists2;5. Symptoms originating from the autonomic nervous system 
are gastrointestinal, urinary, cardiovascular, temperature regulation, and sexual 
problems3. Also weight loss and sleep disturbances are important features of 
the disease2;6;7. Notably the most overt physical signs, such as chorea, do not 
necessarily have the most impact on quality of life of both patients and family 
members. Patients report that psychosocial factors influence quality of life more 
than physical factors8. The mean age of disease onset is between 35-44 years 
of age, with a wide range from early infancy to 90 years of age9. The duration of 
illness, from clinical diagnosis until death ranges from 15-30 years10. The initial 
symptom varies between individuals and can start with problems in any of the 
above described domains. Chorea and balance impairments are easily noticed by 
patients. However, family members may notice psychiatric or cognitive symptoms 
many years prior to diagnosis10. 
Genetics and pathofysiology 
The genetic defect responsible for HD was discovered in 199311.The gene defect is 
located on the short arm of chromosome 4 and consists of an expanded Cytosine-
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Adenosine-Guanine (CAG) repeat in the HTT-gene. The normal gene produces 
huntingtin (HTT) protein. A normal repeat length is up to 26 repeats; extended 
CAG-repeat lengths of 27-35 do not lead to disease but have a potential to expand 
>35 within one or more generations. CAG-repeat lengths above 36 will eventually 
lead to the development of the disease, with repeat lengths of 36-39 with reduced 
penetrance and ≥40 with full penetrance12. Sixty to seventy percent of the variability 
in the age of onset can be explained by the length of the CAG repeat, leaving a 
reasonable amount of unknown factors9. Expected age of onset can be reasonably 
predicted by the formula devised by Langbehn et al. (2004,2010)13;14. However, due 
to various limitations, this formula is usually only used for research purposes and 
not in clinical practice.
The exact pathofysiological mechanism responsible for the neurodegeneration 
is still not understood. The following five neurodegenerative mechanisms 
have been described. First, direct neurotoxic effects of mutant HTT-protein. 
Second, impaired energy metabolism due to mitochondrial disturbances. Third, 
transcriptional dysregulation of multiple genes, encoding for neurotransmitter 
receptors, enzymes and proteins involved in neuronal structure, stress responses 
and axonal transport. Fourth, disrupted dynamic intracellular processes, including 
trafficking of vesicles from the Golgi apparatus and within the cytoskeleton, 
transport along microtubules in axons, and synaptic disruptions. Fifth, excitotoxicity 
based on increased sensitivity to neurotransmitter mediated stimulation, causing 
overstimulation and cell death9;15-17. In recent reports, substantial evidence has 
been found for a role of these mechanisms in the neurodegeneration observed in 
HD. It is not likely that any of these mechanisms are solely responsible. Rather, 
a combination of mechanisms could be responsible with interactions between 
these different pathogenic pathways. This interaction theory is highlighted when 
reviewing the evidence for N-methyl d-aspartate receptor (NMDAR) involvement9. 
Evidence exists for the transcriptional dysregulation of genes involved with the 
NMDAR. Also selectively activated NMDARs in animal models resulted in a HD 
neurodegenerative pattern. Finally, mitochondrial dysfunction has been shown to 
sensitize cells to NMDAR mediated cell death9. Hence, these theories describe the 
complex interaction between multiple pathways in the pathogenesis of HD. 
Neuropathology
George Huntington stated in his opening sentence “chorea is essentially a disease 
of the nervous system”, which of course, as we know now, is certainly the case. 
However, he hypothesized that the cerebellum was responsible for disease 
simon_manuscript_0108.indd   11 1-8-2012   13:16:14
12| Chapter 1
symptoms. Later neuropathological findings pointed towards the striatum being 
the most affected brain regions. Jelgersma was the first to correlate atrophy of 
the caudate nucleus with HD in 1908 and since then many other reports emerged 
on pathologic findings in HD18. In 1985 a grading system was proposed by 
Vonsattel et al, describing the amount of striatal involvement in relationship to 
clinical disability19. The pathologic spectrum however extends greatly beyond the 
striatum18.
On gross examination, atrophy of the striatum and whole brain is apparent, with 
the frontal lobe being more affected than others18. Microscopic findings include 
neuronal nuclear inclusions of mutant HTT, which occur in the striatal, neocortex 
and allocortex neurons20;21. In the striatum reactive fibrillary astrocytosis, increased 
density of oligodendrocytes and reactive microgliocytes can be detected. Mild 
to marked neuronal loss is also seen in globus pallidus, thalamus, subthalamic 
nucleus, substantia nigra, white matter and cortex, usually without reactive gliosis. 
This widespread atrophy is especially evident in grades 3 and 4 of the Vonsattel 
grading18;19. Overall, striatal abnormalities are most evident with other brain regions 
becoming affected at a later stage. Interestingly, involvement of the cerebellum, as 
first thought of by George Huntington, is the one region still heavily debated18. 
The neuropathologic findings are generally limited to end-stage HD patients. It 
does not tell us when, how and where changes begin in premanifest HD gene 
carriers. Nor is a neuropathological outcome suitable for making statements 
regarding the success of a therapeutic strategy. These findings do point out the 
regions most interesting for further study.
Biomarkers
As our understanding of the pathofysiology of the disease increases, the 
development of therapeutic strategies becomes possible. For therapeutic 
strategies the point of application within the pathogenic pathway from mutant gene 
to neuronal loss is vast. Possibilities include gene therapy, post-transcriptional 
alterations, metabolic alterations, neuroprotective agents and more16. Many 
promising strategies are being examined, however no successful compound has 
been found to date. To measure possible effects of such compounds, biological 
markers (biomarkers) are used. A biomarker is defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention”22. 
The application of biomarkers is divers; they can be used in early efficacy and 
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safety evaluations and “proof of concept” applications, mostly for in vitro or in vivo 
studies. Furthermore biomarkers can be used as either a diagnostic tool, for disease 
staging, as indicators of disease progression or prediction and monitoring of clinical 
response to an intervention. The term surrogate endpoint is a specific application of 
biomarker but is often used interchangeably. A surrogate endpoint is defined as: “a 
biomarker that is intended to substitute for a clinical endpoint”. A surrogate endpoint 
is expected to predict clinical benefit (or harm or lack of benefit or harm) based on 
epidemiologic, therapeutic, pathofysiologic, or other scientific evidence22.
The need for robust and sensitive biomarkers in HD is highlighted by the fact that 
several problems are present in measuring effectiveness in HD. First of all HD has 
a very heterogenic clinical profile. We can roughly predict the age of onset, however 
it is not exactly known when or with what set of symptoms the disease will start. 
Motor symptoms are most overt and usually lead individuals to seek medical 
attention. Cognitive decline can develop slowly and even go unnoticed for many 
years. Psychiatric illness can appear as a first symptom of HD or are not related 
to HD at all. A second challenge is the slow rate of disease progression, taking up 
more than a decade from diagnosis to death2. This makes medication trials long 
lasting and very expensive. Thirdly, it is difficult to measure any clinical effect in 
the premanifest stage of the disease, as no symptoms are present. Conversely, 
this group is most likely to benefit from any potential therapeutic strategy when the 
neuronal loss is still limited.
For manifest HD many potential biomarkers could be appropriate, such as the 
quantification of motor or cognitive symptoms. To grade clinical severity the Unified 
Huntington’s Disease Rating Scale (UHDRS) is the most widely applied measure23. 
Premanifest HD-gene carriers can display subtle motor, cognitive or psychiatric 
abnormalities that are not captured by this scale. Therefore this scale is unsuitable 
as a biomarker in the premanifest phase. 
Alternative biomarkers to clinical outcome measures are sought whereby the most 
obvious candidates are magnetic resonance imaging (MRI) parameters. These 
could serve as biomarkers individually or in combination with other measures 
such as chemical markers (blood, urine or cerebral spinal fluid) or other imaging 
techniques such as positron emission tomography. The choice for imaging 
techniques such as MRI seems logical as they allow for direct examination of 
the damaged structure, namely the brain. Furthermore MRI can be applied fairly 
easily and objectively and the biggest advantage is that it can be used in the 
premanifest stage of the disease. Indeed, early MRI studies already showed striatal 
abnormalities in at risk HD gene carriers24;25. 
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In this thesis the term MRI biomarkers refers to indicators of disease progression 
with the purpose of disease monitoring. Ultimately, these measures can serve as 
surrogate endpoints in clinical trials. As a first step, prior to use in clinical trials, it is 
absolutely vital to determine the ‘natural history’ of disease changes as measured 
by MRI biomarkers. 
Magnetic Resonance Imaging
 
MRI can give in vivo insight in HD pathology. Conventional MRI sequences, 
such as T1- and T2-weighted sequences, are based on protons bound to water 
molecules. Relaxation properties of these protons in different tissues provide 
contrast between grey and white matter. A more recently introduced sequence 
of diffusion weighted imaging (DWI) makes use of the displacement or diffusion 
properties of protons. This technique can be extended to diffusion tensor imaging 
(DTI), creating a 3 dimensional image per voxel of the principal movement direction 
of protons. This is especially useful for visualizing white matter tracts, using a 
technique commonly referred to as tractography. 
Protons bound to other molecules than water, have different resonance 
characteristics, creating possibilities to quantify these molecules. Magnetic 
resonance spectroscopy (MRS) is a technique for quantifying concentrations 
of certain metabolites in the brain. An example is N-acetylaspartate (NAA), a 
metabolite considered a marker of neuronal integrity. Magnetization transfer 
imaging (MTI) is based on the exchange of protons between a pool of protons 
bound to macromolecules and a pool of free protons water. 
Functional MRI makes use of the magnetic properties of oxygen-rich and oxygen-
depleted blood in the brain. Oxygen is carried by the molecule hemoglobin, and 
deoxygenated hemoglobin is more magnetic than oxygenated hemoglobin, which 
is virtually nonmagnetic. Utilizing these properties it is possible to map neuronal 
activity. 
These different MRI techniques show the many possibilities MRI has to offer to 
the field of biomarker research. MRI techniques are subject to fast development 
and are still further developing. Techniques such as T2*-weighted imaging, 
susceptibility weighed imaging, asymmetric spin echo and other techniques are of 
importance, however will not be discussed in this thesis.
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Aims and outline of the thesis
The primary aim of this thesis is to search for MRI biomarkers for HD. The value 
of different techniques as biomarkers will be explored for the different stages of 
HD. Neuropathologic findings and previous MRI studies are starting points for the 
study of potential biomarkers. Known genetic and clinical factors will be taken into 
consideration. Finally, based on our observations, a recommendation will be given 
regarding MRI as potential biomarker in HD. 
An overview of all current literature on MRI research in HD is given in chapter 
2. An extensive volumetric MRI analysis of the main structures of the HD brain 
is described in chapter 3. More structures than striatum alone will be addressed 
providing an overview of the atrophy of subcortical grey matter. To gain insight 
into the localized changes in these nuclei, shape analysis has been performed on 
these subcortical structures and is discussed in chapter 4. The more recent MRI 
techniques of MTI, DTI and MRS are discussed in chapters 5, 6 and 7 respectively. 
The technique of MRS diverts somewhat from structural MRI scanning as it 
measures metabolites which can be both markers of neuronal integrity as well 
as part of dynamic processes. How structural integrity changes occur over time 
as measured by MTI is outlined in chapter 8 and how metabolites change over 
time using MRS is discussed in chapter 9. A general discussion of findings, final 
conclusions and future perspectives are outlined in chapter 10.
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Abstract 
Huntington’s disease (HD) is a devastating neurodegenerative disease affecting 
the brain resulting in neuronal dysfunction and neuronal loss. Since the 
identification of the gene responsible for HD, genetic testing has become widely 
available, allowing for genetic status of persons at risk for HD to be determined. For 
the effective evaluation of future therapeutic trials a great need exists for sensitive 
biomarkers. In (premanifest) HD, MRI of the brain is one of the most logical 
candidates as a biomarker, as opposed to clinical measures, since brain neurons 
are the main target of the disease. These biomarkers can facilitate early detection 
of disease related changes, but are also needed to monitor disease progression 
from the premanifest phase of HD onwards. MRI derived parameters have this 
biomarker potential as they have been shown to identify brain abnormalities before 
symptom onset. In this review the available MRI techniques of conventional MRI, 
Diffusion Tensor Imaging, Magnetization Transfer Imaging, Magnetic Resonance 
Spectroscopy and Functional MRI will be discussed and the findings will be placed 
into context of different HD stages. 
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Introduction
Huntington’s disease (HD) is a devastating neurodegenerative disease affecting 
the brain through neuronal dysfunction and loss. The disease is caused by a 
Cytosine-Adenine-Guanine (CAG)-repeat on chromosome four in the HTT gene, 
resulting in a mutant huntingtin protein. The disease is clinically characterized by 
a triad of progressive symptoms that occur with varying severity amongst patients. 
First and foremost HD is regarded as a movement disorder with chorea, dystonia, 
rigidity, bradykinesia and gait impairments. Besides motor disturbances cognitive 
decline is apparent with disturbances in psychomotor speed, executive functioning 
and memory with relative preservation of language and speech tasks. Lastly, 
behavioural abnormalities are characterised by depression, anxiety, disinhibition, 
aggressive behaviour and a tendency to suicide1,2. Besides the classical triad, 
reports also show symptoms of weight loss, sleep disorders and autonomic nervous 
system disturbances3-5.
The onset of Huntington’s disease typically occurs in the third or fourth decade 
of life, with a large range in disease onset, for 60-70% explained by the length of 
the CAG mutation6. Since genetic testing became available in 1993 it is possible 
to determine the genetic status of those at risk of HD. The symptom free period 
of gene carriers prior to inevitable disease onset is typically referred to as the 
preclinical or premanifest phase of the disease and historically has always been 
defined by the absence of motor disturbances. However, it is been recognised for 
some time now that the disease can begin with cognitive or behavioural problems7,8. 
The pathologic hallmark has always been atrophy of the striatum, with further 
histological findings of nuclear inclusions in neurons and atrophy both globally as 
well as specific brain areas9,10. The disadvantage of the available histological data is 
that it is typically only available from end-stage HD patients. For characterisation of 
the brain changes in the premanifest phase and early stages of HD we must rely on 
in vivo imaging techniques.
Since the early nineties reports of in vivo atrophy using MRI appear in the literature. 
These reports followed initial findings using Computerized Tomography, showing 
a decreased bicaudate ratio11. Initially, MRI studies only discussed the manifest 
disease stages, but after the widespread introduction of genetic testing, reports 
have also documented the premanifest phase of HD. MRI is a non-invasive tool for 
imaging the brain in high resolution yielding good contrast between grey and white 
matter. Currently, MRI has progressed from just detecting contrast differences to the 
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development of techniques such as Diffusion Tensor Imaging (DTI), Magnetization 
Transfer Imaging (MTI), Magnetic Resonance Spectroscopy (MRS), functional 
MRI (fMRI) and more. However, given the multitude of possibilities, it is pertinent 
to ask what it is we are measuring with these applications. Atrophy for instance, 
is the consequence or end product of the disease as this is the measurement 
of tissue loss. Newer techniques such as MRS can measure metabolic levels, 
delving further into the pathophysiological processes than atrophy alone. DTI was 
developed to investigate the integrity of brain tissue by quantifying the properties of 
tissues and their boundaries, in terms of the water molecule displacement across 
or alongside these boundaries. Therefore DTI is perhaps able to give insight into 
both deterioration itself as well as the processes underlying such deterioration. 
Therefore it is always important to specify the goal of an MRI study in terms of 
understanding of pathophysiological processes or measuring and quantifying 
change.
In this review we will focus on measurements and quantification of the different 
MRI-studies in HD as our main interest is biomarker research. The MRI 
approaches of conventional or volumetric MRI, DTI, MTI, MRS and fMRI will be 
discussed and the findings will be placed into context of the different HD stages. 
Biomarkers 
To measure and quantify brain changes by means of MRI is to enter the field 
of the biomarker research. A biomarker is defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacological responses to interventions”12. In the 
context of HD research many different measurements could potentially qualify as 
a biomarker, physically (motor, cognitive and psychiatric measures), chemically, 
or by imaging. However, the question remains, what makes a good biomarker 
and furthermore, why is one needed for HD? To start with the latter it is relevant 
to note that currently no cure exists for HD, however there are many potential 
agents currently under investigation13. Given that the symptoms of HD arise as a 
consequence of underlying brain changes, the search for an effective cure should 
embrace the premanifest period in which brain changes have started but have 
not yet resulted in symptom manifestation. In this phase of disease development 
neuroprotective therapies could be at their most effective. Currently, testing new 
agents in manifest HD is difficult as it is a slowly progressive disease taking up 
to 15 to 20 years from disease onset until death. As clinical trials are not deemed 
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effective when a long follow up is required, a shorter set-up is preferential. To 
measure the effect of an agent over a short time an effective biomarker in HD must 
be able to detect change over this relatively short period. Subsequently once an 
agent is found to be effective, the next pertinent question will be when to start with 
the intervention? Is it most effective when applied in the period that symptoms are 
not noticed by gene carriers, but when brain changes have already started? If so, 
another issue arises, when no clinical symptoms can be measured, we must rely 
on other biologically based markers, hence returning to the term biomarker as a so 
called surrogate marker or end-point. In (premanifest) HD, MRI of the brain is one 
of the most logical candidates as a biomarker, as opposed to clinical measures, as 
brain neurons are the main target of the disease, and show the earliest disruption. 
Currently the search for biomarkers in HD has focussed on medical imaging in 
an attempt to provide an in vivo overview of pathological changes in the natural 
course of HD. In essence, what happens to which part of the brain in progressing 
disease states? Aylward et al. (2007) discussed three criteria for a biomarker in the 
context of MRI and striatal volume: first it must be objectively measurable, secondly 
it must be able to predict known endpoints and thirdly it must be associated to 
known mechanisms of pathology of the disease14. The application of these criteria 
can be extended, from the striatal region only, to all brain regions and other MRI 
techniques. 
In summary, the ideal biomarker in HD would measure pathologic change over a 
relatively short period, these changes would be disease specific and reflect specific 
disease stages. Furthermore it would detect brain changes before symptoms are 
present and could therefore be deployed in the premanifest phase. 
Methods 
In reviewing the literature on MRI in HD, a search was performed for all relevant 
articles on HD in the PubMed and Medline databases published up to December 
2010. The following search terms were used for HD: “huntington”, “huntington’s 
disease” or “HD” whether or not in combination with “Neurodegenerative 
Diseases”. Furthermore, the terms for MRI specifically were: “mri”, “magnetic 
resonance imaging”, “mr imaging”, “mrs”, “magnetic resonance spectroscopy”, 
“mrsi”, “fmri”, “dti”, “diffusion tensor”, “mti” and “magnetization transfer imaging” 
in combination with any of the above described HD search criteria. All papers 
that reported on HD with MRI outcome measures were initially included. We then 
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categorized the papers based on the type of MRI research and only those who 
reported on the topics described in the introduction were included. For the section 
on MRS it is noteworthy we only included 1H-MRS studies as opposed to carbon 
or phosphor MRS. Furthermore, we limited our review to reports that included only 
genetically confirmed Huntington’s disease patients or premanifest gene carriers. 
This review will not describe the various techniques with their advantages and 
disadvantages, but rather focus on the outcome of these studies in terms of 
changing brain structures in HD. 
Structural Imaging
Structural or volumetric MRI was the first in vivo imaging application to be 
described in HD15. Since the start of the MRI era the analysis or post-processing 
techniques of these T1-weighted and T2-weighted scans has evolved significantly. 
Various manual segmentation techniques have been described as well as the 
more recent application of semi- to fully-automated techniques such as Voxel 
Based Morphometry (VBM), Boundary Shift Integral (BSI) and FMRIB’s Integrated 
Registration and Segmentation Technique (FIRST)16-18. 
The hallmark of HD has always been atrophy of the caudate nucleus and putamen, 
which together form the striatum. MRI studies from the early nineties report atrophy 
of these structures in manifest HD19-23 and every study since has confirmed this 
finding16-18,24-33. It has also become clear that atrophy is already present well before 
disease onset in premanifest gene carriers16,17,34-42. Earlier reports only make the 
distinction between manifest and premanifest HD, but later reports also include a 
distinction within premanifest gene carriers of “far from predicted disease onset” 
and “close to predicted disease onset”16,17,40,43. These predictions of disease 
onset, or sometimes disease burden, are most regularly based on Langbehn’s 
formula of predicted age of onset6,44,45. Also many studies include correlation 
analysis of predicted disease onset with the amount of atrophy of the striatum in 
premanifest gene carriers37,41,43,46. Exactly when in the disease stages this reported 
atrophy of caudate nucleus and putamen shows significant difference to control 
subjects varies per study, but the reports suggest as early as 11-15 years before 
disease onset43,46,47. Longitudinal analyses of atrophy of the striatum are available 
and demonstrate a relative stable or linear rate of decline from premanifest to 
moderate severe HD onwards26,47. Such changes in premanifest HD could not be 
demonstrated in a cohort “very far from disease onset” of 18.1 years48. The most 
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recent longitudinal publication of the large TRACK-HD study reports atrophy rates 
in the premanifest group of 1.37% higher than controls and 2.86% in manifest 
HD of the caudate nucleus over 12 months follow up49. Cross sectional analysis 
from studies examining more than just two disease phases, but rather making 
subgroups within (pre)manifest HD, suggest that the striatal decline seems to slow 
down the further the disease progresses with little or no differences than is seen 
in the early HD stages16,17. A pilot study from Aylward et al.(2003) rated caudate 
atrophy in a clinical trial investigating remacemide and co-enzyme Q10 and state 
that these atrophy measures show great potential as an outcome measure50. To 
summarize, striatal atrophy seems to begin more than a decade before disease 
onset, displays a rate of decline disproportionate to whole brain atrophy and 
volume seems to decrease substantially until at least the early HD stages. 
Extra-striatal subcortical grey matter structures have been less studied than the 
striatum, yet there is convincing evidence that almost all other subcortical grey 
matter structures are affected to some degree at various disease stages. In 
manifest HD reports exist on atrophy of the thalamus17,19,22,31,33,51, pallidum17,25,30,31,36, 
accumbens nucleus17,25,31,33, amygdala and hippocampus17,25,31. For the premanifest 
phase some controversy exists for the thalamus as some studies report atrophy in 
this stage35,40,43 and others do not42 or report that atrophy is consistent with whole 
brain atrophy17. The report which does not report atrophy is a study with a relatively 
small number of participants and did not discriminate between far and close to 
disease onset. The largest studies, e.g. the PREDICT-HD and TRACK-HD studies 
do report thalamic atrophy in the premanifest phase of HD. When combining 
the evidence it is apparent that although not as significant as in the striatum, the 
thalamus does show reduced volume in the premanifest phase. 
Atrophy of the pallidum is also under some dispute in the premanifest phase as 
two reports did not demonstrate atrophy34,35, however more reports found support 
for atrophy in the premanifest phase17,38,39,42. Furthermore, the reports in favour 
of pallidum atrophy are again the larger and more recent trials. Therefore the 
same conclusion applies for the pallidum as for the thalamus. In a large sample 
of premanifest gene carriers also the accumbens nucleus and hippocampus were 
shown to show signs of atrophy17. 
Longitudinal analysis of extra-striatal structures is underreported, especially in the 
premanifest phase. One report found a significant decrease in accumbens nucleus 
and thalamus over a two year follow up in manifest HD, but not in premanifest 
HD48. The pallidum has been found to show progressive atrophy in manifest HD 
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by Ruocco et al.(2008)52, although this was not found in an earlier study27. The 
two studies on pallidum atrophy in manifest HD were comparable in terms of 
duration of symptoms and mean CAG repeat length of the participants as well as 
scan interval. However the study by Ruocco et al. (2008) included slightly more 
participants and used VBM as opposed to manual segmentation. On the basis of 
these two studies the rate of atrophy is difficult to assess.
Cortical grey matter has repeatedly been shown to be affected in manifest HD, 
as measured by VBM18,31,52,53, cortical thickness measurements16,54-56 or other 
volumetric measures19,33. In the premanifest phase of HD one report exists of an 
enlargement of cortical grey matter volume40, however the same group did not 
replicate this in subsequent studies with larger populations43. It seems apparent 
that cortical grey matter is affected already far (>15 years)43 or midway (9-15 
years)16,57 from predicted disease onset. The cortical areas reported to be affected 
in the earliest premanifest stage are the posterior frontal16, parietal and occipital 
regions57. Other studies who did not specify the number of predicted years to onset 
of their group, report atrophy of insular regions38, superior temporal, precuneus, 
middle and pre-central frontal regions55 and prefrontal cortex58. Longitudinal 
analysis of cortical disturbances has not been reported to a great extent. Ruocco 
et al. (2008) observed in manifest HD progressive volume loss in the insula, 
cingulate, prefrontal, medial temporal and frontal cortex over a follow up period 
of 1 year52. Hobbs et al. (2010) reported progressive frontal, occipital and parietal 
cortex loss over a 2 year period in manifest HD, but not in premanifest HD48. When 
summarizing the findings it appears that regionally specific cortical atrophy appears 
in premanifest HD around a decade before disease onset, and spreads over almost 
the entire cortex in early HD stages. 
 
Besides grey matter, also white matter demonstrates volume reductions in both 
manifest19,25,33,59,60 and premanifest38,40,43 HD. The earliest report of white matter 
volume loss is in a “far from predicted disease onset” premanifest HD group 
(<15 years) and the authors report this as a good predictor of disease onset43. 
Longitudinal analysis demonstrated severe progressive white matter loss in early 
HD48,49, and the TRACK-HD study showed this progressive white matter loss 
already in the premanifest phase far from disease onset49.
 
With reports on cortical grey, subcortical grey and white matter loss, whole brain 
atrophy is a logical consequence in premanifest and manifest HD16,43. This measure 
demonstrated significant difference from controls in “far from”43 and “close to”16 
predicted disease onset groups. Longitudinal analysis seems to indicate this is a 
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fairly stable and easy measure in manifest HD only, as this change is relatively 
severe in early HD and can be demonstrated with just a six month follow up 
period61-63. The most recent study found a 0.20% higher atrophy rate in premanifest 
HD and 0.60% in manifest HD in one year follow up49. 
 
To capture all the literature into one overview we have constructed hypothetical 
models. These models are our own interpretation of the combined evidence 
and are therefore not to be taken as proven fact, rather as a way of providing a 
guide towards temporal changes in the brain of HD. Figure 1 graphically displays 
the hypothetical model for atrophy of different brain regions and their relation to 
disease stage. 
Atrophy of cerebral structures depicted by percentage of atrophy 
Figure 1. Atrophy of cerebral structures depicted by percentage of atrophy. The x-axis displays time, the 
y-axis displays percentage of remaining tissue of the different brain structures. GM = grey matter.
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Diffusion tensor Imaging
Diffusion Tensor Imaging (DTI) is based upon the diffusion properties of protons in 
the intra- and extracellular space, and was developed to investigate the integrity 
of tissue matter. During a DTI scan the preferential orientation of the diffusion 
as well as the strength or directionality of the diffusion of water molecules is 
measured throughout the brain. In highly organised tissue, such as the white 
matter comprising of dense axon bundles, the diffusion properties are dramatically 
influenced because of the ‘boundaries’. In essence the axons in white matter 
provide a pathway for diffusion along the axonal axis, whereas diffusion is 
frustrated by cellular barriers perpendicular to axis of axons. DTI is not restricted 
for use in white matter only, but can be applied in grey matter as well. The two 
most widely derived measures from DTI scans are fractional anisotrophy (FA) 
representing the strength of the main direction of diffusion, and mean diffusivity 
(MD) portraying the speed of the diffusion, although Apparent Diffusion Coefficient 
(ADC) is also used in this regard. Sometimes TraceD is used, which is the total 
diffusivity, meaning the sum instead of the mean of the three eigenvalues. An FA 
value close to 0 is representative of equal diffusion in all directions, as is seen in 
cerebral spinal fluid. In contrast an FA value close to or equal to one represents 
highly directional diffusion. High MD values represent unrestricted diffusion (for 
example in CSF) and low MD values suggest restricted diffusion. The post-
processing techniques used for DTI consisted of either a (manual) region of 
interest (ROI) segmentation technique (combined with computed tracts between 
ROI’s) or a voxel wise statistical approach such as tract based spatial statistics 
(TBSS).
In manifest HD disturbances in either FA or ADC in white matter have been 
reported in the corpus callosum64-67, fornix66, internal capsula65, external capsula66, 
capsula extrema66, frontal subcortical white matter65,67, sensorimotor white matter 
pathway67, inferior fronto-occipital fasciculus66, inferior longitudinal fasciculus66 
and total white matter28. The grey matter is also reported to show disturbances 
in the putamen28,65,68-70, caudate nucleus28,67-70, pallidum65,69,70 and thalamus70. It 
is important to note that these studies report increased FA in the grey matter, 
whereas in white matter a decrease in this measure is apparent. Douaud et 
al. (2009) explains this as a decrease of dispersion of the fibre orientation, 
characterising a loss of connections from these structures70. 
In premanifest HD the findings seem comparable to the findings in manifest HD, 
only not as extensive. General widespread white matter71 is reported to display 
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disturbed DTI properties, as well as specific areas such as the corpus callosum64,65, 
external capsula72, putamen72 and different areas of frontal white matter73. 
Furthermore specific pathways to the sensorimotor cortex67 and the fronto-striatal 
connections74 have been found to be affected. The integrity of the corpus callosum 
has been reported affected in a far from predicted disease onset group (>11 
years)64. The disturbances were found to correlate well to predicted time to disease 
onset67,71,72.
 
Longitudinal findings from Weaver et al. (2009) show FA reduction in white matter 
throughout the brain, which increased during a one year follow up in manifest 
HD, and not in controls75. Sritharan et al. (2010) examined the subcortical grey 
matter structures over a one year period using the MD instead of FA and found 
higher values in the putamen and caudate nucleus at both time points, however 
no longitudinal change was observed76. Similarly, Vandenberghe et al. (2009) 
did not demonstrate a longitudinal change over two years in the striatum in a 
manifest population and even suggests that volumetric change is more sensitive 
as a longitudinal marker. When considering this conclusion it must be noted that 
this report only examined TraceD in the striatum and not diffusion properties in the 
rest of the brain68. When combining the information from these three longitudinal 
studies it is evident that these studies all included relatively small samples, ranging 
from 7 gene carriers (mixed premanifest and manifest) in the study by Weaver et 
al. (2009)75 to 8 manifest HD by Vandenberghe et al. (2009)68 up to a maximum of 
18 manifest HD by Sritharan et al. (2010)76. On examination of the data it can be 
seen that all the measures used change over time in the expected direction in each 
study, yet none but the study by Weaver et al. (2009) demonstrates significant 
results75. It is likely that the results of these studies were influenced by power 
issues which hindered demonstration of significant change over time.
 
In summary, widespread diffusion abnormalities have been demonstrated in both 
manifest and premanifest HD, most notably the white matter, but also in subcortical 
grey matter. Measuring longitudinal change of the diffusion properties of white 
matter seems more promising than those in grey matter. It remains the question 
whether FA, MD or TraceD (or some combination) is the best single measure. 
Furthermore the choice of post-processing technique can affect the outcome. A 
priori a voxelwise approach may have a greater sensitivity for detecting change 
as opposed to a region/tractography based method, yet how sensitive this is 
over time remains unclear. Noteworthy is also the introduction of radial and axial 
diffusivity, making use of more than only the principal diffusion direction70,75, as this 
may provide not only be a more sensitive measure, but could also shed light on 
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pathophysiological processes. Weaver et al. (2009) reported larger decreases of 
axial diffusivity (a marker of the stability of axons), than radial diffusivity (a marker 
for demyelinisation), and concluded that axonal injury plays a larger role than 
myeline disturbances75.
 
Also for DTI we have constructed the same type of hypothetical model as with the 
volumetric MRI data. Figure 2 graphically displays the hypothetical model for DTI 
changes in different brain regions and their relation to disease stage.
Diffusion tensor imaging values in relation to time. 
Figure 2: Diffusion tensor imaging values in relation to time. The x-axis displays time, the y-axis displays 
percentage of diffusion measure value. FA = fractional anisotropy.
Magnetization Transfer Imaging
Magnetization Transfer Imaging (MTI) offers a way of examining tissue structure 
and structural components in a different way than conventional MRI. The 
technique of MTI relies on interaction between protons in free fluid and protons 
bound to macromolecules. The magnetization saturation and relaxation within 
macromolecules affect the observable signal. The magnetization transfer ratio 
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(MTR), representing the percentage of variation in the MR signal between the 
saturated and unsaturated acquisitions, is a measure used in clinical studies77. MTI 
differs from other techniques such as DTI in the sense that it measures properties 
of macromolecules found in cells as opposed to the properties of water molecules. 
Two main outcome measures are reported, the mean MTR and the MTR peak 
height from histogram analysis. 
In manifest HD, Mascalchi et al. (2004) reported no differences between a group 
of 21 gene carriers (of which 19 manifest HD) and 21 controls examining the mean 
MTR28. In contrast Ginestroni et al. (2010) found a statistically significant decrease 
of the MT ratio in all subcortical grey matter structures (except putamen) and in 
the cerebral cortex diffusely. The whole brain white matter was not significantly 
decreased78. There was a close correlation found to clinical measures of motor 
and neuropsychological testing and disease duration78. The difference between 
these studies are only obvious in post-processing methodology, Ginestroni et al. 
(2010) used the automated segmentation tools provided by FSL and Mascalchi et 
al. (2004) used manual segmentation. In terms of the patient characteristics we 
cannot determine if any differences exist in clinical severity due to the fact that 
mainly by Mascalchi et al. (2004) this is not described in detail, only by a gross 
measure, namely the TFC28. Based on these two studies it is not possible to draw 
any definite conclusions.
 
In premanifest HD only one study has published results examining not only 
the mean MTR, but also the MTR histogram peak height. There were no group 
differences, however there was a good correlation between this measure and 
subtle motor disturbances and CAG repeat length79. Unpublished results from our 
own study group confirm the findings by both Jurgens et al. (2010) and Ginestroni 
et al. (2010) whereby group differences exist in the manifest stage of the disease 
only and that there is a relation to clinical78,79. 
 
In summary, there is a lack of sufficient data, but the data at hand suggests that 
MTI is only potentially useful as a biomarker in the manifest stages of the disease. 
More studies, particularly longitudinal studies, should be performed to examine MTI 
measures in HD. 
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Magnetic Resonance Spectroscopy
Whereas conventional MRI uses hydrogen protons to characterize different 
tissues, MRS uses these hydrogen protons to measure metabolite concentrations. 
This technique therefore does not give direct structural information, rather this 
enables interpretation of changes in physiologically related processes. This is 
based on quantifications of a number of different metabolite compounds which 
reflect underlying processes. The most common metabolites examined are: 
N-acetylaspertate (NAA), which is seen as a marker for neuronal and axonal 
integrity, creatine which is regarded a marker for brain energy metabolism, choline 
reflecting membrane turnover, myo-inositol (MI) is seen as an osmolyte and 
astrocyte marker, lactate which is regarded as representing interruption of oxidative 
processes and beginning of anaerobic glycolysis, and glutamate, with its precursor 
glutamine, is a neurotransmitter80.
 
In manifest HD lower NAA and creatine has been demonstrated in putamen 
and/or caudate nucleus81-85 and thalamus86. Furthermore an increase in glutamate 
has been demonstrated87-89 however, this is under some dispute as this is not a 
consistent finding in all studies81,82, and has even been reported to be lower than 
in controls81. A consideration with the reports on increased glutamate may be the 
fact that glutamate was reported as a ratio to creatine, however, creatine itself does 
not appear to be a stable metabolite in HD. Furthermore, the reports on increased 
glutamate were performed in the early nineties, use different methodology, have 
lower field strength and have a smaller sample size. This is all in contrast to recent 
reports. Therefore we are of the opinion that based on the reports, it is more likely 
that glutamate is lowered rather than increased in HD.
Increased Ml in manifest HD has been reported in the putamen and therefore 
a ratio between MI and NAA could be a useful marker for tracking disease 
pathology81. Energy metabolism disturbances can be demonstrated with creatine 
measurements, but also lactate is important in this respect. Increased lactate 
(or ratio of lactate to either NAA or creatine) has been found in basal ganglia, 
cerebellum, occipital, parietal and frontal cortex83,84,90,91. It must be noted, that 
although quite some studies suggest impaired energy metabolism, not all studies 
concur, as Hoang et al. (1998) conclude that no evidence can be found for 
impaired energy metabolism using a combination on 1H-MRS and 31P-MRS92, 
and furthermore Reynolds et al. (2005) stress the issue of heterogeneity in MRS 
findings in HD, stating that there is no pathognomic alteration of any metabolite 
for HD93. There is substantial evidence from non-clinical studies that energy 
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metabolism is impaired in HD94, also the number of positive results from in vivo 
MRI-studies described above is quite substantial, therefore we feel that it is 
not really a question if energy metabolism is impaired, but rather how it can be 
measured accurately. Finally, only one report found an alteration of choline, with a 
decreased NAA/choline ratio in the frontal cortex90. 
 
Conflicting results exist for the premanifest stage of HD with regards to alterations 
of metabolites. As in manifest HD, lower creatine and NAA are reported in putamen 
and caudate nucleus81,85, although other studies did not find these differences95,96. 
Of the other metabolites, only choline is reported to be decreased in the frontal 
cortex96. There are important differences between the studies in favour and those 
in dispute of NAA or creatine changes in the premanifest stage, Sturrock et al. 
(2010) used a higher magnetic field (3 Tesla as opposed to 1.5 Tesla) and had the 
largest sample size as well the benefit of occurring as part of the methodologically 
well set up TRACK-HD study81. The higher magnetic field has a definite theoretical 
advantage to obtain good quality spectra. In light of the above described findings 
the evidence in favour of premanifest changes in the concentrations of these 
metabolites weighs more heavily than against the presence of such changes.
 
There appears to be a relationship between alterations in metabolites and 
measures of motor performance81,85, disease severity90, neuropsychological 
assessment96 and disease burden81. Another interesting feature of MRS has 
been demonstrated by using MRS in the evaluation of high dose oral creatine as 
a treatment of HD. The brain concentrations were shown to be elevated by this 
therapy and even had an effect on the glutamate concentration, however no clinical 
improvement was shown, nevertheless it does show a potential application of this 
technique97,98. 
 
A great lack of longitudinal MRS studies exists. Sturrock et al. (2010) is the only 
available longitudinal study as it is part of the TRACK-HD study16. Preliminary data 
presented at the European Huntington’s Disease Network congress did not show 
any longitudinal change over a one year follow-up period99.
 
Overall, creatine and NAA are reported to be lowered in different brain regions and 
lactate possibly increased. Choline has not been reported as widely and it remains 
unclear whether or not glutamate is different in HD. The alterations of metabolites 
is likely to occur already in the premanifest stage, not only based on the above 
described studies, but also from a hypothetical point of view, where structural 
changes normally would occur simultaneously or be preceded by metabolic 
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changes. Figure 3 graphically displays the hypothetical model for metabolite 
concentration changes and their relation to disease stage. 
Magnetic Resonance Spectroscopy in Huntington’s Disease in relation to 
disease stage
Figure 3: Magnetic Resonance Spectroscopy in Huntington’s Disease in relation to disease stage. The 
x-axis displays time, the y-axis displays percentage concentration of metabolite. NAA = 
N-acetylaspartate. Glutamate is not depicted due to conflicting data in the literature.
Functional MRI
Event related functional MRI (fMRI) uses the blood-oxygen-level-dependent 
(BOLD) signal to discriminate brain regions with altered activation. Simply put, 
this means that when a brain region is activated it will require an increase in 
energy resulting in blood demand, which is measurable with this method. Different 
functional tasks can be employed during fMRI scanning to measure activation in 
different brain regions or networks. 
 
In HD research several studies are available with reports in both premanifest and 
manifest HD of aberrant connectivity or activation patterns. In manifest HD one 
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case report and five studies are available. The first fMRI report is a case study 
with a clock reading task whereby increased parietal activation suggested a 
higher neuronal effort was required to perform the task100. Subsequently several 
case control studies were performed: using a verbal working memory task lower 
activation of parietal cortex, putamen and cerebellum were shown in HD101. 
Using a porteus maze task a reduced signal in occipital, parietal and somato-
motor cortex and the caudate nucleus, and furthermore an increased signal in 
the postcentral cortex and right middle frontal gyri was demonstrated102. Using a 
Simon task, which activates the lateral prefrontal and anterior cingulate cortex, 
reduced functional connectivity of this region was found103. In a mixed premanifest 
and manifest population, using a serial reaction time task a reduced activation 
of middle frontal, occipital, and precuneus regions was demonstrated104. In slight 
contrast to these reports increased activation of the anterior cingulated-frontal- 
motor-parietal circuit was found using a Simon task105. The two studies using 
the Simon task are from the same research group, whereby they differ as one 
examines functional connectivity103 and the other activation patterns105, both using 
fMRI. Although measuring different parameters the two studies seem at conflict 
with each other. However one might argue that when there is reduced connectivity 
the cortical recruitment of these regions can (or must) be enhanced. Currently 
definite conclusions on activation cannot be drawn as many different tasks have 
been utilised and therefore also different cortical regions have been examined. 
Although both increased and decreased activation have been reported, it seems 
that predominantly reduced activation patterns are found in manifest HD.
In premanifest HD a pattern of increased activation of several regions was 
demonstrated in premanifest gene carriers ‘far from predicted disease onset’ 
whereas premanifest gene carriers ‘close to onset’ show a reduction of 
activation106,107. Reductions in activation in premanifest HD were specifically 
reported in areas such as left anterior cingulate cortex, lateral prefrontal cortex, 
parietal cortex, putamen108-111. An interesting finding by the authors is that the 
change in activation pattern from far from onset to close to onset is related to the 
presence of atrophy in the striatum106,107. 
 
The use of different methodology and tasks applied during scanning complicates 
summarizing the results from the fMRI studies. Overall, the regions and networks 
shown to be affected in fMRI studies appear to widespread, confirming that HD 
is more than just a basal ganglia disorder, even in the premanifest stages of the 
disease. There appears to be mainly decreased activation in manifest HD and 
premanifest close to disease onset, although the study by Georgiou et al. (2007) 
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contradicts this105. The interesting finding of increased activation in premanifest 
gene carriers far from onset HD is hypothesized to be the result of cortical 
recruitment, in essence HD gene carriers need activation of more neurons and/or 
higher activity of these neurons in order to achieve the same task performance as 
controls. The pro’s and con’s of fMRI are discussed in a review by Paulsen et al. 
(2009) with commentary in Georgiou-Karistianis et al. (2009)112,113.
Discussion 
Temporal relationships of MRI measures with HD have been extensively examined 
making use of the many and diverse capabilities of MRI. However, drawing 
decisive conclusions from all these studies together is challenged by a number 
of issues. Firstly, when a particular MRI technique is applied, many options in 
terms of acquisition and post-processing remain undecided, resulting in different 
methodology across studies. Secondly, when comparing studies, it is evident that 
differences in definition exist for even the most basic principles which can lead to 
different inclusion criteria, the most pertinent being the definition of premanifest 
and manifest HD. Although many studies use some form of motor examination, 
even when the same standard (e.g. the UHDRS motor score) is applied, different 
cut-off points are used for determining disease manifestation. Thirdly, MRI is 
ever evolving, using evermore sophisticated techniques, therefore the validity of 
comparing a study from 1991 versus one from 2010 can be questioned. Finally, 
the comparison of a study with more than 300 participants, to a study of 6 controls 
versus 6 manifest HD is also challenging. This is not to say that the validity of 
smaller studies is less than larger studies. One might in fact argue the opposite, 
when something can be demonstrated using only 12 participants, this can be 
a much stronger argument when needing 300 participants to prove a point. 
Despite the difficulties posed in providing an overview, this review has discussed 
many different studies using various techniques in an attempt to combine their 
findings into a hypothetical temporal model of brain changes (figure 4). This 
hypothetical model is constructed based on all the literature available and is our 
own interpretation of the data available. When conflicts in literature exist, we have 
weighed the different studies as described in the specific MRI subsections. Figure 
4 depicts the temporal MRI changes in relation to disease stage and to each other. 
When summarising the literature it seems apparent that striatal atrophy is the 
first measurable brain change, starting between 10 to 20 years before disease 
onset16,17,40,46. DTI measures reflect signs of abnormal structure, especially in 
the white matter, at the same time or shortly afterwards the striatal atrophy, with 
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reports of change in the corpus callosum being the most consistent64,65,67,75. With 
the combination of subcortical grey matter, cortical grey matter and white matter 
disturbances, whole brain atrophy is no more than a logical consequence16,62. 
The longitudinal change of whole brain atrophy seems especially apparent in the 
early manifest stage49,61,62. MTI seems to be sensitive only in the early manifest 
stage onwards78,79. MRS demonstrates changes in metabolites before disease 
onset with changes in NAA and creatine81,85. Functional MRI seems to start with 
a form of enhanced activation in the premanifest stage106,107, which is depicted 
by the negative curve in figure 4, and shows reduced activation in later disease 
stages101,102.
MRI changes in HD brains depicted as a function of time 
Figure 4. MRI changes in HD brains depicted as a function of time. Functional MRI displays a negative 
curve in the premanifest ‘far from onset phase’ as literature suggests increased activation. This is infact 
also a pathologic change, however this is displayed as opposite of reduced activation patterns in later 
stages. The x-axis displays time, the y-axis displays amount of pathologic change. DTI= diffusion tensor 
imaging, MTI = magnetization transfer imaging, MRS = magnetic resonance spectroscopy, fMRI = 
functional MRI. 
This model, however is not at all without it limitations. The s-shaped curves are 
assumptions made on available data. The curves are, from a pathophysiological 
point of view, a common form, where some minor changes occur, a certain 
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threshold is subsequently reached and there is some form of exacerbation 
which slows down eventually. The use of such temporal models for biomarkers 
has been reported on in Alzheimer’s disease114 and seems plausible for more 
neurodegenerative diseases. For understanding temporal changes, longitudinal 
assessments are the most relevant, however cross-sectional analysis of multiple 
disease stages are also very relevant and also more abundant. The literature is 
however too limited to make very firm claims. These models should therefore not 
be taken as proven fact, but rather be used to test further research on and provide 
a framework for future clinical trials. Furthermore this model is deficient in the 
sense that it is limited to the most commonly used techniques and therefore not 
all MRI-techniques available are included and we appreciate the fact that possibly 
more sensitive techniques exist. 
The most abundantly researched candidate biomarker technique is volumetric MRI. 
It seems to be quite robust and fairly easy to use. The use of T1-weighted MRI is 
part of routine MRI and therefore easily implemented in any type of study. However, 
volumetric measurements can be performed in a many different ways from simple 
hand-drawn measurements to newer techniques such as VBM, which also has its 
pitfalls115. Nonetheless, this technique is claimed to be robust and suitable to use in 
a clinical trial by many studies such as the large cohort studies PREDICT-HD and 
TRACK-HD14,16,49,116. 
DTI has been applied extensively the last decade and has the advantage that 
it can detect abnormalities in integrity in multiple ways, with different outcome 
values such as FA and MD, but also more recently applied measures such as 
radial or axial diffusivity, all with different proposed pathological meaning70. The 
potential use of DTI measures as a biomarker in HD has been suggested by 
many authors67,69,71,72,75. There is also a downside of DTI as the options available 
of examining DTI are plentiful in terms of not only outcome measure, but also 
software programme used for analysis and the choice of the examined structure, 
e.g. ROI-based, voxel-based or specific pathway based analysis. The most 
sensitive DTI marker is difficult to identify from all these studies. However, taking 
this into account, the number of studies combined with the rapid expansion and 
standard clinical use of DWI/DTI makes this technique very promising and in 
our view can rival with volumetric outcome measures in terms of early detection, 
robustness and rate of decline. More so, it has the added bonus of detecting 
a more pathophysiological process i.e. structural integrity, rather than only the 
outcome of neuronal loss, namely atrophy.
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For MTI the s-shaped curve and the model itself is the one being least supported 
by literature, with the obvious reason of the absence of large numbers of studies. 
This technique has been used in many other diseases including neurodegenerative 
diseases77, however the use in HD is limited. The evidence suggests that this 
technique is only sensitive at later stages than volumetric or DTI measures28,78,79.
MRS has some clear advantages over the other techniques described 
because it can be used for biomarker research, but also inevitably adds to our 
pathophysiological understanding of the disease as the measured metabolites 
represent changes in more functional processes. Every metabolite has a different 
substrate in the physiological processes in the brain80, and therefore informs us 
about different pathologic processes. The downside of MRS lies in the fact that 
measuring techniques can influence the outcome severely, with the field strength 
used being the most apparent one. Also, the use of metabolite ratios versus 
absolute quantification is another important issue. For example using a ratio to 
creatine when creatine is reported to be lowered in HD81,85 is a serious issue. The 
absence of longitudinal reports of MRS, makes it difficult to make any firm claim 
regarding its use for biomarker research, although the cross sectional results are 
promising81,85.
Finally, fMRI is a technique where the use as a biomarker is clouded by the many 
studies using different paradigms, besides the, again, many analysis options. 
However, fMRI does give us a great insight into which functional deficits occur, 
or in case of premanifest HD, compensation strategies in brains activation 
patterns106,107. The temporal changes described are all based on cross-sectional 
results, rather than longitudinal changes. However the potential of this technique 
is clear and can provide possible markers for early diagnosis and possibly disease 
monitoring107,112. Also, fMRI showed us that brain changes do not limit themselves 
to the frontostriatal circuitry but were more widespread110,111 and will provide more 
understanding of the brain networks in both disease and healthy states. 
In general, when considering the use of MRI derived measures as biomarkers it is 
worth noting that scanning is non-invasive, generally well tolerated by participants 
and easily applied in the daily clinic as many techniques are available in a 
standardized form for hospital care. Claustrofobia and metal implants, however, are 
always of some concern and can cause patient drop out in studies. Furthermore 
costs can be quite high as a single MRI scanning session usually costs several 
hundred dollars/euro’s. However, high costs are also associated with many 
potential biomarkers such as any biochemical or DNA marker. As MRI becomes 
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more and more the standard, the costs will be limited and in our opinion does not 
outweigh the potential gain for HD patients. Furthermore, we envision MRI will not 
be used for diagnostic purposes but only for evaluating therapeutic interventions. 
 
Conclusion
MRI could be used as outcome measure for clinical trials in HD. Overall a 
combination of MRI techniques is most appropriate with different modalities being 
the most suitable biomarker at different disease stages. For large multicenter trials 
an automated set up with standardized scanning protocols and post-processing 
is essential. However for many volumetric and DTI measures the exact analysis 
method chosen for the specific techniques is relatively unimportant as studies 
consistently report the same changes. In our opinion striatal volumetric measures 
and white matter (DTI) integrity measures are most appropriate for the premanifest 
stage of HD. These measures are the best described and deemed to be robust 
with consistent results throughout studies. In the transition phase to early manifest 
HD more measures become suitable, such as whole brain atrophy, MTI and 
possibly MRS. The role for fMRI lays more in the understanding of brain network 
functioning in neurodegeneration, although early diagnosis seems plausible as 
well. Therefore, we recommend constructing multimodal MRI approaches and 
choosing the technique, or combination of techniques, depending on the disease 
stage being examined in order for MRI to fulfil its role as a biomarker.
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Abstract
In Huntington’s disease (HD) atrophy of the caudate nucleus and putamen has 
been described many years before clinical manifestation. Volume changes of the 
pallidum, thalamus, brainstem, accumbens nucleus, hippocampus, and amygdala 
are less well investigated, or reported with contradicting results. The aim of our 
study is to provide a more precise view of the specific atrophy of the subcortical 
grey matter structures in different stages of Huntington’s disease, and secondly to 
investigate how this influences the clinical manifestations. All TRACK-HD subjects 
underwent standardised T1-weighted 3T MRI scans encompassing 123 manifest 
HD (stage 1, n = 77; stage 2, n = 46), 120 premanifest HD (close to onset n = 58, 
far from onset n = 62) and 123 controls. Using FMRIB’s FIRST and SIENAX tools 
the accumbens nucleus, amygdala, brainstem, caudate nucleus, hippocampus, 
pallidum, putamen, thalamus and whole brain volume were extracted. Results 
showed that volumes of the caudate nucleus and putamen were reduced in 
premanifest HD far from predicted onset (> 10.8 years). Atrophy of accumbens 
nucleus and pallidum was apparent in premanifest HD in the close to onset group 
(0–10.8 years). All other structures were affected to some degree in the manifest 
group, although brainstem, thalamus and amygdala were relatively spared. The 
accumbens nucleus, putamen, pallidum and hippocampus had a strong significant 
correlation with functional and motor scores. We conclude that volume changes 
may be a sensitive and reliable measure for early disease detection and in this 
way serve as a biomarker for Huntington’s disease. Besides the caudate nucleus 
and putamen, the pallidum and the accumbens nucleus show great potential in this 
respect.
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Introduction
Huntington’s disease (HD) is an autosomal dominantly inherited, slowly 
progressive, neurodegenerative disease localised on chromosome four. The 
pathophysiological mechanism is complex and although impaired energy 
metabolism and neuronal excitotoxicity are named as major contributors1;2, it is still 
not fully understood, but the main result is neuronal dysfunction and loss in the 
brain. The disease is characterised by clinical symptoms in the motor, cognitive, 
and psychiatric domains. 
Loss of brain cells and their connections, referred to as atrophy, can be visualised 
with Magnetic Resonance Imaging (MRI) techniques and has been the focus of 
many studies in search of objective biomarkers for tracking disease progression. 
The striatum has been the primary region of interest, due to previous findings in 
pathological studies that demonstrated the most severe loss of neurons in this 
region3. In manifest HD, the evidence for widespread atrophy is extensive, whereby 
several MRI studies showed striatal4-12 and cortical atrophy13;14. The striatal atrophy 
occurs in the premanifest stages of HD, with atrophy of the caudate nucleus and 
putamen present up to a decade or more before clinical manifestation15-20.
Other subcortical grey matter structures have been examined to a lesser degree. 
Thalamic4;5;9;21 and pallidum9;10;22;23 atrophy is apparent in the manifest stages of HD; 
however, findings are controversial in the premanifest stage, as not all studies are 
in agreement16-19;22;24. Atrophy of the hippocampus, amygdala, accumbens nucleus, 
and brainstem has only been reported in the manifest stage in a very limited 
number of studies9;22. Whole brain atrophy has been demonstrated in HD25;26. 
However, the rate of volume reduction of the subcortical structures as compared to 
whole brain atrophy has not been reported in any of the above mentioned studies 
and is of importance as this regional atrophy may very well only be a reflection 
of whole brain atrophy. Correlation studies have been performed for volume 
reductions and global clinical measures in manifest HD8;9;22. However, reports on 
the relationship of atrophy with clinical measures of all these structures in different 
disease stages in one large cohort has not been previously reported. 
With the possibilities of new therapies for HD, there has been increasing interest 
in the development of robust, reproducible biomarkers to assess the efficacy of 
potential treatments. The TRACK-HD study is an international multi-centre study 
investigating candidate biomarkers for HD and encompasses a large, well defined, 
sample of HD gene carriers26. Application of a fully automated MRI-analysis tool to 
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this study sample provides the opportunity to study brain atrophy in detail within a 
very large HD cohort. The aim of this study is to provide a more precise overview 
of the specific atrophy of the subcortical grey matter structures in different disease 
stages, whilst taking into account whole brain atrophy and provide better targets for 
biomarker research. Secondly, we aim to examine the relationship of all subcortical 
grey matter structure volumes to clinical measures for HD. 
Methods
Subjects
The TRACK-HD study recruited 366 participants from four centres (the National 
Hospital for Neurology and Neurosurgery in London, the Department of Medical 
Genetics at University of British Columbia in Vancouver, the Department of 
Genetics and Cytogenetics at the Hôpital de la Salpetrière-Université Pierre and 
Marie Curie in Paris and the Department of Neurology at Leiden University Medical 
Center in Leiden) totalling 123 early manifest HD, 120 premanifest HD and 123 
control subjects. Inclusion criteria for the early manifest HD group consisted of 
genetic confirmation of an expanded CAG repeat of ≥ 40, presence of motor 
disturbances on the Unified Huntington’s Disease Rating Scale (UHDRS), defined 
as a diagnostic motor confidence score of 4 and a total motor score (TMS) 
of > 5, and a Total Functional Capacity (TFC) of ≥ 7. Inclusion criteria for the 
premanifest group consisted of genetic confirmation of an expanded CAG repeat 
of ≥ 40, absence of motor disturbances on the UHDRS, defined as a TMS of ≤ 5. 
Furthermore, premanifest gene carriers required a burden of pathology score >250, 
based on CAG length and age27, to ensure a premanifest HD sample close to 
onset. Spouses or partners of premanifest and affected subjects or gene-negative 
siblings were recruited as healthy control subjects. The control group was age-and 
gender-matched to the combined premanifest and manifest HD group. Further 
subdivision of the premanifest group was performed on the basis of predicted years 
to diagnosis into preHD-A (10.8 or more years to disease onset) and preHD-B 
(closer than 10.8 years to disease onset) based on Langbehn’s et al. (2004)
survival analysis formula28;29. The early manifest HD subjects were also divided into 
two groups based on disease stage by means of TFC score, the HD1 group (TFC 
score: 11-13) and the HD2 group (TFC score: 7-10)30. The study was approved by 
the local ethical committees and written informed consent was obtained from each 
subject. For full details on study design see Tabrizi et al. (2009)26. 
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Clinical measures
From the total TRACK-HD assessment battery, the UHDRS motor scale and 
TFC were used for this study. The UHDRS TMS is a representation of the 
severity of motor disturbances, scores potentially range from 0-124, with higher 
scores indicating more severe motor abnormalities. The TFC is a scale used for 
assessment of global impairments within daily activities, ranging from 0-13, with 
lower scores indicating impaired global functioning.
MRI acquisition
All participants underwent 3Tesla MRI scanning. T1-weighted image volumes 
were acquired using a 3D MPRAGE acquisition sequence on a 3.0T Siemens or 
a 3.0T Phillips whole body scanner with the following imaging parameters: TR 
= 2200ms (Siemens) / 7.7ms (Philips), TE=2.2ms (Siemens) / 3.5ms (Philips), 
FA=10° (Siemens) / 8° (Philips), FOV= 28cm (Siemens) / 24cm (Philips), matrix 
size 256x256 (Siemens) / 224x224 (Philips), 208 (Siemens) / 164 (Philips), 
sagittal slices to cover the entire brain with a slice thickness of 1.0 mm with no gap 
between slices.
Post-processing
All T1-weighed scans were analysed using software provided by FMRIB’s Software 
Library (FSL)31. Eight subcortical regions were assessed using FMRIB’s integrated 
registration and segmentation tool (FIRST)32-34, namely the accumbens nucleus, 
amygdala, brainstem, caudate nucleus, hippocampus, pallidum, putamen, and 
the thalamus. Total brain tissue volume was estimated with SIENAX35;35;36;36. For 
details on MRI post-processing please see the Supplementary Material. The whole 
brain volume was used to calculate ratios of atrophy of the subcortical structures 
to whole brain atrophy. The obtained ratio was divided by the control group value 
in order to obtain an easily interpretable ratio whereby 1.00 is the control (normal) 
value ratio. The following formula was used: 
[volume structure / (whole brain volume - volume structure)] / control group value
A value below 1.00 demonstrates that the structure displays more atrophy than the 
overall whole brain atrophy. A value greater than 1.00 demonstrates that the overall 
whole brain atrophy is greater than the atrophy of the structure at hand.
Statistics
Analysis of variance for group comparison was performed for volumes and ratios 
of the eight different subcortical structures, whilst correcting for intracranial volume, 
study site, age and gender. (Note that each site used a different MRI Scanner 
model, and thus potential scanner effects can not be differentiated from site 
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effects.) Comparisons of each structure were made for each disease group as 
compared to the control group, and as compared to the previous disease stage 
group, e.g. the preHD-B group was, besides comparison to the control group, also 
compared to the preHD-A group. We calculated partial correlations between the 
various subcortical structures and total motor score (TMS) and total functional 
capacity (TFC) from the UHDRS battery. These correlations used volumes 
corrected for intracranial volume and were further controlled for age, site, and 
gender by “partialing” these covariates out during the correlation calculations. The 
UHDRS TMS and TFC analyses were performed on the basis of a two-way group 
division, namely the premanifest gene carriers and the manifest HD group in order 




The clinical characteristics of the five study groups are shown (Table 1). The 
progressive nature of HD inherently leads to a higher age of the manifest HD 
groups. Except for the HD2 group, which displayed lower levels of education, there 
were no significant differences in education level between the disease groups and 
the controls. For full details on group characteristics we refer to the recent baseline 
TRACK-HD paper26.
Table 1: Group characteristics
Control PreHD-A PreHD-B HD1 HD2
N 123 62 58 75 46
Leiden 30 16 14 76 14
London 30 14 16 19 11
Paris 30 14 16 25 4













Women (%) 68 (55%) 33 (53%) 33 (57%) 45 (60%) 21 (46%)
Education (SD) 
levels 1-6 4.0 (1.3) 4.1 (1.1) 3.8 (1.3) 3.8 (1.3) 3.2 (1.4)
Disease-burden 
score (SD) n.a. 259.1 (30.1) 333.1 (30.0) 364.1 (75.0) 397.6 (67.5)
Descriptive statistics of the five different groups. Data are mean (SD, range) or number (%).
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Volumes
Examples of a typical output from the segmentation by the FIRST and SIENAX 
tools are depicted (Figure 1), for the FIRST examples only the left hemisphere 
segmentations are shown, however both sides were segmented for the analysis. 
Figure 1: FSL-FIRST and SIENAX. A. Example segementations by FSL FIRST. Dark blue = brainstem, 
blue = pallidum, light blue = thalamus, green = caudate nucleus, dark red = accumbens nucleus, red = 
putamen, copper = hippocampus, pink = amygdala. B. Example output from the FSL SIENAX tool. Red 
depicts the final sienax segmentation results.
Volume comparisons for eight subcortical structures in five groups are shown 
(Table 2). Furthermore, figure 2 shows the amount of volume reduction in terms 
of percentage of the control value. The putamen and the caudate nucleus show a 
similar pattern of a smaller volume in the preHD-A group and in every subsequent 
disease stage group with a continuous decline in volume. The accumbens nucleus 
and pallidum show a decreased volume in the preHD-B group and from every 
following disease stage group as compared to the controls as well as to the 
previous disease stage group except for the accumbens nucleus between HD1 and 
HD2.
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The brainstem and thalamus show signs of reduced volume in preHD-B, HD1 and 
HD2 as compared to the control group. 
The amygdala showed no reduced volume as compared to the control group. The 
hippocampus showed volume reduction in stages preHD-B, HD1 and HD2 as 
compared to controls. In terms of percentages of volume reduction as compared 
to the control group value it is apparent that the pallidum and accumbens nucleus 
show marked atrophy with only 62% and 60% of the normal volume remaining in 
the HD2 group, respectively. These structures are closely followed by the putamen 
and the caudate nucleus with 67% and 70% remaining volume, respectively. 
Percentages for all structures in the four disease stages are also available in the 
supplementary material.
Ratios
Comparisons for volume ratio of eight structures as compared to whole brain 
atrophy are shown (Table 3). A smaller ratio indicates that the volume of this 
specific structure declines faster than the overall brain atrophy. The putamen 
atrophy ratio showed a continuous smaller value across subsequent disease stage 
groups. The caudate nucleus atrophy ratio showed a similar pattern, except within 
the manifest stage this ratio did not show a significant difference across HD1 and 
HD2. The accumbens nucleus and the pallidum atrophy ratio showed a decrease 
over disease stages from the preHD-B group onwards. 
The ratio of whole brain atrophy to amygdala atrophy is comparable or slightly 
higher to the control group ratio. The atrophy ratio for the brainstem and thalamus 
shows no or slightly higher ratios as compared to the control group, stating that 
atrophy of these structures is comparable or slower to whole brain atrophy. Finally, 
the hippocampus atrophy ratio shows a drop in value in HD2 as compared to 
control and HD1.
Clinical measures
The UHDRS total motor score in the premanifest stage is most strongly correlated 
to the atrophy of the caudate nucleus (R=-0.272, p=0.003) and putamen (R=-
0.240, p=0.009), but also to the atrophy of accumbens nucleus, pallidum and 
thalamus. The TFC demonstrates a strong ceiling effect in the premanifest stage 
and no significant correlations are to be found. In the manifest stage of the disease 
the UHDRS total motor score is most strongly related to the putamen (R=-0.530, 
p <0.0001), pallidum (R=-0.390, p <0.0001) and accumbens nucleus (R<-0.380, 
p<0.0001), but also to the hippocampus, thalamus, and brainstem.
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The TFC is most strongly correlated to atrophy of the putamen (R=0.270, p=0.004), 
hippocampus (R=0.240, p=0.01) and pallidum (R=0.230, p=0.01) and a weak 
correlation to accumbens nucleus and brainstem.
Figure 2: Percentage of volume for eight structures as compared to the control value. PreHD-A = 
premanifest gene carriers far from expected disease onset, preHD-B = premanifest gene carriers close 
to disease onset, HD1 = manifest HD stage 1, HD2 = manifest HD stage 2. 
Discussion
The aim of this study was to provide a comprehensive overview of the atrophy 
of subcortical structures, with respect to disease stage while taking into account 
whole brain atrophy. The main findings show that all subcortical grey matter 
structures at some point have a reduced absolute volume. However, the 
accumbens nucleus, the caudate nucleus, the pallidum and the putamen display 
a true progressive decline in volume reduction which is disproportionate to overall 
whole brain atrophy and this is already visible in the premanifest stages of HD. 
Conversely, the amygdala, brainstem and thalamus do show reduced volumes, 
but this merely reflects the overall whole brain atrophy rate. The hippocampus is 
exceptional in the fact that only in the manifest stage a true rapid decline in this 
structure is observed. Furthermore, the volume reductions of the accumbens 
nucleus, putamen, pallidum and hippocampus have a severe impact on clinical 
measures in manifest HD. 
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The atrophy of the caudate nucleus and putamen in the premanifest stages 
confirms earlier studies. The fact that this happens a decade or more before 
estimated time to onset is in accordance with the findings of Aylward et al.(1996)37, 
the findings of the PREDICT-HD study20;20 and with the results reported in TRACK-
HD baseline paper26.
Atrophy of the pallidum and thalamus in the premanifest stages of HD is 
controversial. Campodonico et al.(1998) and Harris et al.(1999) report no 
significant reduction in volume of the pallidum18;24, while others do report this 
finding16;17;19. With regard to the thalamus in the premanifest stage, reports 
of reduced volume are available in favor16;24 and in dispute19;38 of thalamic 
involvement. Our findings, using 3T MRI and in the largest cohort reported thus far, 
confirms that atrophy in the pallidum is apparent in the premanifest stage closer to 
predicted disease onset, but not in the further from predicted onset stage. Although 
thalamic atrophy is also apparent in the premanifest close to onset stage, this 
merely reflects the whole brain atrophy. 
The brainstem, thalamus, and amygdala follow the normal atrophy rate of 
the whole brain in the manifest stages of the disease. In fact, in HD stage 1 
the brainstem and the amygdala show signs of being relatively spared. The 
hippocampus shows a different pattern of atrophy as it starts to show signs of 
atrophy in preHD-B stage, but really becomes significant in terms of volume loss 
in HD stage 2. To some degree the above described findings have been reported 
by Rosas et al.(2003) and Douaud et al.(2006)9;22. The added value of our study 
lies not only in the large sample size facilitating the further specification of the 
premanifest and manifest groups, but particularly in the fact that the atrophy 
described takes into account whole brain atrophy. It should be noted that some 
caution is appropriate when interpreting the ratio to whole brain atrophy, as this 
method does not necessarily imply that the volume reduction of a certain structure 
has to be greater than the whole brain atrophy to be of significance in terms of 
clinical symptoms. 
The clinical impact of atrophy of subcortical grey matter is difficult to assess as 
many brain structures are involved in complex functionality. We have demonstrated 
that of the subcortical grey matter structures, specifically volume reductions of 
the accumbens nucleus, putamen and pallidum have the greatest influence on 
predicting the motor disturbances in manifest HD, and perhaps surprisingly, the 
impact of the caudate nucleus is minimal. The role of the pallidum in motor function 
is underestimated and surpasses the caudate nucleus and the thalamus. However, 
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the putamen is the most important structure for this clinical symptom. Our study 
shows that decreased global functioning of manifest HD was mainly related to 
volume loss of the hippocampus, putamen and pallidum. Cognitive and motor 
deficiencies have been shown in a number of separate studies, all examining 
only part of the deep grey matter structures, to relate to volume reductions of 
the basal ganglia, thalamus and frontal lobe4;6;11;18;19;24;39;40. Within one small 
cohort examination of clinical measures with the TFC was carried out by Rosas 
et al.(2003) who provided evidence for an association between each separate 
structure and the TFC in the manifest stage22, which, apart from some differences 
between studies, is largely confirmed by our study. All these studies show that 
there is an association between volumes and clinical measures; however, we hope 
by examining all structures within one large, well defined cohort we can provide 
evidence for which structure has the most contribution (or at least the strongest 
correlation) to global functioning and motor disturbances.
TRACK-HD is a longitudinal observational biomarker study aimed at providing 
essential methodology for the assessment of therapeutic interventions. In 
respect to this goal we can add that the accumbens nucleus and pallidum show 
similar biomarker potential in addition to the well recognised structures putamen 
and caudate nucleus. The hippocampus is also of importance as it has a high 
correlation with clinical symptoms. The important role of the caudate nucleus in 
the premanifest stage of the disease seems to diminish after manifestation, as 
was also suggested by the TRACK-HD baseline paper26. It is possibly fair to say 
that at different disease stages different structures play a role. A biomarker would 
ideally show sensitivity across all disease stages and would reflect the underlying 
pathologic processes. From this cross-sectional analysis it is not possible to draw 
any definitive conclusions, however, the putamen possibly shows the greatest 
potential. Longitudinal evaluation has to be performed to confirm the putamen’s 
true potential. Furthermore we would like to stress how taking whole brain atrophy 
into account aids our interpretation of regional atrophy rates and in this way their 
potential as biomarkers can be assessed more effectively. 
A limitation of our study could be the use of a relatively new software package 
from FSL used for segmentation, which hasn’t specifically been validated in HD. 
Visual inspection, however, did not reveal any significant mismatches. The method 
applied gives structure segmentation on an individual basis and can therefore be 
used to compare groups. In contrast to this limitation several clear reasons exist in 
favor of using FIRST; first of all, compared to manual segmentation the automated 
segmentation uses voxel intensity in contrast to the sometimes difficult visual 
contrast differences, reducing a rater dependent bias. Secondly this automated 
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technique is suitable for implantation on large datasets, whereas manual 
segmentation is labour intensive and prone to human error.
In conclusion, we have demonstrated that atrophy of the pallidum and the 
accumbens nucleus exists in the premanifest stages of the disease and confirmed 
the well known atrophy of the caudate nucleus and putamen. Furthermore, we 
have shown the important correlation of the accumbens nucleus, putamen, 
pallidum and hippocampus with clinical symptoms. The importance of the 
remaining subcortical structures should be regarded when taking into account that 
they show similar amounts of atrophy as the brain as a whole. These findings have 
implications for biomarker research, as several subcortical structures now show 
great potential for use as a disease progression measure. 
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Supplementary Material
Table 1: Percentage of the volume as compared to the control group value for 
eight separate structures.
PreHD-A PreHD-B HD1 HD2
Accumbens Nucleus 97.4 % 86.4 % 72.6 % 60.3 %
Amygdala 99.6 % 100.0 % 97.0 % 87.1 %
Brainstem 99.1 % 95.7 % 92.4 % 87.7 %
Caudate Nucleus 91.5 % 82.8 % 73.1 % 69.8 %
Hippocampus 99.7 % 96.4 % 91.1 % 78.6 %
Pallidum 98.1 % 86.2 % 75.6 % 62.3 %
Putamen 93.5 % 84.1 % 73.4 % 67.5 %
Thalamus 100.3 % 97.0 % 90.2 % 84.9 %
Values represent percentage of the volume as compared to the control group value for eight separate 
subcortical structures. PreHD-A = premanifest gene carriers far from expected disease onset, preHD-B 
= premanifest gene carriers close to disease onset, HD1 = manifest HD stage 1, HD2 = manifest HD 
stage 2. 
Methods: MRI Postprocessing 
All T1-weighed scans were analysed using software provided by FMRIB’s Software 
Library (FSL)1. Eight subcortical regions were assessed using FMRIB’s Integrated 
Registration and Segmentation Tool (FIRST)2-4, namely the accumbens nucleus, 
amygdala, brainstem, caudate nucleus, hippocampus, pallidum, putamen, and 
the thalamus. Using FIRST, the T1 weighted images were first registered to MNI 
(Montreal Neurological Institute) 152 standard space, using linear registration with 
12 degrees of freedom5-6. FIRST draws upon a vast library of manually segmented 
images, which were transformed into deformable surface meshes. These meshes 
were applied to our dataset to be used as subcortical masks to locate the specific 
structures. Subsequently, segmentation was carried out using the voxel intensities 
and mesh models. Finally a boundary correction was applied to prevent overlap 
with adjacent structures. After registration and segmentation the absolute volume 
was calculated having taken into account the obtained information from previous 
steps. A visual inspection of all registrations was performed and of the final 
segmentations 20% were selected at random and visually inspected for accuracy.
Total brain tissue volume was estimated with SIENAX7-8.This program extracts 
brain and skull images from the single whole-head input data9.The brain images 
were then affine-registered to MNI152 space, using the skull images to determine 
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the registration scaling. Next, tissue-type segmentation with partial volume 
estimation was carried out10.
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Abstract
Huntington’s disease (HD) is characterized by brain atrophy. Localized atrophy 
of a specific structure could potentially be a more sensitive biomarker reflecting 
neuropathologic changes rather than global volume variation. We examined 90 
TRACK-HD participants of which 30 were premanifest HD, 30 were manifest HD 
and 30 were controls. Using FMRIB’s Integrated Registration and Segmentation 
Tool, segmentations were obtained for the pallidum, caudate nucleus, putamen, 
thalamus, accumbens nucleus, amygdala, and hippocampus and overall volumes 
were calculated. A point distribution model of each structure was obtained 
using Growing and Adaptive Meshes. Permutation testing between groups was 
performed to detect local displacement in shape between groups. In premanifest 
HD overall volume loss occurred in the putamen, accumbens and caudate nucleus. 
Overall volume reductions in manifest HD were found in all subcortical structures, 
except the amygdala, as compared to controls. In premanifest HD shape analysis 
showed small areas of displacement in the putamen, pallidum, accumbens and 
caudate nucleus. When the premanifest group was split into two groups according 
to predicted disease onset, the premanifest HD group close to expected disease 
onset showed more pronounced displacements in caudate nucleus and putamen 
compared to premanifest HD far from disease onset or the total premanifest group. 
Analysis of shape in manifest HD showed widespread shape differences, most 
prominently in the caudal part of the accumbens nucleus, body of the caudate 
nucleus, putamen and dorsal part of the pallidum. We conclude that shape analysis 
provides new insights in localized intrastructural atrophy patterns in HD, but can 
also potentially serve as specific target areas for disease tracking. 
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Introduction
Huntington’s disease (HD) is a slowly progressive neurodegenerative genetic 
disease that affects the brain. Disease onset occurs typically between the age of 
35 and 45 years, with clinical symptoms in motor, cognitive and behavior domains. 
Since the discovery of the genetic defect on chromosome 4, the gene status of 
at-risk individuals can be determined, making identification of premanifest gene 
carriers possible. This makes examination of brain structures possible in this 
symptom free period, and can provide insight into pathophysiological changes 
underlying the disease.
Currently, many studies focus on finding reliable markers to monitor disease 
progression1;2. MRI measures show great potential of becoming sensitive 
biomarkers for HD, as they are objective and have been applied to demonstrate 
abnormalities of both gray and white matter structures3. Changes in basal ganglia 
are of special interest as these structures display overall volume reduction in the 
premanifest stages of HD. The caudate nucleus and putamen are reported to be 
atrophied up to a decade before disease onset1;2;4. 
Two pathologic studies report on localized loss of neurons within a structure, 
namely within the medial paraventricular portions of the caudate nucleus, in the tail 
of the caudate nucleus, and in the dorsal part of the putamen in a dorsal ventral 
manner5;6. Currently, in vivo measures of atrophy have predominantly reported 
overall volumetric change of a structure, representing a generalized loss of 
neurons and axons. Unrepresented in this approach is localized loss of neurons, 
or any other remodeling effects, which go unnoticed if these local changes do not 
significantly affect the total volume of the structure.
To examine how subcortical nuclei change locally, we have chosen an automated 
MRI analysis set-up using FMRIB’s Integrated Registration and Segmentation Tool 
(FIRST) and the Growing and Adaptive Meshes (GAMEs) tools. This approach is 
chosen because in this way we obtain a per participant individual segmentation 
and outer surface of several subcortical structures. This approach is fundamentally 
different from Voxel Based Morphometry (VBM) where a voxel wise comparison 
is made between groups, also in this way we avoid some known methodological 
issues associated with VBM7;8. 
The TRACK-HD study is a biomarker study1, dedicated to finding objective and 
sensitive measures for disease progression. This study allows examination of a 
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well defined cohort of premanifest gene carriers, manifest HD and controls. The 
aim of our study is to determine how the subcortical nuclei locally change in shape 




The multicentre Track-HD cohort consists in total of 366 participants. All of the 90 
participants enrolled at the Leiden University Medical Centre from the TRACK-HD 
cohort were included for this analysis (premanifest HD n=30, manifest HD n=30, 
control n=30). Inclusion criteria for the premanifest group consisted of a CAG 
repeat length ≥ 40, absence of motor disturbances on the Unified Huntington’s 
Disease Rating Scale (UHDRS) defined as a total motor score (TMS) ≤ 5. The 
UHDRS TMS is a clinical rating of the amount of motor disturbances, grading 
several distinct motor features separately such as chorea, dystonia, rigidity, 
bradykinesia and eye movements, resulting in a sum score ranging from 0 to124. 
Additionally a disease burden score of ≥ 250 was mandatory to ensure that the 
premanifest group was within 16 years of the predicted age of onset9;10. For an 
additional analysis within the premanifest group, a further subdivision of the 
group was performed on the basis of the median predicted years to diagnosis 
into premanifest A (10.8 or more years to disease onset, N = 16) and premanifest 
B (closer than 10.8 years to disease onset, N = 14) based on Langbehn’s et al. 
(2004, 2010) survival analysis formula10;11 identical to previous reports from the 
TRACK-HD study1;12. Inclusion criteria for the manifest HD group consisted of 
a CAG repeat ≥ 40, a TMS > 5 and a Total Functional Capacity (TFC) ≥ 7. The 
TFC is a clinical scale assessing the activities in daily life (range 0-13) such as 
job capability, finances, daily chores and self care. Healthy gene negative family 
members or partners/spouses were included as controls. Exclusion criteria 
consisted of any significant (neurological) comorbidity, history of severe head 
trauma, a major psychiatric diagnosis and MRI incompatibility. The medical ethical 
committee approved the study, and written informed consent was obtained from all 
participants. Detailed description of recruitment and inclusion criteria is given in the 
TRACK-HD baseline paper1. 
MRI acquisition
In accordance with the TRACK-HD protocol, all participants underwent MRI 
scanning on a 3 Tesla Philips whole body scanner (Philips Medical Systems, 
Best, The Netherlands) with an eight channel receive and transmit coil array. T1-
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weighted image volumes were acquired using a 3D MPRAGE acquisition sequence 
with the following imaging parameters: TR = 7.7ms, TE= 3.5ms, FA= 8°, FOV= 
24cm, matrix size 224x224x164 with sagittal slices to cover the entire brain with a 
slice thickness of 1.0 mm with no gap between slices, total acquisition time was ~9 
minutes.
Post-Processing and Statistics
The analysis pipeline is depicted in figure 1. 
Analysis processing pipeline 
Figure 1: Analysis processing pipeline from MRI acquisition to Hotelling’s T2 statistics
Overall volume analysis
Using FMRIB’s Integrated Registration and Segmentation Tool (FIRST), 
subcortical nuclei were affine registered to MNI152 standard space using linear 
registration and subsequently automatically segmented13;14. Volumes for pallidum, 
caudate nucleus, putamen, thalamus, accumbens nucleus, amygdala, and the 
hippocampus were calculated. Analysis of variance was performed, correcting for 
age, gender and intracranial volume (ICV). 
The rationale to use FSL FIRST as our registration and segmentation tool was the 
fact that the tool has an automated set-up and is therefore an unbiased approach. 
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The validity of the tool to register and segment with great accuracy is described 
by Patenaude et al. (2007, 2008)13-15. Furthermore the automated set-up makes it 
relatively easy to use in large cohorts. A previous study showed the reliable use of 
this tool in HD for volumetric analysis in HD12. This tool has been and is currently 
being used in many other studies regarding different neurological disorders, 
among others in Alzheimer’s Disease16. FSL FIRST has been compared to another 
automated segmentation tool, namely Freesurfer, with comparison to manual 
segmentation. It was concluded that Freesurfer provided better results for the 
hippocampus and FIRST for the amygdala in terms of segmentation and shape 
analysis. However, also relevant is the comparison they made to expert manual 
segmentation, where no significant difference was found for the amygdala volume 
manual versus FIRST segmentation17. FIRST performed better in the smaller 
subcortical structures in a scan-rescan study18, and since TRACK-HD is set-up as a 
longitudinal study this is the logical choice considering all of the above arguments. 
However, it must be noted that all these methodological studies make use of a 
healthy control group, and to our knowledge no study comparing expert manual 
tracing versus automated segmentation in diseased/atrophied states exists.
Additional quality control was performed via a visual inspection of all the 
segmentations using the original T1-weighted scans and projecting the individual 
segmentations on top of these images. Special attention was given to the outliers 
in terms of volume. Several registration errors resulted in erroneous segmentations 
and subsequently these scans were re-run until satisfactory segmentations were 
acquired. No significant mismatches were visually seen after these steps.
Shape Analysis
To perform shape analysis, comparative meshes for each structure were built. 
For this purpose the Growing and Adaptive Meshes (GAMEs) algorithm was 
utilized19, making use of the segmentations acquired from FIRST. GAMEs has 
been previously successfully applied for analyzing shape variations in Alzheimer’s 
disease20;21. This algorithm builds a deformable surface mesh model based on 
an average of the 30 control group segmentations. This general mesh model 
consists of numerous nodes which are equal in number for all meshes used for the 
comparative analysis across groups. Using these meshes, local shape analysis 
was performed by repeated permutation tests via a Hotelling’s T2 statistical test. 
The following procedure was applied: a subsampling process was performed, 
with random samples taken from the control and the HD group; subsequently, 
permutation test (based on 10.000 iterations, in order to allow for p-values as low 
as 10-4) were performed to detect significant different location between groups, at a 
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confidence level of 99%. In total 25 sub-sampling iterations were performed, each 
sub-sample containing a minimum of 60% of the entire group population. For each 
node the significance level was assessed for all structures analyzed. The latter 
step is to ensure that the findings are not due to outliers in either the control or the 
HD group. True findings appear in the majority of the subsample analyses, which 
can be defined as either 80 or 95% of the subsamples depending on the desired 
statistical scrutiny. Graphical display does not only show the area of the surface 
affected in 80-95% of the sub-sampling, but also the amount of displacement in 
millimeters. We have chosen to use the most conservative option, namely the 95% 
level; thus the significant locations are at an α=0.01, 95% of the times in which the 
sub-sampling was performed. Three groups were included in the analysis, and the 
comparisons are displayed for the premanifest group versus the control group and 
secondly the manifest HD group versus the control group. An additional analysis 
was performed in an identical manner with the premanifest A and premanifest B 
groups both compared to the control group. The rationale to perform this additional 
analysis lies in the fact that there were only limited findings in the premanifest 
group, which could be due to the fact of a heterogenous premanifest group in 
terms of predicted years to disease onset. This was addressed by the subdivision 
of the premanifest group according to predicted disease onset as described above; 
however noted was the potential disadvantage of loss of statistical power.
Results 
Demographic characteristics of the study groups
The clinical features of the three groups are shown in table 1. There were no 
statistically significant differences between the control and premanifest group. The 
UHDRS total motor score and total functional capacity were different between the 
manifest and control or premanifest group. 
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Age 48.6 ± 8.3 43.3 ± 8.0 47.6 ± 10.3
CAG n.e. 42.5 ± 2.4 43.6 ± 2.6
Years to onset n.a. 11.6 ± 4.3 n.a.
UHDRS TMS 2.6 ± 2.4 2.5 ± 1.4 21.9 ± 11.1 *
TFC 13.0 ± 0.2 12.6 ± 0.8 10.4 ± 2.0 *
Gender (N ♀/♂) 16/14 18/12 21/9
Demographic variables of the three groups. CAG = Cytosine-Adenosine-Guanine repeat. UHDRS = 
Unified Huntington’s Disease Rating Scale Total Motor Score, TFC = Total Functional Capacity. n.a. = 
not applicable, n.e = not examined.* = significant different from the control and premanifest HD group 
with p < 0.05.
Volumetric analysis
Significant differences in overall volumes between the premanifest and 
control group were apparent in the accumbens nucleus, caudate nucleus, 
left hippocampus and putamen. In the manifest HD group all volumes were 
significantly reduced as compared to controls, except for the amygdala. The overall 
volumes are shown in table 2.
Shape analysis
The shape analyses for the basal ganglia structures accumbens nucleus, caudate 
nucleus, pallidum and putamen are displayed in figure 2. The remaining structures 
amygdala, hippocampus and thalamus are shown in figure 3. The displacements 
shown in the figures are all significant at the 99% significance level, with the colour 
coding of the amount of displacements in millimeters. All displacements were 
inwards, representing atrophy. No significant areas of hypertrophy were observed.
For the accumbens nucleus it is apparent that the shape changes were 
localized at the caudal side, most prominently seen in the manifest stage. In the 
premanifest stage a displacement is seen in the right accumbens nucleus. The 
caudate nucleus showed displacements in both the premanifest and manifest HD 
groups. A generalized displacement is seen across the whole caudate nucleus, 
most significantly in the body on the medial side. In premanifest HD significant 
displacement is seen in some areas more towards the tail. The pallidum showed 
a diffuse pattern of displacement in the manifest HD group, with the dorsal part 
displaying the most extensive displacements. Displacement is also seen in this 
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part of the dorsal pallidum in the premanifest HD group. The putamen showed 
displacement over the entire structure in the manifest stage, small patches were 
found in the premanifest stage on the medial side of the left putamen.
For the amygdala the shape changes were seen in the manifest stage, specifically 
on the cranial side. No displacements were seen in the premanifest group. The 
hippocampus showed patchy displacement areas at the ventral as well as the 
dorsal part, this displacement being limited to the manifest group only. Finally the 
thalamus showed some patchy displacements on the ventro-medial and ventro-
lateral side of the structure, but no real displacement areas could be found in the 
premanifest group.
Table 2: Volumes of subcortical nuclei
















































































































Volumetric analysis of seven structures. Means are the absolute measured values (mm3). Significance is 
after correction for intracranial 
volume, gender and age
* significant difference from controls p < 0.05
** significant difference from controls p < 0.001 
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Shape analysis of accumbens nucleus, caudate nucleus, pallidum and 
putamen in premanifest and manifest HD
Figure 2: Shape analysis of accumbens nucleus, caudate nucleus, pallidum and putamen. On the left 
a T1-weighted image with one sided location of the structure analyzed. Group comparison of shape 
changes between the premanifest and control group on the second and third image. Left and right are 
separately displayed, and different views are provided. The fourth and fifth images display the control 
group versus the manifest HD group. The color bar on the right indicates the significant displacement in 
mm, white/gray indicates no significant displacement, while red indicates a displacement of 1,5 mm or 
higher
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Shape analysis of amygdala, hippocampus and thalamus in premanifest and 
manifest HD
Figure 3: Shape analysis of amygdala, hippocampus and thalamus. On the left a T1-weighted image 
with one sided location of the structure analysed. Group comparison of shape changes between the 
premanifest and control group on the second and third image. Left and right are separately displayed, 
and different views are provided. The fourth and fifth images display the control group versus the 
manifest HD group. The colour bar on the right indicates the significant displacement in mm, white/gray 
indicates no significant displacement, while red indicates a displacement of 1,5 mm or higher
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Shape analysis of accumbens nucleus, caudate nucleus, pallidum and 
putamen in the premanifest groups A and B 
Figure 4: Shape analysis of accumbens nucleus, caudate nucleus, pallidum and putamen in the 
premanifest groups A and B.Group comparisons of shape changes between the premanifest far from 
expected onset (A) and close to expected onset (B) versus control group are shown. Left and right 
are separately displayed, and different views are provided. The colour bar on the right indicates the 
signifi cant displacement in mm, white/gray indicates no signifi cant displacement, while red indicates a 
displacement of 1,5 mm or higher
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Shape analysis of amygdala, hippocampus and thalamus in the premanifest 
groups A and B
Figure 5: Shape analysis of amygdala, hippocampus and thalamus in the premanifest groups A and B. 
Group comparisons of shape changes between the premanifest far from expected onset (A) and close 
to expected onset (B) versus control group are shown. Left and right separately displayed, different 
views are provided. The color bar on the right indicates the significant displacement in mm, white/gray 
indicates no significant displacement, while red indicates a displacement of 1,5 mm or higher
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The additional analysis within the premanifest group shows significant results 
in portions of the caudate nucleus, pallidum and putamen for the premanifest B 
group and hardly any significant results in premanifest A group (figures 4 and 5). In 
general this seems to point out more pronounced shape changes closer to disease 
onset.
Discussion
The main focus of this study was to investigate shape changes as a potentially 
sensitive measure to quantify pathologic changes in subcortical nuclei in HD, and 
in this way provide us with understanding of the atrophy patterns. The atrophy 
patterns acquired show localized changes in almost all structures in manifest 
HD, with a limited result in premanifest HD, most pronounced closer to predicted 
disease onset. Our analysis provides potential specific target areas for disease 
tracking measures, although longitudinal confirmation is needed.
Localized in vivo shape analysis is a relatively new analysis technique, not 
previously implemented in HD research. The potential scope for application of this 
analysis is evident as several studies demonstrated atrophy of the basal ganglia. 
Overall volume estimates may not capture the highly localized changes in these 
subcortical gray matter structures as these may not have a significant impact on 
overall volume. Shape analysis may bridge this gap. We emphasize that the shape 
analysis approach can be used in all stages of the disease, whereas microscopic 
studies can only be performed in the post-mortem stage. Post-mortem neuron
counts imply that the parts where the most significant losses of neurons are seen 
in very advanced stages of HD, are also the areas where the shape or volume 
change would occur first. The pathologic studies available seem to point towards 
neuronal changes in specific portions of the caudate nucleus, namely the earliest 
changes are seen in the medial paraventricular portions of the caudate nucleus 
and in the tail of the caudate nucleus5, which are also the areas seen in our shape 
analysis. According to Vonsattel et al. (1985) the neuropathological changes are 
seen along the antero-posterior, lateral-medial and ventro-dorsal axis. Also the 
dorsal part of the putamen, along the dorsal-ventral axis, has been reported to 
show the most significant neuronal loss5;6, in our study the whole putamen seems 
affected and no specific conclusions on pattern can be drawn from this cross 
sectional analysis. 
Our findings are in concurrence with the in vivo findings of Kassubek et al. (2005), 
who used a VBM approach describing regional striatal changes corresponding 
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to the dorso-ventral gradient of neuronal loss described in neuropathological 
studies22. Furthermore, regarding the thalamus, Kassubek et al. (2005) found 
thalamic subnuclei projecting to prefrontal areas (dorso-medial subnucleus) 
and connections to the striatum (ventromedian/parafascicular and ventrolateral 
nuclear complex) to display volume loss23. In our study the thalamus shows patchy 
displacements in predominantly ventral-medial and ventral-lateral areas. Although 
a VBM approach is methodologically very different from our approach, both give 
indications on local changes, and more importantly, the findings do seem to point to 
the same general areas.
The volume analysis in our cohort is in accordance with the literature1;2;4;24. 
Possibly, shape analysis is sensitive in detecting some changes that volumetric 
analysis could not pick up. The pallidum does show some regions being affected in 
the premanifest group, yet no significant result in overall volume difference could 
be detected. It must be noted that there is a decline in volume detectable when 
the left and right pallidum are combined and the premanifest group is split into two 
groups according to the predicted years to onset (data not shown). In contrast, 
in the premanifest group the accumbens nucleus, caudate nucleus and putamen 
show only minor regional shape changes, alongside their overall volume change, 
resulting in the conclusion that a more overall volume decrease is observed in 
these specific structures, rather than any specific regional change only. However, in 
manifest HD the shape differences provides specific knowledge about the location 
of the most significant neuron losses, and gives insight into the non-uniform pattern 
of atrophy of the subcortical gray matter structures. It might be that these specific 
areas could be targeted for sensitive assessment of pathological change, possibly 
correlating to disease onset. Perhaps the body of the caudate nucleus is in respect 
the most promising candidate as this is already demonstrated in the premanifest 
close to disease onset
As this regional shape analysis approach brings new insights as to where 
specifically these neurons are lost, it is possible to extend this in vivo knowledge 
to known anatomical regions within these structures. For example, the 
hippocampus anatomy is complex with multiple distinct functional substructures25. 
Neuropathologic reports on specific regions of the hippocampus being involved, 
such as the CA1 region in the R2/6 HD mouse model26, could be supported by 
this type of in vivo analysis. This is also true for the thalamus, whose anatomy 
is known to be subdivided into several substructures. Our analysis shows the 
medial side to be affected, which could correspond to the mediodorsal part of the 
thalamus. Interestingly, Heinsen et al. (1999) reported that this part of the thalamus 
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is specifically affected in HD27. This part of the thalamus receives input from the 
prefrontal cortex and the limbic system and in turn relays them to the prefrontal 
association cortex. As a result, it plays a crucial role in cognitive functions such as 
attention, planning, organization, multi-tasking and memory which are known to 
be impaired in HD28. Haber et al.(2009) reviews all cortico-basal ganglia-thalamus 
circuits, and when correlating our findings to the described pathways one might 
argue that the regions found in our study correlate to the orbital frontal cortex and 
the anterior cingulate cortex (ventromedial striatum) and the (pre-) motor cortex 
(ventral anterior and ventral lateral nuclei) and to circuits between thalamus and 
basal ganglia in general as the mediodorsal part of the thalamus receives the bulk 
of the basal ganglia output29. 
More specific pathways on striatal-cortical connections are described by Lehericy 
et al.(2004)30. Extending this knowledge Draganski et al.(2008) demonstrated in 
healthy subjects in vivo the coexistence of clearly segregated and also overlapping 
connections from cortical sites to basal ganglia subregions31. They found that 
the the basal ganglia are connected in a rostrocaudal gradient of prefrontal 
connections in addition to projections to sensorimotor and parietal cortical areas. 
Using this knowledge we can extract from our own results the most severely 
affected subregions of the basal ganglia and their associated cortical projections. 
One example is the severe shape change in the body of the caudate nucleus which 
is, according to the connections described by Draganski et al.(2008), strongly 
connected to the dorsolateral prefrontal cortex31. This seems to be consistent with 
the above described thalamic connections of the prefrontal cortex which seem to 
be affected in HD. Another example is the dorsal part of the pallidum which has 
strong connections to the motor cortex, known to be affected in HD1;31;32. In this 
way the locally found shape changes in subcortical nuclei can be used to extend 
knowledge on affected pathways.
However, some caution must be taken not to over interpret these results, as the 
outer surface of a structure does not necessarily mean that neurons are lost 
within one small specific subnuclei, as the outer surface cannot give information 
about remodeling within one large structure or the specific neuronal cell changes, 
although it does give important clues as such. 
A limitation of our study could be the usage of a relatively new software package 
from FSL for segmentation, which hasn’t specifically been validated in HD. Visual 
inspection, however, did not reveal any significant mismatches. The method 
applied gives structure segmentation on an individual basis and can therefore be 
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used to compare groups. In contrast to this limitation clear several reasons exist in 
favor of using FIRST; first of all, compared to manual segmentation the automated 
segmentation uses voxel intensity in contrast to the sometimes difficult visual 
contrast differences, reducing a rater dependent bias. Secondly this automated 
technique is suitable for implantation on large datasets, whereas manual 
segmentation is labour intensive. Other techniques such as VBM, although proven 
to adequately compare groups, is prone to registration artifacts in the deep gray 
matter and may not be suitable for analysis of the pattern of atrophy in an individual 
subject7;33. 
Another limitation of this study is apparent in applying a statistical paradigm not 
specifically set for detecting changes in the premanifest group, where changes 
are relatively small. When less statistical scrutiny would be applied larger regions 
may show displacement, yet these standards were set before the analysis was 
performed and did not interfere with achieving the goal of the study, namely finding 
specific regional shape changes. Another limitation could also be the fact that our 
premanifest group is quite heterogeneous, in regards to the disease burden which 
has a substantial range. This disease burden score can be calculated by: (CAG 
repeat length – 35.5) x Age, and correlates well with striatal damage and expected 
age of onset9. This heterogeneity within the premanifest group has been addressed 
by performing an additional analysis within the premanifest group, showing the 
relationship of shape changes with disease onset. A final limitation is the cross 
sectional design, which is unsuited to prove the biomarker quality of localized 
shape changes and longitudinal follow up should be performed. 
In conclusion, shape analysis provides new insights in patterns of atrophy in 
Huntington’s disease. Specific parts of the subcortical gray matter structures 
are demonstrated to show major shape changes besides an overall volume 
change. This study assesses these differences in vivo and finds support in known 
pathologic findings in advanced HD. These localized areas provides not only 
additional knowledge in localized intrastructural atrophy patterns, but can also 
potentially serve as specific target areas for disease tracking. 
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Abstract
Background and Purpose 
Magnetization Transfer Imaging (MTI) has the potential to detect abnormalities 
in normal-appearing white and gray matter on conventional MR imaging. Early 
detection methods and disease progression markers are needed in Huntington’s 
Disease (HD) research. Therefore we investigated MTI parameters and their 
clinical correlates in premanifest and manifest HD. 
Method
From the Leiden TRACK-HD study, 78 participants (28 controls, 25 premanifest HD 
gene carriers, 25 manifest HD) were included. Brain segmentation of cortical grey 
matter, white matter, caudate nucleus, putamen, pallidum, thalamus, amygdala 
and hippocampus was performed using FSL’s automated tools FAST and FIRST. 
Individual Magnetization Transfer Ratio (MTR) values were calculated from these 
regions and MTR histograms constructed. Regression analysis of MTR measures 
from all gene carriers with clinical measures was performed.
Results
MTR peak height was reduced in both cortical grey (p=0.01) and white matter 
(p=0.006) in manifest HD compared to controls. Also mean MTR was reduced in 
cortical grey matter (p=0.01) and showed a trend in white matter (p=0.052). Deep 
grey matter structures showed a uniform pattern of reduced MTR values (p<0.05). 
No differences between premanifest gene carriers and controls were found. MTR 
values correlated with disease burden, motor and cognitive impairment.
Conclusion
Throughout the brain disturbances in MTI parameters are apparent in early HD 
and are homogeneous across white and grey matter. The correlation of MTI with 
clinical measures indicates the potential to act as a disease monitor in clinical trials. 
However, our study does not provide evidence for MTI as a marker in premanifest 
HD.
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Introduction
Huntington’s disease (HD) is a progressive neurodegenerative genetic brain 
disorder with clinical features consisting of motor signs, cognitive impairment and 
psychiatric disturbances. Disease onset is typically during mid-life1. Since genetic 
testing became available for this autosomal dominant inheritable disease, it has 
become possible to identify premanifest gene carriers and in this way ascertain 
with certainty that they will eventually develop the disease. The disease is caused 
by a genetic defect on chromosome 4 which results in an expanded polyglutamine 
in the gene coding for the huntingtin protein2. This mutant huntingtin predominantly 
affects the brain, resulting in malfunction and loss of neurons. Histopathologically, 
the disease is characterized by cellular loss of grey matter structures, most 
profoundly that of the medium spiny neurons within the striatum, but also significant 
white matter volume loss3.
Sensitive and reliable biomarkers are needed for evaluating clinical trials in HD. 
The challenges in this field lay in the fact that a biomarker should be able to 
monitor pathophysiological changes not only in the manifest phase, but also in the 
preceding premanifest stage, when no overt symptoms exist. MRI characterization 
of brain changes is regarded as a potential source of biomarkers as previous 
studies have shown that atrophy of the striatum is apparent already a decade 
or more before symptom onset4-6. Also, abnormalities in white matter7;8 and 
cortical grey matter5 have been reported. It is likely that the underlying pathologic 
processes resulting in brain atrophy occur before or in concurrence with the 
volumetric changes. 
Magnetization Transfer Imaging (MTI) has the potential to quantify the pathologic 
changes in central nervous system disorders in the normal appearing white 
and grey matter on conventional MRI sequences9;10. MTI offers a way of 
examining tissue structure and structural components, normally not resolvable 
with conventional MRI11. This allows for examination of structural integrity in a 
different and possibly more sensitive manner than volumetric changes alone. 
The technique of MTI relies on interaction between protons in free fluid and 
protons bound to macromolecules. The magnetization saturation and relaxation 
within macromolecules affect the observable signal. The MTR, representing the 
percentage of variation in the MR signal between the saturated and unsaturated 
acquisitions, is an effective and simple MTI measure to use as a clinical 
application. MTI has been used to characterize many different disorders, including 
Multiple Sclerosis, Alzheimer’s and Parkinson’s disease9. 
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This study aims to examine MTR measures in a well defined premanifest and 
manifest HD population, and to determine associations between MTR and 
clinical features of HD. By examining MTR in this sample we aim to advance 
understanding of the timing of pathophysiological changes in HD and we also 
evaluate the suitability of MTI/MTR as a potential biomarker for HD.
Materials and Methods
Subjects 
Of the 90 participants from the Leiden TRACK-HD study, 12 did not receive MTI 
scanning due to either unexpected claustrophobia or time constraints of the full 
TRACK-HD protocol, resulting in 78 participants. The cohort consisted of three 
groups; 28 healthy controls, 25 Premanifest HD gene carriers (PMGC) and 25 
manifest HD (MHD). Inclusion criteria for the PMGC consisted of genetically 
confirmed expanded CAG repeat ≥40, a disease burden score (calculated as: 
((CAG repeat length–35.5) x Age) of >25012 and absence of motor abnormalities 
on the Unified Huntington’s disease rating scale (UHDRS), defined as a total motor 
score (TMS) of ≤5. Inclusion criteria for MHD consisted of genetically confirmed 
CAG repeat ≥40, presence of motor abnormalities on the UHDRS-TMS of >5. Also 
a total functional capacity (TFC) score of 7 or higher was required to ensure that 
the HD group was in the earliest disease stages. Healthy gene negative family 
members, spouses or partners were recruited as control subjects. Exclusion 
criteria consisted of significant (neurological) co-morbidity, active major psychiatric 
disturbance and MRI incompatibility. Full details on recruitment are available from 
the TRACK-HD baseline paper5. Local IRB approval and written informed consent 
were obtained from all participants.
Imaging sequences
All 78 participants underwent scanning on a 3 Tesla Philips whole body scanner 
(Philips, Best, The Netherlands) with an 8-channel receive and transmit coil. 
T1-weighted image volumes were acquired using an ultrafast gradient echo 3D 
acquisition sequence with the following imaging parameters: TR = 7.7ms, TE= 
3.5ms, FA= 8°, FOV= 24cm, matrix size 224x224x164 with sagittal slices to cover 
the entire brain with a slice thickness of 1.0 mm.
A 3D gradient MTI sequence was subsequently performed with the following 
parameters: TR = 100 ms, TE = 11 ms, FA = 9°, matrix 224x180x144 mm, voxel 
size:1.0x1.0x7.2 mm. Two consecutive imaging sets were acquired, one with and 
one without a saturation pulse. The imaging parameters are identical to those 
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described by Jurgens et al. (2010)13. Total scanning time for T1-weighted and MTI 
sequences was 12 minutes maximum.
Post-processing
T1-weighted images were segmented using FAST14 and FIRST15;16 from FSL17. This 
provided individual brain masks for: total white matter, cortical grey matter, caudate 
nucleus, putamen, pallidum, thalamus, amygdala, and hippocampus. To correct 
for possible partial volume effects, an eroded mask of these segmentations was 
created by removing one voxel in plane for all above named volumes of interest 
(VOI). All brain masks were then registered to the MTI volumes using the transform 
obtained from linear registration of the T1-weighted volume with 7 degrees of 
freedom (FSL FLIRT). MTR is calculated per voxel as M0-Ms / M0, whereby Ms 
is the saturated image and M0 the unsaturated image. The mean MTR per VOI 
was calculated. Additionally, to represent voxel based MTR variations/variability 
within each VOI we constructed MTR histograms and calculated MTR peak height 
using FSL-STATs. Mean MTR and MTR peak height, normalized for the size of the 
volume of interest, were the primary outcome variables.
Clinical Measures
A total measure of motor dysfunction was obtained with the UHDRS-TMS (range 
0-124). Quantification of subtle motor dysfunction by measuring variability of 
dominant hand finger tapping and tongue protrusion force was achieved with force 
transducer based quantitative motor assessments18;19. The tapping and tongue 
measures are expressed as a logarithmic number, higher numbers representing 
more motor disturbances. TFC score (range: 0-13) and mini-mental state exam 
(MMSE) for global assessment of cognitive functioning (range: 0-30) were 
obtained. Cognitive scores included the total scores from the symbol digit modality 
test (SDMT), Stroop word reading card, trail making test (TMT) A and B and 
verbal fluency (VF). For the TMT a subtraction of TMT B minus TMT A was used 
to minimize the potential effects of motor speed on performance. The university 
of Pennsylvania smell identifaction test (UPSIT) (Sensonics, Haddon Heights, 
New Jersey) quantifies smell ability with a 20-item smell test, and is known to 
correlate to clinical features of neurodegenerative diseases20. An IQ estimate was 
obtained with the Dutch adult reading test (DART) (a validated translation of the 
National Adult Reading Test). For assessment of psychiatric disturbances the Beck 
Depression Inventory II, the Problem Behaviour Assessment, short version, and 
the Frontal Systems Behavior21 were used. Predicted years to disease onset were 
calculated for PMGC as described in the TRACK-HD baseline paper. For a more 
detailed description of these clinical assessments see Tabrizi et al.(2009)5.
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Statistics
Statistical analysis was performed using the Statistical Package for Social Sciences 
(Version 17.0.2, Chicago, USA). An analysis of variance was conducted for all 
demographic variables. For group comparisons, all MTR values were analysed in 
a three group analysis of variance with post hoc analysis to determine differences 
between groups. Hierarchical multiple regression analysis was performed to 
ascertain the relationship of MTR values with clinical measures. For this analysis 
only gene carriers (premanifest + manifest) were included as the aim was to 
examine the relationship to disease progression. MTR values and 14 different 
clinical assessments were assessed for all regions of interest. In the hierarchical 
regression age and gender were entered at step 1, thus correcting for the influence 
of these variables. This was applied for all motor and general assessments, for the 
specific cognitive tasks (SDMT, Stroop word reading, VF and TMT) IQ was also 
entered at step 1 as IQ can have a significant impact on cognitive scores. 
Results
Demographic variables (table 1) show that there were no differences between 
the groups in terms of age or CAG repeat length, but that there was a significant 
difference (p < 0.05) between groups for all clinical tests, except for IQ and the 
FrSBe-scores. 
MTR peak height was significantly reduced in the MHD group as compared 
to either controls or PMGC in the following regions: white matter, grey matter, 
putamen, pallidum, amygdala, left thalamus (with a trend for the right thalamus) 
and the right hippocampus. No significant results were found between the control 
and PMGC. The mean MTR value was significantly lower between MHD and 
controls in the following regions: grey matter, both caudate nuclei, both thalami and 
right putamen. All MTR values are shown (table 2) for all regions as examined for 
each group.
Overall, the MTR histograms showed similar patterns for all study groups in white 
and cortical grey matter (figure 1) as well as all subcortical grey matter regions 
separately (figure 2). Whereby, in all histograms the MHD group displayed a lower 
and broader histogram, as compared to controls and PMGC.
The regression analysis revealed several highly significant correlations between 
the MTR values and clinical measures (Table 3). The disease burden score was 
significantly correlated with both cortical grey and white matter MTR peak height 
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and mean MTR. The deep grey matter structures mainly showed a correlation of 
MTR peak height to the disease burden except the right caudate nucleus and right 
putamen. The motor tests also correlated significantly with the MTR values in most 
regions of interest, predominantly with the UHDRS-TMS and the tapping measure 
and only minimally with the tongue measure. The cognitive measures showed 
correlations in the following regions; cortical grey matter, white matter, thalamus, left 
putamen, right pallidum and left amygdala. The TFC showed a correlation with white 
matter and the left putamen. The smell identification test was correlated to MTR 
values in both cortical grey and white matter as in the caudate nucleus, amygdala 
and thalamus. The MMSE and the measures of behavioural/psychiatric functioning 
revealed no correlation to any structures and are therefore not displayed in table 3.









N 28 25 25
Age 48.3 (8.0) 43.8 (8.5) 48.4 (10.9) 0.131
CAG larger allel n.a. 42.72 (2.6) 43.73 (2.8) 0.182
UHDRS TMS 2.3 (2.3) 2.5 (1.5) 22.9 (11.4) 0.000
TFC 12.96 (0.2) 12.56 (0.8) 10.2 (2.1) 0.000
YTO n.a. 7.06 (1.99) n.a. n.a.
IQ 104 (9) 100 (11) 99 (12) 0.260
MMSE 29.1 (1.2) 28.7 (1.5) 27.2 (2.6) 0.001
Tongue Force 3.56 (0.40) 3.97 (0.51) 4.88 (0.65) 0.000
Tapping 11.6 (5.8) 16.7 (8.5) 30.9 (18.2) 0.000
SDMT 50.6 (9.3) 50.7 (10.2) 35.7 (11.10 0.000
Stroop 98.1 (14.2) 93.0 (13.7) 76.7 (20.6) 0.000
TMT 33.5 (23.5) 43.2 (26.9) 90.3 (73.6) 0.000
Verbal Fluency 26.8 (8.7) 33.3 (14.1) 20.8 (14.5) 0.016
UPSIT 15.89 (2.9) 14.6 (2.5) 12.23 (3.8) 0.000
BDI-II 4.8 (5.9) 7.0 (7.7) 11.1 (10.2) 0.020
PBA-s 6.4 (8.1) 7.6 (8.5) 14.6 (14.7) 0.017
FrSBe 78.1 (19.6) 85.9 (23.8) 87.3 (21.6) 0.259
PMGC= Premanifest HD gene carriers, MHD= manifest Hutington’s Disease, CAG= Cytosine-Adenine-
Guanine, UHDRS TMS = Unified Huntington’s Disease Rating Scale Total Motor Score, TFC = Total 
Functional Capacity, YTO = Expected years to onset, IQ = Intelligence Quotient based on the Dutch 
Adult Reading Test, MMSE = Mini Mental State Exam, Tapping = Average speeded tapping for left 
and right index finger, Tongue = sustained tongue force measure, SDMT = Symbol Digit Modalities 
test, Stroop = Stroop word reading task, TMT = Trail making test, UPSIT = University of Pennsylvania 
Smell Identification Test, BDI-II = Becks Depression Inventory 2nd version, PBA-s = Problem Behaviour 
Assessment-short version, FrSBe = Frontal Systems Behaviour rating scale Self Report, n.a. = not 
applicable. 
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Table 2: MTR values for all brain regions
Control PMGC MHD P-value
Mean (SD) Mean (SD) Mean (SD) C - P C - M P - M
White matter
Peak height 1.080 (0.271) 1.118 (0.212) 0.860 (0.234) 0.859 0.006 0.001
Mean MTR 0.389 (0.017) 0.389 (0.015) 0.378 (0.017) 0.986 0.052 0.086
Cortical Grey matter
Peak height 0.769 (0.121) 0.723 (0.118) 0.610 (0.145) 0.435 0.000 0.010
Mean MTR 0.330 (0.131) 0.326 (0.125) 0.314 (0.174) 0.687 0.001 0.010
Right Caudate
Peak height 0.804 (0.209) 0.871 (0.198) 0.757 (0.198) 0.486 0.701 0.144
Mean MTR 0.349 (0.029) 0.341 (0.027) 0.325 (0.035) 0.603 0.020 0.199
Left Caudate
Peak height 0.884 (0.203) 0.949 (0.207) 0.812 (0.231) 0.550 0.474 0.084
Mean MTR 0.367 (0.029) 0.359 (0.021) 0.346 (0.036) 0.586 0.041 0.330
Right Putamen
Peak height 1.223 (0.388) 1.238 (0.292) 0.976 (0.288) 0.985 0.029 0.023
Mean MTR 0.341 (0.019) 0.333 (0.024) 0.325 (0.023) 0.448 0.034 0.410
Left Putamen
Peak height 1.316 (0.329) 1.299 (0.241) 1.050 (0.290) 0.977 0.006 0.014
Mean MTR 0.358 (0.018) 0.351 (0.022) 0.356 (0.017) 0.475 0.932 0.711
Right Pallidum
Peak height 1.449 (0.400) 1.587 (0.296) 1.324 (0.400) 0.404 0.480 0.049
Mean MTR 0.385 (0.022) 0.382 (0.014) 0.385 (0.022) 0.850 0.996 0.816
Left Pallidum
Peak height 1.563 (0.369) 1.514 (0.285) 1.268 (0.332) 0.868 0.008 0.038
Mean MTR 0.382 (0.027) 0.384 (0.015) 0.394 (0.018) 0.951 0.098 0.197
Right Thalamus
Peak height 0.995 (0.297) 1.027 (0.215) 0.864 (0.227) 0.896 0.173 0.078
Mean MTR 0.369 (0.028) 0.360 (0.025) 0.340 (0.038) 0.536 0.005 0.093
Left Thalamus
Peak height 1.055 (0.253) 1.114 (0.241) 0.906 (0.278) 0.711 0.115 0.021
Mean MTR 0.380 (0.035) 0.372 (0.018) 0.355 (0.040) 0.709 0.024 0.168
Right Amygdala
Peak height 1.299 (0.318) 1.294 (0.228) 1.127 (0.263) 0.998 0.080 0.105
Mean MTR 0.362 (0.020) 0.361 (0.020) 0.355 (0.020) 0.977 0.463 0.607
Left Amygdala
Peak height 1.462 (0.343) 1.399 (0.231) 1.178 (0.280) 0.733 0.003 0.032
Mean MTR 0.373 (0.028) 0.374 (0.021) 0.368 (0.021) 0.997 0.679 0.648
Right Hippocampus
Peak height 1.220 (0.334) 1.266 (0.239) 1.081 (0.195) 0.821 0.170 0.054
Mean MTR 0.369 (0.025) 0.363 (0.016) 0.357 (0.021) 0.592 0.122 0.593
Left Hippocampus
Peak height 0.954 (0.273) 0.965 (0.207) 0.882 (0.230) 0.985 0.555 0.473
Mean MTR 0.390 (0.027) 0.382 (0.018) 0.383 (0.017) 0.400 0.540 0.972
MTR values for white matter, cortical grey matter and subcortical grey matter structures. Peak height 
represents a normalized for volume peak height. PMGC= Premanifest HD gene carriers, MHD= manifest 
Hutington’s Disease C = controls, P = premanifest HD, M = Manifest HD
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Table 3: Regression analysis per region of interest
Burden TMS TFC Tap Tongue SDMT Stroop TMT VF UPSIT
WM
Peak height .204** .257** .074* .168** .110* .097* .060 .089* .000 .151**
Mean MTR .114* .163** .025 .080 .034 .057 .036 .037 .004 .160**
CGM
Peak height .193** .189** .061 .111* .049 .062 .063 .092* .003 .058*
Mean MTR .083* .152** .110* .098* .062 .114* .125* .136** .034 .122*
Right CN
Peak height .059 .054 .019 .040 .001 .021 .061 .009 .000 .014
Mean MTR .076* .153** .036 .105* .008 .050 .052 .034 .003 .101*
Left CN
Peak height .083* .160** .034 .116* .104* .038 .070 .010 .022 .104*
Mean MTR .047 .111* .017 .094* .037 .012 .026 .025 .000 .141*
Right Putamen
Peak height .055 .181** .053 .112* .044 .067 .067 .038 .001 .061
Mean MTR .000 .077 .038 .013 .001 .021 .037 .005 .001 .002
Left Putamen 
Peak height .076* .209** .090* .117* .060 .054 .077* .035 .000 .070
Mean MTR .025 .000 .007 .010 .002 .041 .035 .006 .078* .008
Right Pallidum 
Peak height .110* .175** .035 .174** .051 .071 .048 .041 .004 .075
Mean MTR .001 .017 .046 .003 .001 .001 .006 .019 .033 .010
Left Pallidum 
Peak height .104* .164** .043 .131* .051 .060 .070 080* .000 .045
Mean MTR .001 .001 .026 .000 .012 .036 .053 .011 .034 .004
Right Amygdala
Peak height .145** .128* .023 .098* .016 .037 .034 .020 .002 .116*
Mean MTR .026 .033 .034 .058 .009 .025 .043 .044 .036 .041
Left Amygdala
Peak height .252** .184** .060 .216** .134* .170** .116* .086* .071 .172**
Mean MTR .000 .000 .007 .003 .005 .038 .047 .068 .109* .003
Right HC
Peak height .190** .091* .002 .075 .002 .073 .026 .010 .001 .061
Mean MTR .015 .041 .075 .037 .012 .043 .073 .070 .025 .034
Left HC
Peak height .095* .062 .000 .020 .015 .022 .085* .026 .039 .011
Mean MTR .003 .006 .002 .013 .001 .015 .027 .006 .010 .008
Right Thalamus
Peak height .124* .099* .025 .100* .007 .043 .055 .015 .002 .045
Mean MTR .162** .215** .057 .172** .033 .072* .066 .061 .009 .156**
Left Thalamus 
Peak height .154** .223** .065 .167** .122* .075 .110* .030 .032 .122*
Mean MTR .117* .156** .027 .134* .046 .035 .044 .042 .004 .158**
Regression analysis between 14 clinical and 2 MTI measures in regions of interest. Values stated are R square 
changes. WM=White Matter, CGM=Cortical Grey Matter, CN=Caudate Nucleus, HC =hippocampus, TMS = 
Unified Huntington’s Disease Rating Scale Total Motor Score, TFC = Total Functional Capacity, Tap= speeded 
tapping, Tongue = tongue force, SDMT = Symbol Digit Modalities test, Stroop = Stroop word reading task, TMT 
= Trail making test, VF = verbal fluency, UPSIT = University of Pennsylvania Smell Identification Test, *=p<0.05, 
**=p<0.005
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Figure 1: (A & B) example segmentations acquired with FAST software showing white matter (red), grey 
matter (white) and cerebral spinal fluid (blue). The subcortical grey matter structures were subtracted 
from these masks. Magnetization Transfer Ratio Histogram for the white matter (C) and cortical grey 
matter (D), corrected for volume size of the region for 3 groups. 
Discussion
MTI applied in HD reveals disturbances throughout the brain in early HD as 
compared to controls and PMGC. Disease burden, quantitative motor and cognitive 
measures have a strong correlation to MTR values, leading to the conclusion 
that MTI can possibly be used to track disease progression. No abnormalities are 
quantifiable in the premanifest stages of the disease compared to controls, which 
leads to suggest that MTI, although perhaps a good disease monitor, is not an 
early marker of the disease.
Currently, conventional structural MRI and Diffusion Tensor Imaging (DTI) are the 
two most widely applied methods in HD research with respect to the search for a 
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MRI biomarker covering all disease stages of HD. Only three reports on MTI in HD 
are available13;22;23. The value derived from MTI is the MTR value per brain voxel 
and is thought to represent structural integrity. The value quantifies the exchange 
of magnetization from the non-water components in the region at hand. The most 
frequently reported outcome measures of MTR are mean MTR and MTR peak 
height. Mean MTR represents the average MTR value of all voxels in a region of 
interest, with lower mean MTR corresponding to poorer integrity. MTR peak height 
reflects the most frequently occurring MTR value in a region of interest when all 
the MTR values are set out in a MTR histogram. When each MTR value occurs 
less frequently, the histogram becomes broader, and the maximum peak height 
decreases. This reduction represents reduced capacity to optimally exchange 
magnetization over the region of interest, hence representing reduced structural 
integrity24;25. For example in white matter, myelin is the main component and 
therefore MTR is thought to relate to myelinisation or myelin integrity. To which 
cellular structure, whether neurons or glia cells, MTR in gray matter specifically 
refers is unknown.
Figure 2: Magnetization Transfer Ratio histogram for 6 deep grey matter structures bilaterally, corrected 
for volume size of the region for 3 groups. Red = caudate nucleus, dark blue = putamen, light green = 
pallidum, dark green = thalamus, yellow = amygdala, light blue = hippocampus. Con = controls
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In our study it does not solely reflect atrophy, as the differences found in peak 
height were corrected for size of the volume examined, thereby accounting for 
atrophy. From histopathological studies we know that medium spiny neurons in HD 
are most affected, making these the most likely source of the differences. 
In the current study, we found that both MTR measures were significantly reduced 
in the manifest stages of HD in cortical grey matter, deep gray matter structures 
and white matter. This finding conflicts with the findings by Mascalchi et al. (2004), 
who reported no differences between a group of 21 gene carriers (of which 19 
manifest HD) and controls22. The differences could be explained by the fact that 
Mascalchi et al. (2004) applied a different (manual) segmentation technique, used 
a lower field strength, included a slightly smaller group and did not examine MTR 
peak height. Mean MTR in our study does show significant results, however not in 
the white matter. In general we found that the peak height tended to be the more 
sensitive MTR measure rather than the mean MTR. The study by Jurgens et al. 
(2010)is comparable to our study with the same type of scanner and analysis. 
We replicate their findings as they also demonstrated a lack of group difference 
between PMGC and controls13. Furthermore, the clinical correlation of the MTI peak 
height with clinical measures in gene carriers is confirmed in our study, and this 
knowledge is extended from a premanifest study group to both PMGC and MHD. 
Ginestroni et al. (2010) applied a similar methodology to our study, as both used 
the FSL tools for segmentation23. The main difference between these two studies is 
that we examined an explicitly premanifest and manifest groups separately, instead 
of a “gene carrier group with a range of clinical severity”. The outcomes of the 
studies are highly comparable with reduced MTR in subcortical and cortical grey 
matter. The absence of white matter differences in mean MTR is similar in both 
reports. However we did find white matter differences with an outcome measure 
not examined by Ginestroni et al. (2010), namely MTR peak height. Finally the 
correlation of MTR values with clinical measures was similarly reported by both 
studies.23.
The finding of reduced MTR measures throughout the brain is remarkably 
homogeneous. This seems in contrast to the volumetric data available in HD 
research. Striatal degeneration is the key feature of brain pathology in HD, yet 
evermore evidence is building up that, although the damage starts in the striatum, 
HD is truly a whole brain disease, as numerous volumetric studies demonstrate 
widespread volumetric loss in both gray and white matter26. So the seemingly 
paradoxal homogeneity is really not that surprising.
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The application of MTI and its relationship to clinical severity has been 
demonstrated in other neurological diseases such as Multiple Sclerosis and 
Alzheimer disease10;27;28;28-31. Our findings indicate that MTI measures in HD 
correlate to disease burden, specific motor tasks and cognitive measures in this 
study population. The finding of correlations of MTI with specific clinical parameters 
indicates that MTI is a good reflection of the disease status as shown by motor and 
cognitive measures. Furthermore the disease burden, which encompasses the 
CAG-repeat length, has been demonstrated to correlate with striatal degeneration 
and predicted time to disease onset12, therefore indirectly linking MTI outcomes to 
such measures.
The lack of significant group differences between PMGC and controls was 
unexpected. We anticipated differences on the basis of previous reports on white 
matter integrity loss in premanifest HD using DTI7;8;32. DTI can be used to examine 
protons in free water and their diffusive properties in more than one way, namely 
the strength of the directional of diffusivity (FA), the average amount of diffusivity 
(mean diffusivity), but also the amount of diffusivity in either the radial and axial 
direction. DTI has the potential for examining and quantifying many features of 
brain tissue, all captured by the terms structural integrity and/or organization. In 
white matter DTI is heavily influenced by axonal membranes and myelin sheats33. 
In contrast MTI can be used to examine tissue structure according to the protons 
bound to macromolecules34. As myelin is the main component of white matter, 
MTI is thought to mainly represent myelin integrity. Therefore, these techniques 
characterize fundamentally different aspects of brain tissue, possibly explaining 
(part of) the differences found between DTI-studies and MTI-studies. The question 
remains whether DTI or MTI is more sensitive in detecting the pathologic neuronal 
integrity breakdown. However, answering this question was not the aim of this 
study. 
 
The potential role for MTI as a biomarker in HD is apparent as there are both 
significant differences between groups and a clear relationship to clinical 
measures. However, MTI may be sensitive to a particular (early) disease state 
and not to all disease stages in HD. Longitudinal follow up is needed to confirm 
this. The biomarker role for MTI has already been suggested in Alzheimer 
disease by Ridha et al. (2007)31 and the reports for using MTI as a biomarker 
in MS are building35, strengthening the possibility for MTI as a biomarker in 
neurodegenerative disorders such as HD. TRACK-HD is specifically designed for 
longitudinal assessment of potential biomarkers, and is therefore the ideal platform 
to confirm the findings longitudinally. 
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Limitations of our study lay in the fact that the automated segmentation technique 
has not specifically been validated for HD. However, we used these only for 
obtaining the brain regions of interest. Furthermore, we accounted for some 
possible incorrect segmentation and/or partial volume effects by using an eroded 
version of the brain masks. A limitation could also be that we have chosen a region 
of interest (ROI) based analysis as opposed to voxelwise analysis. However as 
the morphology of the structures at hand change due to the disease, registration 
issues could be a severe problem, not to mention that the mean MTR can remain 
constant while intensities do change. Therefore ROI based analysis is potentially 
more sensitive. Futhermore, we examined voxel based variations within structures, 
by representing this in histograms of each VOI. Another limitation could be that 
the exploratory nature of this study accounted for a high number of correlations 
included, which could lead to false positive results. It seems, however, that MTI 
measures are fairly stable in every region we examined and provides a rather 
uniform picture of group differences and clinical correlation outcomes. Finally, a 
limitation of MTI in general has been the limited reproducibility across centres due 
to the fact that the MT phenomenon is dependent on many technical parameters 
and lack of a standardized protocol9.
Conclusions 
MTI demonstrates that whole brain disturbances are apparent in early HD 
and furthermore, these structural integrity differences seem to be relatively 
homogeneous throughout the brain in early HD. The strong correlations to clinical 
features, especially motor and cognitive measures, suggest that there is potential 
for this analysis to serve as a disease monitor in future clinical trials. However, MTI 
does not seem to be an early marker of HD as no disturbances in MTI measures 
can be detected in the premanifest stages of the disease.
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To investigate the function-structure relationship of white matter within different 
stages of Huntington’s disease using diffusion tensor imaging (DTI).
Experimental design
From the TRACK-HD study, an early stage HD group and a pre-manifest gene 
carrier group (PMGC) were age-matched to two healthy control groups; all 
underwent 3T MRI scanning of the brain. Region of interest (ROI) segmentation 
of the corpus callosum, caudate nucleus, thalamus, prefrontal cortex and 
sensorimotor cortex was applied, and the apparent fiber pathways of these regions 
were analyzed. Functional measures of motor, oculomotor, cognition, and behavior 
were correlated to DTI measures.
Principle observations 
In PMGC versus controls, higher apparent diffusion coefficient (ADC) was seen 
in white matter pathways of the sensorimotor cortex (p<0.01) and in the ROI of 
corpus callosum (p<0.017). In early HD, fiber tract analysis showed higher ADC in 
pathways of the corpus callosum, thalamus, sensorimotor and pre-frontal region 
(p<0.01). ROI analysis showed higher diffusivity in the corpus callosum and 
caudate nucleus (p<0.017). Motor, oculomotor, cognition, and probability of onset 
within 2 and 5 years, correlated well with ADC measures of the corpus callosum 
(p<0.01 – p<0.005), sensorimotor (p<0.01 – p<0.005) and prefrontal region 
(p<0.01). 
Conclusions
Disturbances in the white matter connections of the sensorimotor cortex can be 
demonstrated not only in manifest HD but also in pre-manifest gene carriers. 
Connectivity measures are well related to clinical functioning. DTI measures can be 
regarded as a potential biomarker for HD, due to their ability to objectify changes in 
brain structures and their role within brain networks.
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Introduction
Huntington’s disease (HD) is a neurodegenerative genetic disorder characterized 
by a progressive deterioration of motor control, cognitive functioning, and mood 
and behavioral functioning. The presence of an abnormal expansion of CAG 
repeats in the HTT gene, on chromosome four is responsible for the disease. 
The effect of the HD gene is seen in the brain as progressive cerebral atrophy of 
the basal ganglia and cortex1-4. It has been shown that the onset of atrophy may 
already be present in gene carriers up to 10 years prior to disease manifestation4;5. 
On the contrary, less is known about white matter changes in HD. Some reports 
demonstrate global atrophy of the white matter in manifest HD6;7, whereas others 
show regional differences only8;9. A global volume reduction of white matter was 
seen only in one study of premanifest gene carriers10. The specific impact of HD 
on specific white matter pathways, and the clinical relevance of these changes, 
remains unclear. 
The development and clinical application of magnetic resonance diffusion tensor 
imaging (DTI) has increased knowledge of grey and white matter structure in a 
variety of neurodegenerative diseases11. In patients with HD, a few studies have 
applied DTI to characterize changes in the macrostructure and microstructure 
of the basal ganglia. Lower fractional anisotropy (FA) values were found for 
premanifest gene carriers in the putamen, caudate nucleus12 and thalamus3. On 
the contrary, Rosas et al. (2006) found higher FA in the putamen and pallidum14. In 
healthy subjects, FA values of grey matter structures are generally below 0.15. In 
white matter, values tend to be much higher ranging from 0.2 up to 115. In general, 
the higher the FA value the more directional the organization of the tissue is 
regarded to be - as seen in white matter fiber tracts. For this reason FA is generally 
accepted as an indication of tissue integrity. 
In white matter, lower FA and increased apparent diffusion coefficient (ADC) 
values have been found in the internal capsule and corpus callosum in premanifest 
and manifest HD compared with healthy control subjects13;14. In several of 
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s Disease, ADC 
values have been found to higher, indicating that degeneration negatively affects 
the brain tissue structure16-18. Higher ADC values indicate that the microstructure of 
the tissue allows a faster movement of water molecules. These higher values were 
also found in manifest HD19-22. To find white matter differences that are related to 
the earliest changes in HD, specific white matter fiber tracts that are related to HD 
symptomatology should preferably be investigated. A reduction in cognitive, motor, 
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oculomotor performance is present up to a decade before clinical manifestation 
of HD5;23;24, therefore, it can be hypothesized that the fibers associated with these 
function may also be affected in the premanifest phase. The direct nature of this 
relationship is unknown, and therefore, the aim of the present study is, first, to 
investigate early FA and ADC changes in white matter fiber bundles running to 
and from brain areas known to be affected by HD (e.g. caudate nucleus) or those 
related to the clinical characteristics of HD (e.g sensorimotor cortex or prefrontal 
cortex). Second, to investigate to which extent changes in brain tissue structure 
and integrity in white matter fibers are related to clinical functioning.
Method
Participants 
As part of the Track-HD study 90 participants were included at the Leiden 
University Medical Centre study site (for details see Tabrizi et al., 20094). 
Diffusion tensor magnetic resonance imaging was added to the standard MRI 
protocol. DTI was not performed because of claustrophobia in 10 participants, 
and another nine were excluded from analysis due to movement artifacts. Of 
the remaining 71 subjects, 16 subjects had early HD, 27 were premanifest gene 
carriers and 28 were healthy control subjects. Inclusion criteria for premanifest 
HD gene carriers were a CAG repeat ≥ 40 with a total motor score on the Unified 
Huntington’s Disease Rating Scale 1999 (UHDRS) ≤ 5. Inclusion criteria for the 
early manifest HD patients were a CAG repeat ≥ 40, with a UHDRS motor score 
> 5 and a total functional capacity (TFC) score ≥ 7. Healthy gene negative family 
members or partners were recruited as control subjects. Because the early HD 
group is inherently older than the premanifest group, the control group was split 
into two separate groups of each 14 subjects to achieve age-matching. The 
younger healthy control subjects were age matched to the premanifest gene 
carriers (control group A). The older healthy controls subjects were age-matched 
to the manifest group (control group B). None of the participants suffered from a 
neurological disorder, a major psychiatric diagnosis, or had a history of severe 
head injury. The study was approved by the Medical Ethical Committee of the 
Leiden University Medical Centre. All participants gave informed consent. 
DTI acquisition
MRI acquisition was performed on a 3 Tesla whole body scanner (Philips Achieva, 
Healthcare, Best, the Netherlands) with an eight channel SENSE head coil. 
T1-weighted image volumes were acquired using a 3D MPRAGE acquisition 
sequence with the following imaging parameters: TR = 7.7 ms, TE = 3.5 ms, 
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FOV = 24 cm, matrix size 224x224, number of slices = 164, slice thickness = 
1.00 mm, slice gap = 0. A volumetric T2-weighted image (VISTA) was acquired 
with the same parameters for field of view, acquisition matrix, and slice thickness 
as the T1-weighted images, with TE = 250 ms and TR = 2500 ms. A single-shot 
echo-planar DTI sequence was applied with 32 measurement directions and the 
following scan parameters: TR = 10004 ms, TE = 56 ms, FOV = 220 x 220 x 128 
with an acquisition matrix of 112 x 110, 2.00 mm slice thickness, transversal slice 
orientation, slice gap = 0, flip angle = 90°, single reconstruction voxel dimensions 
were 1.96 x 1.96 x 2.00 mm, number of slices = 64, B factor = 1000, halfscan factor 
= 0.61. Parallel imaging (SENSE) was used with a reduction factor of 2, NSA = 1 
and fat suppression was applied. DTI acquisition time was 6.55 minutes.
Regions of interest segmentation
A priori, the caudate nuclei, thalami, and the corpus callosum were determined as 
regions of interest (ROI). A semiautomatic segmentation and analysis procedure 
was used as part of the software program FibreTrak (release 2.5.3, Philips 
Medical Systems, Best, the Netherlands). The caudate nucleus and thalamus 
were segmented separately on each side, but considered as one ROI during data 
analysis. On the DTI scans, special caution was taken to prevent inclusion of any 
non grey matter voxels, as both the caudate nucleus and thalamus are laterally 
bordered by the internal capsule. All analyses and segmentations were performed 




Fiber analysis of fibers running through the following five structures was performed: 
the corpus callosum (Figure 1A), sensorimotor cortex (Figure 1B), caudate 
nucleus (Figure 1C), superior prefrontal cortex (Figure 1D) and thalamus (Figure 
1E). To analyze fibers running through the corpus callosum, caudate nucleus and 
thalamus, the previously segmented ROIs were used. Additional segmentations 
for ROIs of the superior prefrontal cortex and sensorimotor cortex were performed. 
The superior prefrontal region was segmented on the basis of Brodmann areas 9 
and 10. The sensorimotor cortex on Brodmann areas 1, 2, 3 and 412. To calculate 
the average ADC and FA of the five white matter pathways FibreTrak was used 
(release 2.5.3, Philips Medical Systems, Best, The Netherlands). The software 
applies fiber assignment by continuous tracking25. The following standard 
parameters were implemented: minimum FA value 0.10, maximum angle change 
27º, minimum fiber length 10 mm. For more detailed information on the application 
of the fiber tracking software see the supplementary material.
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Clinical Assessments
From the extensive assessment battery in the TRACK-HD study, specific tasks 
were chosen that gave a representation of functioning in each symptom domain. 
Furthermore, these were tasks that had been proved to provide sensitive outcome 
measures for group comparisons, even in the premanifest stages4: index finger 
speeded tapping and sustained tongue force measures (motor), anti-saccade 
latency and error rate (oculomotor), symbol digit modalities test, the Stroop word 
reading test, trail making task part B, and a visual working memory task – the spot 
the change task (cognition); Beck’s depression inventory 2nd version (BDI-II) and 
the frontal systems behavior inventory which yields three subscores of disinhibition, 
executive functioning and apathy (psychiatry). CAG repeat length and probability 
of onset within 5 years and Burden of pathology ((CAG – 35.5) x age))26 were also 
added to the analysis. For the complete set of clinical assessments and variables 
see Tabrizi et al. (2009)4. 
Statistics
Statistical analyses were performed with the Statistical Package for Social 
Sciences (SPSS for Windows; version 17.0.2, SPSS inc, Chicago, IL). Distributions 
and assumptions were checked. Independent student’s t-tests and Chi-square 
tests were applied where appropriate in the analysis of group differences based 
on descriptive data; age, CAG, Dutch adult reading test (IQ), TFC and UHDRS. To 
test for differences in FA and ADC in the three ROIs and the five white matter fiber 
bundles between premanifest or manifest gene carriers and their corresponding 
control groups, analyses were performed using independent student’s t-tests. 
Correction for multiple comparisons was applied to each analysis. Each analysis 
of ADC in the basal ganglia ROIs, the FA in the basal ganglia ROIs, the FA of the 
fiber pathways, and the ADC of the fiber pathways was regarded as a separate 
analyses. Therefore a Bonferroni correction was applied to each analysis. For the 
ADC and FA ROI analysis this lead to 0.05/3 = 0.017, and for the ADC and FA fiber 
pathways analysis this lead this to 0.05/5 = 0.01. The number of voxels in each 
seed ROI was compared between groups. Partial Pearson correlations analysis 
was performed to explore and test for possible associations between measures 
of white matter fiber pathway integrity and clinical measures. Age and gender 
were added into this analysis as covariates. The number of voxels in a ROI were 
also correlated to the clinical variables in order to examine the possibility that 
grey matter volume explains any possible correlations. The ADC and FA values 
of the white matter fiber pathways were correlated to each other to examine other 
explanations for possible results.




No differences in age, gender, IQ, TFC, and UHDRS motor score between the 
premanifest gene carriers and their controls were present (Table I). The ADC and 
FA values of the ROIs and fiber pathways are shown in Table I. Premanifest gene 
carriers showed increased ADC values in the corpus callosum compared with 
controls. A significant increase in ADC of the white matter fibers of the sensorimotor 
cortex was also found between premanifest gene carriers and controls. No 
differences in ADC were found in the regions of the caudate nucleus and thalamus. 
No difference in FA was found in any of the three regions between the two groups. 
Also, no FA or ADC differences were found in any of the fiber pathways between 
the two groups. The number of voxels in the caudate nucleus ROI of premanifest 
group is significantly lower than the number in the control group ROI.
Early HD
The demographic data of the early HD and control group B showed no differences 
in age, gender or IQ. TFC and UHDRS differed significantly (Table II). In the corpus 
callosum and the caudate nucleus, the ADC values were larger in early HD when 
compared with controls. Between the two groups, no difference in FA was found in 
any of the ROIs. ADC values were significantly increased in fibers from all regions, 
except for the caudate nucleus fibers. FA was decreased in fibers running to and 
from the prefrontal cortex in early HD patients. No difference in FA was found 
in fibers passing through the corpus callosum, caudate nucleus, thalamus and 
sensorimotor cortex. The number of voxels of the caudate nucleus as well as in 
the corpus callosum was significantly lower in the patient group than in the control 
group (Table II). 
Clinical correlations
The correlation analysis between the ADC of the fiber bundles with genetics, 
probability of onset within five years, burden of pathology, motor, oculomotor, 
cognition and behavior in all participants are shown in Table III. 
Tapping was moderately associated with the diffusivity (ADC) of bundles through 
the corpus callosum, thalamus, sensorimotor cortex and prefrontal cortex. For the 
tongue force, similar but weaker associations were found. Latency of anti-saccades 
and the percentage of antisaccade errors in the oculomotor task were found to 
correlate with increased diffusivity of the corpus callosum, sensorimotor cortex 
and prefrontal cortex fibers. All cognitive measures were moderately to strongly 
associated with the ADC of fibers through the corpus callosum, sensorimotor cortex 
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and to a lesser extent the prefrontal cortex. In premanifest gene carriers, probability 
of expected onset within 5 years and burden of pathology showed a high positive 
correlation with the diffusivity of the corpus callosum fibers and with those of the 
sensorimotor cortex, whereby a loss of integrity related to a higher probability 
of onset within five years and higher burden of pathology. No association in any 
cognitive domain with fibers of the thalamus was found. CAG repeat length and 
behavioral measures did not show association with the ADC of any of the fiber 
bundles studied. No measures showed association with the fibers of the caudate 
nucleus. FA of the corpus callosum and sensorimotor cortex fibers negatively 
correlated with the latency (r = -0.52, p < 0.001) and percentage of errors 
(r = -.038, p= 0.001) in the anti-saccade oculomotor task. FA did not demonstrate 
any significant correlation with genetics, motor, cognition, and behavior.
The results from a correlational analysis between number of voxels in a seed 
region and clinical variables showed five significant moderate correlations. Only 
one of these also showed a significant correlation in the analysis of ADC values 
with clinical variables. This was the correlation between the caudate nucleus 
and TMT task performance (r = -0.36, p< 0.01). Directly correlating the ADC and 
FA values of the white matter pathways with each other revealed a number of 
significant correlations which is shown in table IV in the supplementary material. 
The direct correlation of ADC and FA of the same fiber bundle shows that the 
ADC and FA of the sensorimotor cortex and prefrontal white matter pathways are 
correlated. 
Figure 1. Typical 





in a premanifest 







cortex (E) and 
thalamus (F). 3D 
crosses depict 
orientation, 
whereby H = 
head, F = feet, A 
= anterior, P = 
posterior, R = 
right, L = left.
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Table 1. Group demographics, ADC and FA values, and number of seed 
voxels per region of interest for the premanifest gene carriers and their 
controls. 
Control group A 
n: 14, male: 7
Premanifest gene carriers
n: 27, male: 16
Mean (SD) range Mean (SD) range
Age (yrs) 46 (7,5) 35 - 58 43 (8,3) 26 - 61
CAG - (-) - 43 (2,5) 39 – 50
IQ 105,6 (11,3) 88 - 130 101,3 (11,3) 76 - 118
TFC 13 (0) 13 - 13 12,6 (0,8) 10 - 13
UHDRS 1,9 (1,8) 0 - 6 2,4 (1,4) 0 - 4
ADC ROI # voxels ± SD mean ± SD # voxels ± SD mean ± SD p
Corpus Callosum 1884 ± 378 0.78 ± 0.028 1767 ± 319 0.81 ± 0.033* 0.014
Caudate Nucleus 58 ± 13 0.73 ± 0.071 47 ± 11*** 0.76 ± 0.053 0.160
Thalamus 2700 ± 843 0.73 ±0.023 2601 ± 657 0.73 ± 0.023 0.994
FA ROI
Corpus Callosum 1884 ± 378 0.76 ± 0.019 1767 ± 319 0.75 ± 0.021 0.461
Caudate Nucleus 58 ± 13 0.17 ± 0.015 47 ± 11*** 0.18 ± 0.023 0.058
Thalamus 2700 ± 843 0.34 ± 0.025 2601 ± 657 0.33 ± 0.022 0.368
ADC Fiber pathway # voxels ± SD mean ± SD # voxels ± SD mean ± SD
Corpus Callosum 1884 ± 378 0.89 ± 0.049 1767 ± 319 0.91 ± 0.054 0.206
Caudate Nucleus 58 ± 13 0.98 ± 0.116 47 ± 11*** 0.94 ± 0.075 0.166
Thalamus 2700 ± 843 0.87 ± 0.055 2601 ± 657 0.89 ± 0.071 0.476
Motor cortex 595 ± 86 0.78 ± 0.017 580 ± 71 0.80 ± 0.029** 0.009
Prefrontal cortex 1136 ± 183 0.88 ± 0.044 1117 ± 322 0.89 ± 0.037 0.631
FA Fiber pathway
Corpus Callosum 1884 ± 378 0.49 ± 0.015 1767 ± 319 0.49 ± 0.016 0.785
Caudate Nucleus 58 ± 13 0.36 ± 0.017 47 ± 11*** 0.35 ± 0.031 0.683
Thalamus 2700 ± 843 0.42 ± 0.018 2601 ± 657 0.41 ± 0.021 0.515
Motor cortex 595 ± 86 0.40 ± 0.017 580 ± 71 0.39 ± 0.020 0.190
Prefrontal cortex 1136 ± 183 0.41 ± 0.018 1117 ± 322 0.40 ± 0.021 0.120
SD: standard deviation, CAG: CAG repeat length, IQ: estimate of premorbid intelligence quotient. 
TFC: Total Functional Capacity score.UHDRS: Unified Huntington’s Disease Rating Scale total motor 
score. ROI: Region of interest analysis. ADC: Apparent Diffusion Coefficient in μm2/ms, FA: Fractional 
Anisotropy (no unit), Fiber pathway: fiber pathways analysis between the listed region and the rest of 
the brain. *p <0.017, **p<0.01 (adjusted for multiple comparisons). # voxels: mean number of voxels in 
the listed seed region. ***Number of voxels differs significantly from healthy controls
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Table 2. Group demographics, ADC and FA values, and number of seed 
voxels per region of interest for the early HD patients and their controls.
Control group B
n: 14, male: 7
Early HD
n: 16, male: 12
Mean (SD) range Mean (SD) range
Age (yrs) 51.4 (7.9) 42 - 65 48.2 (10) 31 - 63
CAG - (-) - 43 (1.6) 41 - 46
IQ 102.6 (6.6) 88 - 115 99.6 (12) 72 - 118
TFC 12.9 (0.3) 12 - 13 10.6§ (2) 7 - 13
UHDRS 3.1 (2.8) 0 - 7 18.3§ (10.4) 6 - 45
ADC ROI # voxels ± SD mean ± SD # voxels ± SD mean ± SD p
Corpus Callosum 1934 ± 312 0.80 ± 0.031 1445 ± 371*** 0.85 ± 0.040* 0.000
Caudate Nucleus 57 ± 12 0.74 ± 0.048 40 ± 7*** 0.83 ± 0.069* 0.001
Thalamus 2480 ± 531 0.74 ± 0.032 3102 ± 1062 0.74  ± 0.034 0.863 
FA ROI
Corpus Callosum 1934 ± 312 0.75 ± 0.012 1445 ± 371*** 0.73 ± 0.033 0.046 
Caudate Nucleus 57 ± 12 0.17 ± 0.018 40 ± 7*** 0.19 ± 0.019 0.072
Thalamus 2480 ± 531 0.33 ± 0.021 3102 ± 1062 0.32 ± 0.034 0.95
ADC Fiber pathway # voxels ± SD mean ± SD # voxels ± SD mean ± SD
Corpus Callosum 1934 ± 312 0.89 ± 0.051 1445 ± 371*** 0.95 ± 0.067** 0.008
Caudate Nucleus 57 ± 12 0.88 ± 0.107 40 ± 7***  0.97 ± 0.079 0.023
Thalamus 2480 ± 531 0.85 ± 0.080 3102 ± 1062 0.93 ± 0.063** 0.007
Motor cortex 589 ± 117 0.79 ± 0.023 593 ± 110 0.82 ± 0.027** 0.001
Prefrontal cortex 1118 ± 239 0.88 ± 0.023 1202 ± 274 0.95 ± 0.056** 0.000
FA Fiber pathway
Corpus Callosum 1934 ± 312 0.48 ± 0.013 1445 ± 371*** 0.47 ± 0.017 0.027 
Caudate Nucleus 57 ± 12 0.35 ± 0.027 40 ± 7*** 0.35 ± 0.021 0.592
Thalamus 2480 ± 531 0.41 ± 0.016 3102 ± 1062 0.41 ± 0.024 0.644
Motor cortex 589 ± 117 0.38 ± 0.019 593 ± 110 0.37 ± 0.024 0.059
Prefrontal cortex 1118 ± 239 0.39 ± 0.016 1202 ± 274  0.38 ± 0.014** 0.006
SD: standard deviation, CAG: CAG repeat length, IQ: estimate of premorbid intelligence quotient. TFC: 
Total Functional Capacity score. UHDRS: Unified Huntington’s Disease Rating Scale total motor score. 
§Significant difference from control group, p< 0.01. ROI: Region of interest analysis. ADC: Apparent 
Diffusion Coefficient in μm2/ms, FA: Fractional Anisotropy (no unit), Fiber pathway: fiber pathways 
analysis between the listed region and the rest of the brain. *p <0.017, **p<0.01 (adjusted for multiple 
comparisons). # voxels: mean number of voxels in the listed seed region. ***Number of voxels differs 
significantly from healthy controls.
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Discussion
The main finding of this study is that in premanifest gene carriers, the white matter 
pathway of the sensorimotor cortex is impaired. Furthermore, our data show that 
in the early manifest phase of the disease impairment is more widespread and 
present in the white matter pathways of the sensorimotor cortex, corpus callosum, 
thalamus, and prefrontal cortex. Finally, a relationship is seen between the changes 
in white matter pathways and functionality in the domains of motor, oculomotor 
and cognition. Moreover this study confirms findings of regional differences in the 
corpus callosum of premanifest and the caudate nuclei and corpus callosum of 
early HD14;27.
In the premanifest phase of the disease, our study demonstrated a reduction of 
integrity of only the sensorimotor cortex fibers pathway, therefore this suggests 
that this pathway may be one of the first to be affected by HD. This is supported 
by the positive relationship between a higher probability of onset within 5 years, 
and a higher burden of pathology, with the loss of integrity of the sensorimotor 
cortex fibers. This premanifest cohort is ‘free’ of motor symptoms, and therefore 
these findings in a truly ‘premotor’ premanifest group further support the idea that 
these white matter changes are among the first to occur. This study is the first 
to demonstrate this change across the whole pathway; however, other studies 
examining this area do provide support for this finding. The findings of the voxel–
by–voxel white matter analysis of Reading et al. (2005)12 found differences in a 
cluster of voxels coinciding with the primary motor cortex (Brodmann area 4). 
Atrophy of the sensorimotor cortex was demonstrated as the only cortical region 
to be affected in premanifest gene carriers far from predicted onset4. Furthermore 
differences have been reported in functions that utilize this area in premanifest 
gene carriers, such as measures of motor function5;28. The other important 
finding of our study in premanifest gene carriers is the differences in diffusivity 
in the corpus callosum, thereby replicating previous findings by Rosas et al. 
(2006,2009)14;27. However we add that these differences are not seen in the white 
matter projections specifically going to and from the corpus callosum. Therefore, 
when looking beyond the main structure it can be suggested that the loss of 
integrity of the main structure is apparent, but not spread over its entire network, as 
is the case in manifest HD. 
In the early manifest phase of HD, our data show that the diffusivity of the fiber 
pathways of the thalamus, corpus callosum, sensorimotor, and prefrontal cortex 
was higher in HD than in healthy controls. This suggests a disintegration of these 
structures. Of the five white matter pathways examined in HD all were found to be 
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affected except the pathways of the caudate nuclei. The absence of affected white 
matter from the caudate nucleus should be interpreted with some caution. It may 
suggest that the magnitude of integrity loss may not be the same for a structure 
as for its fibers at a given stage of the disease. However the variance of these 
measurements is larger than that of the other fibers pathways. The remaining 
results, such as that of reduced integrity of the prefrontal cortex fibers, find support 
in the regional differences demonstrated by Rosas et al. (2006)14. Our results show 
changes in ADC and almost no changes in FA. This suggests that of these two 
closely related measures, ADC is more sensitive in demonstrating changes across 
large pathways in HD. The results of the regional analysis showed higher diffusivity 
in the caudate nucleus and corpus callosum in HD than in healthy controls. This 
was not the case in the thalamus, whereby similar diffusion properties were seen 
in both HD and controls. Our findings concur with previous cross-sectional and 
longitudinal findings of a widespread effect of HD on white matter14;20;22;29. The 
finding that a region was not affected, but its fibers were, demonstrates the need 
to embrace the full potential of DTI measures for HD, as this shows that despite 
a structure not showing integrity differences, the fibers that are needed for this 
structure to communicate with the brain may well be affected. In the case of the 
thalamus this is especially relevant to the clinical expression of the disease as this 
structure is vital to a large number of functional processes. 
The previously discussed outcomes demonstrate that almost all fiber pathways 
that we examined are affected in early manifest HD and that one specific pathway 
is also affected in premanifest gene carriers. In exploring the clinical implications 
of these findings we see strong relationships between both motor, oculomotor 
and cognitive measures, and diffusivity measures of the pathways of the corpus 
callosum, thalamus, sensorimotor and prefrontal cortex. Although one cognitive 
measure does correlate to the prefrontal cortex fiber the cognitive measures 
are most strongly related to the sensorimotor cortex fibers. This finding can be 
explained with two complementary hypotheses. First, as seen in the premanifest 
group, the fibers of the sensorimotor cortex are the first to show decreased 
integrity. This suggests that these are the most severely affected fibers in the 
earliest (premanifest) stages of HD; therefore, it is not surprising that the clinical 
measures of decline relate to these fibers. Second, HD effects both cognition and 
motor function, and all cognitive tests require a motor response. A consequent 
finding in cognitive HD literature is that cognitive tests sensitive to psychomotor 
speed are the most sensitive tasks. A great deal of voluntary motor functioning is 
initiated in the sensorimotor cortex. Because of this we were not entirely surprised 
that cognitive tests relate strongly to the fibers of the sensorimotor cortex. The 
tasks chosen for analysis were those that provide meaningful outcomes for all 
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study groups, and did not show ceiling or floor effects. Therefore, we can conclude 
that fibers associated with higher order cognitive and motor coordination are 
affected in a manner that is congruent to clinical manifestations and that for 
this reason, DTI measures can be applied to characterize the structure-function 
relationship of white matter. This conclusion is supported in other studies of white 
and grey matter and clinical measures6,30. In another study of eye movements and 
fiber tracking, similar results were found as ours, especially finding a relationship 
between eye movements and fiber FA31. We did not show a relationship between 
CAG repeat length or behavioral processes and changes in white matter integrity. 
The CAG repeat length is not dependent on disease progression or white matter 
pathways and this stable quality may, in part, explain this finding. A possible 
explanation for the absence of a relationship between behavioral measures and 
diffusivity may be the complex pathophysiological and psychological process 
underlying these behavioral changes that may not be primarily dependent on white 
matter. Alternatively, the use of medication may be a factor in the level of symptoms 
reported (full details of medication use are outlined in Tabrizi et al. (2009)4 leading 
to an underestimation of neuropsychiatric problem behavior. However, a recent 
study has shown that behavioral changes in premanifest HD remain stable32, 
thereby reinforcing the idea that degenerative processes are not at the root of 
these neuropsychiatric differences. Therefore we conclude that behavioral changes 
may not be directly reflected by white matter changes. 
This study examined and demonstrated differences in white matter pathways of 
five HD relevant regions, this restriction is a limitation of the study. Differences 
were found in the number of seed voxels in the caudate nucleus in premanifest 
gene carriers and in the caudate nucleus and corpus callosum in manifest HD. On 
the contrary, differences were not seen in the number of voxels in the thalamus, 
sensorimotor region, or prefrontal regions in the patient group. These reductions 
do seem to reflect expected atrophy, but do not follow the pattern of differences 
found in ADC. Therefore these differences do not seem to explain the differences 
in diffusivity. The results from a correlation analysis between number of voxels 
in a seed region and clinical variables reveal only five significant moderate 
correlations. This is in contrast to the analysis of relationship between average 
ADC and the clinical variables whereby 25 moderate to high correlations were 
significant. Furthermore only one of these five was the same as one of the 25 
clinical correlations. These results suggest the volume of the seed region does not 
explain the observed original correlations. With this possibility excluded, it can be 
stated with more certainty that the relationships observed reflect the underlying 
changes in structure of the white matter pathways. Furthermore, direct correlation 
of the ADC and FA of the white matter pathways also supports this conclusion. 
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It can be seen that only significant relationships between the ADC and FA of the 
same pathways were apparent for pathways that showed (nearly) significant 
group differences. Overall, the results call for further examination of white matter 
pathways. The findings warrant confirmation with longitudinal follow-up.
In conclusion, we demonstrated that the sensorimotor cortex fibers are affected 
already in the premanifest phase of HD and therefore may be a good target for 
following progression of the disease. Our data show that impairment is seen in 
corpus callosum, nuclei and fiber projections of HD relevant brain regions in both 
premanifest and early manifest HD. These impairments relate to proven correlates 
of clinical dysfunction. Overall, the findings of this study confirm the feasibility 
and use of DTI measures in HD research, whereby we show that ADC is a good 
measure in characterizing the impaired function-structure relationship present in 
HD.
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Based on the anatomical co-registration images, the ROIs were segmented in 
native space for each individual. This was done by two experienced radiographers, 
blinded to patient group. Two types of ROIs were defined. Basal ganglia ROIs 
for analysis, and seed-ROIs as starting point for fiber tracking. The basal ganglia 
ROIs were segmented as follows. For the caudate nucleus all voxels clearly 
bounded by the lateral ventricle and the anterior limb of the internal capsule were 
selected. The putamen segmentation included all voxels within the structure 
bounded on the medial side by the globus pallidus and the anterior limb of the 
internal capsule, and on the lateral side by the capsula extrema. The thalamus 
segmentation was performed by allocating all voxels to the ROI that medially 
bordered the third ventricle, were superiorly bordered by the lateral ventricle, and 
were laterally bordered by the internal capsule. The seed ROIs were cortically 
based, and because these areas were not as clearly anatomically bounded as the 
other structures, Brodmann areas were used to define the segmentation. Reading 
et al. (2005) defined areas of the cortex in their analysis of presymptomatic HD by 
means of these Brodmann areas1. The superior prefrontal region was segmented 
on areas 9 (frontal portion) and 10. Brodmann area 10 is medially bound by 
the superior rostral suclus, and dorsally by the inferior frontal suclus and the 
frontomarginal sulcus. Area 9 bordered inferiorally by area 10 and dorsally by the 
superior frontal sulcus. After all ROIs were drawn, the radiographers switched 
scans and carefully checked the segmentations for potential miss-segmentation. 
After all scans had been segmented a random 20% were selected for verification 
by a neurologist specialized in neuro-imaging. Any segmentation voxels that were 
felt to be outside of the targeted anatomy were discussed until a consensus was 
formed and these few voxels were changed accordingly.
Analysis
We applied the software supplied by the manufacture by transferring the raw DTI 
data and the anatomic co-registration images to an off-line manufacturer provided 
console. In doing so the data were loaded into the Philips Research Image-
processing Development Environment (PRIDE) (Philips Medical Systems). Then 
the diffusion tensor and derived measures, including ADC and FA, were calculated 
using the Philips PRIDE Fiber Tracking tool (version 2.5.3). This allows fiber 
tracking based on the Fiber Assignment by Continuous Tracking (FACT) algorithm2. 
The algorithm values for restricting fiber tracking were kept at default 
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Supplementary Results
Table 4. Cross tabulation of correlation coefficients of the FA and ADC of the 









ADC FA ADC FA ADC FA ADC FA ADC FA
Corpus 
Callosum
ADC - -.123 .482 -.262 .705 .069 .644 -.312 .572 -.432
FA - .002 .136 -.065 .472 -.439 .581 -.272 .516
Caudate 
Nucleus
ADC - .028 .594 .153 .185 .091 .206 -.077
FA - -.116 .404 -.052 .190 -.352 .046
Thalamus
ADC - .034 .476 -.145 .353 -.183
FA - -.021 .290 -.050 .126
Motor 
cortex
ADC - -.604 .548 -.530





ADC: Apparent Diffusion Coefficient, FA: Fractional Anisotropy. Bold = significant correlation
and were: minimum FA value of 0.10, maximum angle change: 27°, and a 
minimum fiber length of 10mm. This same method and software has been applied 
in a number of disorders of both brain and muscle, such as developmental 
CNS anomalies3, corticospinal tract stroke4, lateral patellar dislocation5 and 
Lissencephaly6.
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Huntington’s Disease (HD) is a genetic disorder affecting the brain. Atrophy of deep 
grey matter structures has been reported and it is likely that underlying pathologic 
processes occur before or in concurrence with volumetric changes. Measurement 
of metabolite concentrations in these brain structures has the potential to provide 
insight into pathological processes. We aim to gain understanding of metabolite 
changes with respect to the disease stage and pathophysiological changes. 
Methods
We studied five brain regions using magnetic resonance spectroscopy (MRS) 
using a 7-Tesla MRI scanner. Localized proton spectra were acquired to obtain five 
metabolite concentrations. MRS was performed in the caudate nucleus, putamen, 
thalamus, hypothalamus and frontal lobe in 44 control subjects, premanifest gene 
carriers and manifest HD.
Results
In the caudate nucleus HD patients display lower NAA (p=0.009) and lower 
creatine concentration (p=0.001) as compared to controls. In the putamen, 
manifest HD patients show lower NAA (p=0.024), lower creatine concentration 
(p=0.027) and lower glutamate (p=0.013). Although absolute values of NAA, 
creatine and glutamate were lower, no significant differences to controls were 
found in the premanifest gene carriers. 
Conclusion
The lower concentrations of NAA and creatine in the caudate nucleus and putamen 
of early manifest HD suggest deficits in neuronal integrity and energy metabolism. 
The changes in glutamate could support the excitotoxicity theory. These findings 
not only give insight in neuropathological changes in HD, but also indicate that 
MRS can possibly be applied in future clinical trials to evaluate medication targeted 
at specific metabolic processes.
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Introduction
Huntington’s Disease (HD) is a neurodegenerative autosomal dominant disorder. 
The causative gene mutation is located on the short arm of chromosome 4 and 
consists of an expanded Cytosine-Adenine-Guanine (CAG)-repeat within the Htt-
gene. This expansion results in the synthesis of an abnormal huntingtin protein 
that causes neuronal damage, brain atrophy, ultimately leading to functional 
disturbances of motor, cognition and behavior. 
HD research has revealed widespread changes throughout the brain1. Controversy 
remains as to which structures are affected at different disease stages. Atrophy 
of the striatum is regarded as the hallmark of the pathologic findings in HD2. 
MRI studies demonstrate that the caudate nucleus and putamen begin to show 
atrophy up to a decade before clinical manifestations occur3. Structures such as 
the thalamus, hypothalamus, the frontal lobe, white matter and cortical grey matter 
have all been implicated to some degree at this pre-manifest stage, although 
findings differ1;4-6. 
The pathophysiological mechanism leading to neuronal damage remains unclear. 
Currently the two most accepted hypotheses describe impaired energy metabolism 
and the excitotoxicity of neurons7;8. Both hypotheses can potentially be explored 
by means of non-invasive in vivo measurements of metabolites such as creatine 
and glutamate, using localized magnetic resonance spectroscopy (MRS). However, 
previous studies measuring the changes in the metabolite levels related to the 
damaging processes in HD have reported conflicting results. In one study a lower 
level of N-acetylaspartate (NAA) was confirmed post-mortem in the putamen 
and cortex in manifest HD9. In vivo altered levels of NAA, creatine, choline and 
glutamate have been reported in both premanifest and manifest HD in several 
brain structures, such as the striatum and thalamus using MRS10-16. However, 
in contrast, other studies using localized MRS did not detect changes in these 
metabolite levels in either manifest or premanifest HD17-19.
One of the factors that might explain discrepancies between previous studies is the 
relatively poor spatial and/or spectral resolution of localized spectra. Improvement 
in MRS methodology in terms of spectral resolution in combination with small voxel 
size and total scanning time can be achieved using a high field MRI scanner20;21. 
This allows metabolite quantification in small, well defined anatomical structures, 
such as the caudate nucleus and putamen. 
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The major aims of the present study were to assess metabolite differences 
between manifest HD patients or premanifest HD gene carriers and controls, 
and to assess the association between these metabolite differences and clinical 
measures of disease severity in order to obtain a greater understanding of 
the pathophysiological changes in HD with respect to the disease stage. The 
hypotheses were as follows; as the neuronal integrity and the energy metabolism 
would be compromised, we expected the NAA and creatine to be lower in 
premanifest and manifest HD, especially in the striatum. Possible changes in 
glutamate could be expected based on the excitotoxicity theory, with higher levels 
in both premanifest and manifest HD. 
Materials and Methods
Subjects 
Participants were recruited from the outpatient neurology clinic of the Leiden 
University Medical Center. Inclusion criteria for the early manifest HD consisted 
of genetic confirmation with a CAG repeat ≥ 39, and the presence of motor 
disturbances as measured by the Unified Huntington’s Disease Rating Scale 
’99 (UHDRS) defined as a total motor score (TMS) > 5 and a Total Functional 
Capacity (TFC) ≥ 7. All participants received a diagnostic confidence rating of 
4, representing “motor abnormalities that are unequivocal signs of HD (>99% 
confidence)”. Inclusion criteria for the premanifest HD participants consisted 
of genetic confirmation with a CAG repeat ≥ 39, and the absence of motor 
disturbances on the UHDRS defined as a TMS ≤ 5. Healthy gene negative family 
members or partner/spouses were recruited as control subjects in an effort to 
reduce influences of environmental factors. Exclusion criteria for all participants 
consisted of significant (neurological) comorbidity, a major psychiatric diagnosis, 
history of severe head injury or incompatibility for MRI. In total 44 subjects 
were recruited to undergo MRS in one or more regions of interest (ROI). Time 
constraints and HD related issues (such as patient motion) accounted for not all 
participants completing the MRS protocol in all five of the ROI’s. The study was 
approved by the local Medical Ethical Committee of the Leiden University Medical 
Center. All participants provided written informed consent.
Clinical measures
Clinical evaluation for all subjects consisted of the UHDRS motor scale (score 
0-124) and TFC, a global scale of impairment in daily life activities, score 0 -13. 
Furthermore, a short cognitive battery was administered, consisting of the Mini 
Mental State Exam (MMSE), Stroop test word reading card (Stoop-II), the Symbol 
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Digit Modality Test (SDMT), Trail making Test part B (TMT-B), the Wechsler 
Memory Scale (MQ) and premorbid IQ estimation using the Dutch Adult Reading 
Test (DART)22. Behavioural disturbances were evaluated with the Beck Depression 
Inventory 2nd version (BDI-II)23 and the Problem Behaviour Assessment short 
version (PBA-s). Predicted years to onset were calculated from current age and 
CAG repeat length using the formula by Langbehn et al.(2004)24.
MRI/MRS acquisition: 
MRI and MRS were performed on a Philips 7-Tesla Achieva whole body scanner 
(Philips Healthcare, Best, The Netherlands) with a NOVA Medical quadrature 
transmit coil and 16 channel receive coil array. For accurate planning, a high 
resolution, three-dimensional T1-weighted GRE scan was acquired (TR/TE = 
11/5.4 ms, voxel size 0.44 x 0.44 x 0.84 mm, total scan time 1:46). Localized 
proton spectra were acquired using a stimulated echo acquisition mode (STEAM) 
sequence. The voxel was placed within the region of interest with the maximum 
volume containing only tissue from the intended structure, minimizing the 
contribution from surrounding tissue, and also partial volume effects. Regions of 
interest consisted of the caudate nucleus, putamen, thalamus, hypothalamus and 
the prefrontal white and cortical grey matter. For the prefrontal voxel, positioning 
included approximately 50% white and 50% cortical grey matter. Only for the 
hypothalamus voxel was some cerebral spinal fluid (CSF) necessarily present 
since the voxel was placed bilaterally. For each voxel in each ROI a water 
reference signal was acquired for adequate quantification. The following scan 
parameters were used for the STEAM spectra: TR/TE/TM = 2000/19/25 ms, BW 4 
kHz, 2048 complex data points and 128 signal averages, giving a data acquisition 
time of approximately 5 minutes per spectrum. The chemical shift artifact was 
minimal (<1 mm), which is shown in figure 1. Water suppression was performed 
using a frequency-selective RF pulse and gradient spoiling, six saturation bands 
were additionally applied to suppress signal from surrounding tissue. All scans 
included a reference scan without water suppression for quantification. When an 
MRS scan failed (for example due to motion) it was standard protocol to try the 
same ROI again: however, this did, in some cases, result in insufficient time for 
the full protocol to be completed since the time for each patient in the magnet was 
strictly limited to one hour.
MRS post-processing
MRS data were analyzed with LCModel25;26, using the unsuppressed water 
as an internal reference to calculate the concentrations of metabolites. 
Concentrations of choline, creatine, glutamine+glutamate (Glx), total NAA 
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(N-acetylaspartateglutamate + NAA), myo-inositol and lactate were calculated for 
analysis. 
Figure 1. Example of chemical shifts at 7-Tesla using STEAM provided for an actual planning. Red box 
= NAA, white box = metabolite as stated below each figure. Only a minimal chemical shift exists. The 
chemical shift of water is almost zero, as the separate water file is planned according to the NAA-voxel. 
NAA= N-acetylaspartate
Stringent quality control was enforced to exclude data with high estimated errors. 
A signal to noise ratio of ≤ 3 and very high values of residual errors in the LCmodel 
fitting were applied as initial spectral exclusion criteria. Furthermore, the LCModel 
fit for metabolites were required to have a Cramér-Rao Lower Bound (CRLB) 
of 20% or less. This was required for all metabolites within a single spectrum, 
with the exception of lactate. For lactate CRLB above 100% were excluded from 
further analysis. If lactate was not quantified with CRLB <100% in at least 50% of 
analyzed spectra, the analysis of lactate was deemed not detectable; this method 
was first presented by Tkac et al.(2009)20. In total 30 spectra were included in the 
analysis for the hypothalamus , 36 of the thalamus, 28 of the caudate nucleus, 27 
of the putamen and 32 subjects of the prefrontal region.
Statistics
Statistical analyses were performed using SPSS for Windows (SPSS version 
17.0, SPSS inc, Chicago, IL). All clinical variables were assessed between groups 
with a one-way analysis of variance (ANOVA), with post-hoc testing. To compare 
all metabolites in the five brain regions between the manifest and premanifest 
HD group versus the control group, an ANOVA with planned comparisons was 
performed. The nature of this study is exploratory, and therefore in order to 
prevent inflation of type II errors and avoid important results going unreported, no 
correction for multiple testing was performed, as is accepted practice in such types 
simon_manuscript_0108.indd   134 1-8-2012   13:27:11
|1357T Magnetic Resonance Spectroscopy
of study27. To examine the relationship between metabolic concentrations and 
clinical measures in gene carriers (manifest and premanifest HD), partial Pearson 
correlation analysis corrected for age was performed.
Results
Demographics
No differences in age, education level or IQ were present between the manifest HD 
and control group, or between the premanifest HD and control group. No significant 
difference exists in CAG repeat length between the premanifest and the manifest 
HD group. For all other clinical assessments variables we refer to the results in 
table 1.
Voxel planning
Typical examples of localized proton spectra for the five examined regions, along 
with metabolite identification, are shown in figure 2. The voxel location is shown on 
the left side, for clarity the voxel is only shown in one orientation. Actual planning 
of the voxel required oblique planning in all three dimensions. Figure 3 provides a 
typical example spectrum and fit from the LCmodel.
Voxel sizes were individually set, based upon the different sizes of structures 
in different individuals, although the voxel size was never below 1.0 ml. With 
these sizes it was possible in all cases to include only the intended (grey matter) 
structure, without contamination of other (white matter) structures, the exception 
being the prefrontal region. The voxel size ranged from 1.0 ml in the caudate 
nucleus for a manifest HD participant to a maximum of 3.4 ml for the putamen of a 
participant in the control group. 
Metabolite analysis
The concentrations of the six metabolites (NAA, creatine, choline, glutamate, 
lactate and myo-inositol) in the five brain regions are shown in table 2 for the three 
groups. In the caudate nucleus the manifest HD group demonstrated significantly 
lower NAA (F = 8.12, p= 0.009) and lower creatine concentration (F = 13.60, p= 
0.001) compared to control subjects. In the putamen, manifest HD showed
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Table 1: Demographic variables and scores on clinical assessments for the 
three groups.
Control
n: 18 (♂:9 ♀:9)
Premanifest
n: 14 (♂:6 ♀:8)
Manifest
n:12 (♂:5 ♀:7)
 Mean SD Mean SD Mean SD
Age 47.7 7.4 42.9 11.0 48.6 7.0
Years of education 15.9 3.2 14.3 3.3 15.3 2.7
IQ 106.7 7.8 102.2 12.5 102.3 9.5
CAG 20.3 c 2.9 43.1 3.4 43.7 2.3
Disease burden n.a. n.a. 306.4 87.0 385.4 e 72.5
Predicted YTO n.a. n.a. 10.4 8.2 n.a. n.a.
UHDRS TMS 2.0 2.4 2.6 1.3 20.9 a 14.1
UHDRS TFC 12.9 0.2 12.6 0.6 11.3 a 1.9
PBA-s 5.9 1.4 5.0 1.3 13.2 a 3.8
BDI-II 3.9 4.6 5.2 5.5 6.4 6.1
MMSE 29.5 0.7 28.5 1.7 28.3 b 1.6
SDMT 59.2 8.9 48.5 10.8 37.3 d 6.7
TMT-B 46.7 15.1 67.8 27.8 101.4 a 51.2
Stroop II 104.0 15.4 95.1 19.4 79.3 b 19.9
MQ 127.3 11.5 115.5 23.2 99.7 b 13.2
SD = Standard Deviation. CAG = CAG repeat length of larger allele. Predicted YTO = predicted years to 
onset. UHDRS TMS = Unified Huntington’s Disease Rating Scale Total Motor Score, PBA-s = Problem 
Behaviour Assessment short version, TFC = Total Functional Capacity, BDI-II = Beck Depression 
Inventory 2nd version, MMSE = Mini Mental State Exam, TMT = Trail Making Test part B, SDMT = 
Symbol Digit Modality Test, MQ = Memory Quotient, Stroop II = Stroop word reading card, n.a.=not 
applicable. a = significant differences between early HD compared to both premanifest and controls. b 
= significant differences between early HD and controls. c=significant differences between control and 
both premanifest and manifest HD. d=significant differences between all three groups. e=significant 
difference between premanifest and manifest HD
significantly lower NAA (F = 5.81, p= 0.024), lower creatine concentration (F = 5.58, 
p= 0.027) and glutamate/glutamine (F = 7.21, p= 0.013) compared to controls. 
No significant differences were found in the hypothalamus, thalamus or prefrontal 
region. Comparison of the premanifest gene carrier group and the control group did 
not show any significant differences in any of the regions. However, the absolute 
values of NAA, creatine and glutamate were lower in the caudate nucleus and 
putamen in the premanifest gene carrier group, but did not reach significance.
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Table 2: Metabolite concentrations from five brain regions in HD
Control Premanifest Manifest
N Mean SD N Mean SD N Mean SD
Hypothalamus 11 10 9
Creatine 10.7 2.1 9.4 2.0 9.3 1.7
Choline 3.7 0.7 3.4 0.6 3.3 0.8
NAA 12.1 1.9 11.9 1.5 11.3 2.1
Glx 12.5 3.0 12.0 4.0 11.0 4.8
Myo-inositol 13.4 4.8 12.7 3.1 13.3 2.8
Lactate 1.5 1.0 1.1 1.1 1.0 1.4
Thalamus 14 13 9
Creatine 12.7 3.5 12.8 3.6 12.1 1.6
Choline 3.1 0.8 3.0 0.7 3.1 0.4
NAA 17.8 6.0 15.8 2.6 15.9 1.6
Glu/Gln 14.8 5.1 15.1 3.4 12.8 3.4
Myo-inositol 8.5 4.1 7.3 2.6 9.5 4.4
Lactate 1.1 1.0 0.5 0.7 1.8 0.9
Caudate nucleus 12 11 5
Creatine 12.5 1.7 11.7 2.2 8.9* 1.2
Choline 3.1 0.7 2.8 0.5 2.6 0.6
NAA 12.1 2.3 10.8 2.0 9.0** 1.1
Glx 15.4 5.2 13.3 5.7 10.8 1.6
Myo-inositol 6.2 1.4 7.1 2.0 7.9 2.0
Lactate 1.2 0.9 1.5 0.9 0.5 0.8
Putamen 13 9 5
Creatine 13.6 2.3 12.1 2.2 10.9* 0.9
Choline 3.4 0.8 3.1 0.5 3.0 0.4
NAA 14.8 1.6 14.4 1.7 12.8* 0.9
Glx 16.3 3.4 14.2 3.4 11.4* 3.8
Myo-inositol 7.3 2.1 6.5 3.1 10.5 4.0
Lactate 0.8 0.6 1.0 1.3 0.3 0.4
Prefrontal 13 9 10
Creatine 9.1 2.4 9.2 1.6 9.9 2.1
Choline 2.3 0.5 2.4 0.4 2.3 0.5
NAA 11.7 2.4 11.6 1.5 11.9 3.0
Glx 11.3 2.8 9.8 2.2 13.3 4.0
Myo-inositol 9.5 2.4 8.8 1.9 11.9 4.9
Lactate 1.2 1.1 1.5 1.5 0.8 0.9
Concentrations of metabolites in the three groups. Since the water concentration and the T1 and T2 
relaxation times of the individual metabolites in the specific voxels of interest are unknown at the field 
strength of 7 Tesla, data are expressed as relative values to the water peak in arbitrary units (AU). NAA 
= N-acetylaspartate, Glx = glutamate + glutamine, *p<0,05, ** p<0.005
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Relationship to clinical measures 
The association of metabolite levels with clinical measures is shown in table 3. 
TFC was associated with creatine levels in caudate nucleus and putamen and with 
NAA in the putamen, showing decreased metabolite levels corresponding to poorer 
clinical scores. The NAA concentration in the putamen was associated with higher 
scores on the UHDRS TMS, indicating lower NAA to correspond to more motor 
disturbances. Lower glutamate/glutamine related to poorer scores on the cognitive 
tests SDMT and TMT. Finally, a higher PBA score, indicating more behavioural 
disturbances, corresponded to lower creatine in the caudate nucleus.
Table 3: Relationship of the clinical measures with metabolite concentration 
in the caudate nucleus and putamen
Caudate nucleus Putamen
Creatine NAA Creatine NAA Glx
Disease burden
R -0,266 -0,473 0.168 0.284 -0.400
p 0.339 0.075 0.584 0.347 0.157
UHDRS TMS
R -0.280 -0.228 -0.324 -0.415 -0.255
p 0.157 0.253 0.106 0.035* 0.200
PBA-s
R -0.545 -0.207 -0.063 0.064 0.052
p 0.003* 0.300 0.758 0.754 0.797
TFC
R 0.409 0.106 0.440 0.556 0.095
p 0.034* 0.598 0.025* 0.003* 0.636
BDI-II
R -0.256 -0.022 0.005 0.206 0.152
p 0.197 0.914 0.983 0.323 0.457
MMSE
R -0.196 -0.106 -0.070 -0.108 -0.223
p 0.328 0.598 0.735 0.601 0.265
TMT-B
R 0.310 0.270 0.185 0.049 0.438
p 0.115 0.173 0.366 0.813 0.022*
SDMT
R 0.171 0.133 0.239 0.125 0.555
p 0.404 0.518 0.250 0.552 0.003*
MQ
R 0.151 0.078 -0.049 -0.013 0.326
p 0.451 0.700 0.811 0.951 0.097
Stroop II
R -0.196 -0.106 -0.070 -0.108 -0.223
p 0.328 0.598 0.735 0.601 0.265
Correlation analysis of metabolite concentration with clinical measures. UHDRS TMS = Unified 
Huntington’s Disease Rating Scale Total Motor Score, PBA-s = Problem Behaviour Assessment short 
version, TFC = Total Functional Capacity, BDI-II = Beck Depression Inventory 2nd version, MMSE = Mini 
Mental State Exam, TMT = Trail Making Test part B, SDMT = Symbol Digit Modality Test, MQ = Memory 
Quotient, Stroop II = Stroop word reading card, R = partial r correlation coefficient.*p<0.05
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Figure 2: Localized proton MR spectra from different regions of the brain On the left side the voxel is 
displayed in the transverse direction, a typical spectrum of that structure is shown on the right side 
for the three groups. Five different regions are displayed: hypothalamus, thalamus, caudate nucleus, 
putamen, prefrontal region. Cho=choline, Cr=creatine, NAA=N-acetylaspratate, mI=myo-inositol, 
Glx=glutmate+glutamine, Lac=lactate, PPM=parts per million. A Gaussian filter of 4 Hz was applied. 
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Figure 3: LCmodel output example. The black line is the raw spectrum, the red line is the fit by 
LCmodel. PPM = parts per million
Discussion
The major findings of this study are lower concentrations of creatine and NAA 
in the caudate nucleus and the putamen, and a reduction of glutamate in the 
putamen in manifest HD. A relationship between differences in these metabolic 
levels and clinical measures of disease severity, especially global functioning, 
was demonstrated. No statistically significant differences in any metabolite 
concentration were observed when the premanifest group was compared to 
controls, although the absolute lower values could indicate a subtle decline. 
As creatine is considered an important marker for brain energy metabolism28, 
the finding of lower creatine levels suggests impaired energy metabolism in 
manifest HD. In the healthy population, the concentration of creatine in the brain 
is considered to be fairly stable, however, specific pathology has been shown to 
influence creatine concentrations28. The finding of lower creatine in putamen and 
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caudate nucleus is supported by findings of Sanchez et al.(1999), who observed a 
reduction of both creatine and NAA in the striatum10. Reynolds et al.(2005) went on 
to propose creatine as a possible biomarker, when they demonstrated lower levels 
in the caudate nucleus in premanifest HD18. Contrary to our findings, Reynolds 
et al. (2005) did not report altered creatine levels in the putamen. Results from 
the TRACK-HD study reported by Sturrock et al.(2010) show similar lower values 
of creatine in the putamen as our study29. Jenkins et al. (1998) found additional 
evidence for impaired energy metabolism as displayed by elevated lactate levels 
in HD within the occipital cortex11;12. However, our study did not show elevated 
lactate in any of the examined structures. This finding can possibly be explained 
by the fact that Jenkins et al.(1993) used a more severely affected HD population 
with a lower mean TFC score of 7.311. Moreover, the region analyzed by Jenkins 
et al.(1993, 1998)11;12 did not consist of the basal ganglia, but of the occipital 
cortex, which is a very metabolically active area of the cortex and is also severely 
atrophied in HD30. Although, these studies are not completely comparable on the 
basis of methodology and results, they do all point towards the importance of 
assessment of metabolic changes and specifically the energy metabolism markers 
such as creatine. 
NAA is a marker for the integrity of neurons and axons28 and lower NAA levels 
suggest a decrease in neuronal integrity. As atrophy of numerous brain structures 
is apparent in manifest HD, it is likely that neurons are affected and decrease in 
NAA may occur. This hypothesis was previously confirmed within the striatum10;11;17. 
Again the recent report from Sturrock et al.(2010) is similar to our findings of 
lower NAA in the putamen29. Our study confirms the finding of decreased NAA 
in the striatum (caudate nucleus plus putamen), and more importantly, our data 
show that neuronal damage may be present in both the caudate nucleus and 
putamen separately. The ability to acquire spectra from relatively small voxels is an 
important advantage of higher magnetic fields in localized MR spectroscopy. 
Glutamate is of interest in light of the excitotoxicity theory which states that an 
overstimulation of neurons causes cell damage and eventually cell death. In 
neurons this can occur either due to increased levels of glutamate (and/or its 
precursor glutamine) or due to an increase in sensitivity of the glutamate receptors, 
both resulting in the same effect7;8. Taylor et al.(1994,1996) described increased 
levels of glutamate, supporting this theory14;15. However, the glutamate levels in 
these studies were expressed as a ratio to creatine, and could also be influenced 
by changes of the creatine level. Our study demonstrates reduced glutamate 
levels in the putamen. An explanation may be that the number of viable neurons is 
decreased to an extent where glutamate is lowered along with the neuron count. 
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Also, the sensitivity of glutamate receptors could be altered, resulting in altered 
levels of glutamate. However, without further investigation these propositions are 
highly speculative.
In the premanifest HD group no changes in any of the examined metabolites levels 
could be demonstrated. This was an unexpected finding, as previous studies 
have reported structural abnormalities, e.g. atrophy, at this stage1;31;32 and some 
reports exist of lowered levels of metabolites in premanifest HD gene carriers10;18. 
Sanchez-Pernaute et al. (1999) did report lower NAA and lower creatine in the 
striatum in 4 premanifest gene carriers; however the article already stated that 
there were soft motor signs present in two out of four in this group10. Reynolds et 
al. (2005) reported on lower values of creatine and NAA, yet he concluded that 
there was no pathognomonic profile in metabolite changes, but stated that there 
was great heterogeneity in this respect18. Nonetheless, we did hypothesize that 
premanifest HD would show altered levels of metabolites as atrophy (which is 
already present more than a decade before disease onset3;30-32 is logically the 
result of underlying processes. We must therefore conclude that either we cannot 
(yet) measure these changes or the processes involved are more complex than 
simple linear correlation between metabolite levels and disease severity. For 
instance the excitotoxicity theory can possibly be a process measured by increased 
(damaging effects) or decreased (loss of healthy neurons) levels of glutamate 
depending on the individual disease stage. When performing group analysis, these 
measurements can become diluted. Individual assessment of longitudinal changes 
could shed more light on these changes. An explanation as to why no significant 
differences in our premanifest population were found, may be that our premanifest 
group was too heterogeneous in terms of proximity to disease onset. When 
taking into consideration the ‘disease burden score’, a proven correlate of striatal 
damage and thereby proximity to onset33, a range of 121.5 to 450.5 exists within 
our premanifest HD sample. This large range suggests a great deal of variability in 
striatal damage and therefore of possible metabolite differences. Even so, despite 
this large range in disease burden score, a decline in absolute values of NAA 
and creatine was observed in the premanifest group, although this did not reach 
statistical significance. A second explanation could be our very stringent inclusion 
criteria. Only premanifest participants were included when there was no evidence 
of motor symptoms, as quantified by an UHDRS motor score of 5 or less, whereas 
other studies may have allowed participation of premanifest gene carriers with a 
higher degree of clinical abnormalities. 
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Our data show that metabolite levels are associated with clinical measures of 
disease severity. This finding highlights the feasibility of MRS in clinical trials, 
whereby metabolite levels could be target outcome measures. Endeavours using 
creatine as a treatment for HD with MRS as a monitoring tool have demonstrated 
the feasibility of this method34. 
This study shows the clinical application of high field 7-Tesla MRI. The spectral 
resolution in combination with small voxel size and total scanning time is a clear 
improvement in MRS methodology21;35. This allows the examination of metabolites 
in small, well defined anatomical structures, such as the caudate nucleus and 
putamen for HD, and can be used in the examination of many other disorders 
where spectral and spatial resolution is of great importance.
A limitation of our study was the fact that the premanifest group was not uniformly 
distributed according to expected disease onset, which may have lead to a 
relatively large spread of the metabolite concentrations. A more homogeneous 
group close to onset could possibly reveal more significant results already in the 
premanifest stage of the disease. Also the small number of participants included 
in the manifest groups could be seen as a limitation. However, despite the 
small amount of participants the results were still significant. Furthermore, the 
hypothalamus region (bilaterally) included some CSF in the voxel, especially in 
the manifest HD group, as a result of atrophy, which could account for less reliable 
measurements. This was not a problem for any of the other regions. Finally, the 
frontal region consisted of approximately 50 % of both grey and white matter, which 
could lead to false negative findings if grey or white matter would be unequally 
affected.
In conclusion, in manifest HD, lower NAA and creatine were found in the caudate 
nucleus and putamen, supporting the theory of impaired energy metabolism as part 
of the pathophysiology of Huntington’s disease. Glutamate levels were lowered in 
the putamen, however to which extent this finding supports the excitotoxicity theory 
remains unclear. The relationship with clinical measures of function makes MRS a 
potential disease monitor and could also possibly be used to evaluate therapeutics 
targeted at metabolic processes in HD.
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Magnetization transfer imaging (MTI) is a quantitative MRI technique which 
has recently demonstrated structural integrity differences between controls and 
Huntington’s disease (HD) patients. Potentially MTI can be used as a biomarker for 
monitoring disease progression. To establish the value of MTI as a biomarker, we 
aimed to examine the change of these measures during the course of HD.
Method
From the Leiden TRACK-HD study 25 controls, 21 premanifest gene carriers and 
21 manifest HD patients, participated at baseline and during a 2 year follow up 
visit. Brain segmentation of cortical grey matter, white matter, caudate nucleus, 
putamen, pallidum, thalamus, amygdala, and hippocampus was performed using 
FSL’s automated tools FAST and FIRST. Individual MTR values were calculated 
from these regions and MTR histograms constructed.
Results
In the premanifest HD group stage “far from disease onset” a significant increase in 
MTR peak height of the putamen was observed over time. During the manifest HD 
stage neither the mean MTR nor the MTR peak height showed a significant change 
during a 2 year follow up.
Conclusion
MTI derived measures are not suitable for disease monitoring in Huntington’s 
disease over a 2 year period as there is no decrease in structural integrity detected 
in any of the manifest HD groups longitudinally. The finding of increased putaminal 
MTR peak height in the premanifest “far from disease onset” group could relate to 
a pre-degenerative process, compensatory mechanisms or aberrant development, 
but should be interpreted with caution until future studies confirm this finding.
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Introduction
Magnetization transfer imaging (MTI) is a MRI technique which has been 
developed to perform structural imaging in a different, possibly more sensitive 
way, as it has demonstrated abnormalities in the normal appearing grey and white 
matter on conventional MRI in MS research1;2.  The technique of MTI is based on 
the exchange of two pools of protons: one bound to macromolecular structures 
and one bound to free water molecules3. MTI has first and foremost been applied 
in patients with MS, however many other diseases have been studied using MTI, 
such as Alzheimer’s disease4, Parkinson’s disease5 and Huntington’s disease 
(HD)6;7. 
Previous MRI studies in HD mainly focused on the search for a biomarker for 
monitoring disease progression. In this field lays a great opportunity to study the 
potential of MTI at very early stages of neurodegeneration. The genetic defect 
which is responsible for HD is located on the short arm of chromosome 4 and 
has an autosomal dominant inheritance pattern with full penetrance8. Therefore 
when the gene defect has been established in an individual, this inevitably leads 
to a certain clinical diagnosis at some point in their life. Mean disease onset is 
approximately 35-40 years of age with a wide range partly depended on the length 
of the abnormal CAG-repeat9. The ability to establish the gene defect well before 
any symptoms are present, gives an unique opportunity to study asymptomatic 
gene carriers, commonly referred to as “premanifest gene carriers”(PMGC). 
In previous structural MRI studies significant brain disturbances in terms of striatal 
atrophy10;11, white matter disturbances12;13, cortical thickness reductions14 and whole 
brain volume reduction10;15 have been described. These studies all used either 
conventional MRI or DTI. Some of these measures are well established, however 
no golden standard for disease monitoring by MRI is currently present. In essence, 
what technique and what region are most suitable as a biomarker? Possible 
problems in HD are non-linear and non-uniformly affected brain regions. The need 
for further research into a robust and sensitive MRI measure to monitor disease 
onset and progression is still evident. 
Previous work in HD using MTI consists of four reports, all cross-sectional in 
design6;7;16;17. The main outcome measures used were mean Magnetization 
Transfer Ratio (MTR) and MTR peak height and are thought to represent structural 
integrity17-19. Mean MTR represents the average MTR value of all voxels in a 
region of interest, with a lower mean MTR corresponding to loss of tissue integrity. 
MTR peak height reflects the most frequently occurring MTR value in a region 
of interest when all the MTR values are set out in a MTR histogram, again with 
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lower peak height being associated with loss of structural integrity.  Results from 
these previous studies show reduced structural integrity in manifest HD patients 
(MHD) compared to healthy controls or PMGC in multiple regions, namely the 
white matter, cortical grey matter, caudate nucleus, putamen, pallidum, thalamus 
and amygdala. The results are suggestive of the potential of MTI as a biomarker6;7. 
However no longitudinal reports are available.
TRACK-HD is specifically designed to determine the most valuable measures to 
monitor disease progression20. This study allows following both PMGC as MHD 
over several years. To determine the true value of any potential (MRI) biomarker, 
longitudinal confirmation is crucial. Therefore we aim to examine whether MTI 
measures change over a 2 year period during the progressive course of HD. 
Secondly, if any longitudinal change in a group is present, we sought to determine 
the correlation to clinical measures of disease progression. 
Methods 
Subjects 
Participants were recruited from the Leiden site of the TRACK-HD study. From the 
baseline cohort (n=90) in 2008 a total of 78 participants could be included. This 
cohort consisted of three groups; 28 healthy controls, 25 PMGC and 25 MHD. 
Inclusion criteria for the PMGC consisted of genetically confirmed expanded CAG 
repeat ≥40, a disease burden score (calculated as: ((CAG repeat length–35.5) x 
Age) of >25021 and absence of motor abnormalities on the UHDRS, defined as 
a TMS of ≤5. Inclusion criteria for MHD consisted of genetically confirmed CAG 
repeat ≥40, presence of motor abnormalities on the UHDRS-TMS of >5. Also a 
TFC of 7 or higher was required to ensure that the MHD group was in the early 
disease stage.  Subdivision of the premanifest group was made on the basis 
of their expected years to onset, calculated by the formula from Langbehn et 
al.(2004)9. This results in a premanifest HD group “far from expected disease 
onset” (PreHD-A) and premanifest HD group “close to expected disease onset” 
(PreHD-B). Subdivision of the manifest group was made by their staging according 
to the Shoulson and Fahn Scale, based on the TFC score, resulting in a manifest 
HD group stage 1 (HD 1) and manifest group stage 2 (HD 2). HD 1 describes a 
group of manifest HD in the earliest stage after disease onset, with only minor 
symptoms. HD 2 is the next stage in the disease with increased symptoms and 
impact on daily activities, but these patients are still considered “early manifest”. 
Healthy gene negative family members, spouses or partners were recruited as 
control subjects. Exclusion criteria consisted of significant (neurological) co-
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morbidity, active major psychiatric disturbance and MRI incompatibility. Full 
details on recruitment are available in the TRACK-HD baseline paper10. Local IRB 
approval and written informed consent were obtained from all participants.
The same cohort was scanned 24 months later within a 6 week window of their 
follow up date. Of the 78 participants, 67 participants were available for follow 
up scanning in 2010 with the MTI-protocol included. Reasons for unavailability 
included too advanced disease stage, time restraints on the full TRACK-HD 
scanning protocol and unspecified reasons of withdrawal.
Imaging sequences
At both time points exactly the same study protocol was enforced. The scanning 
protocol described in our cross-sectional report6 was performed in an identical 
manner two years after the baseline visit. In short all participants underwent 
scanning on a 3 Tesla Philips whole body scanner (Philips, Best, The Netherlands) 
with an 8-channel receive and transmit coil.  3D T1-weighted sequences 
(TR = 7.7ms, TE= 3.5ms, FA= 8°, matrix size 224x224x164 mm, voxel size 
1.0x1.0x1.0mm, acquisition time ~9min) and 3D gradient MTI sequences (TR = 
100 ms, TE = 11 ms, FA = 9°, matrix 224x180x144 mm, voxel size1.0x1.0x7.2 mm, 
acquisition time ~3min) were acquired  For the MTI sequences two consecutive 
imaging sets were acquired, one with and one without a saturation pulse. A sinc 
pulse of 25 ms with a maximal B1 of 10 uT and 2 sidelobes on an off-resonance 
frequency of 1100 Hz was applied. Total scanning time for T1-w and MTI 
sequences was maximally 12 minutes.
Post-processing
The post-processing pipeline was identical to that described previously in the cross 
sectional result paper6. T1-weighted images were segmented using FAST22 and 
FIRST23  from FMRIB’s Software Library (Oxford, United Kingdom)24. This provided 
individual brain masks for: total white matter, cortical grey matter, caudate nucleus, 
putamen, pallidum, thalamus, amygdala, hippocampus and whole brain. To correct 
for possible partial volume effects, an eroded mask of these segmentations was 
created by removing one voxel in plane for all above named VOI’s. All brain masks 
were then registered to the MTI volumes using the transform obtained from linear 
registration of the T1-w volume with 7 degrees of freedom (FSL-FLIRT).  MTR 
was calculated per voxel as M0-Ms / M0, whereby Ms is the saturated image and 
M0 the unsaturated image. The mean MTR per VOI was calculated. Additionally, 
to represent the variations of voxel based MTR within each VOI we constructed 
MTR histograms. The MTR peak height was normalized for the size of the volume 
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of interest. MTR peak height and mean MTR were the primary outcome variables. 
For correction of the (largely unknown) influence of age on MTI values, the MTR 
parameters were calibrated to the control values, assuming no changes in the 
control subjects. This entailed scaling the individual premanifest and manifests 
values according to the mean MTR parameter difference between baseline and 
follow up of the control group, which could either be an increase or a decrease over 
time. In the supplementary materials (table 3) actual values of the control group on 
both time points are available.
To compare the biomarker potential of MTI to volumetric analysis, volumes were 
calculated for all subcortical regions, white matter volume and whole brain volume 
using the FSL tools of FIRST23 and SIENAX25. The volume calculation and a 
correction for intracranial volume was performed as described previously11. 
Clinical Measures
A total measure of motor dysfunction was obtained with the UHDRS-TMS (range 
0-124). TFC score (range: 0-13) and MMSE for global assessment of cognitive 
functioning (range: 0-30) were obtained. Cognitive scores included the total scores 
from the SDMT and the Stroop word reading card. For assessment of psychiatric 
disturbances the PBA-s was used. For a more detailed description of these clinical 
assessments see Tabrizi et al.(2009)10.
Statistics
To examine the longitudinal change in clinical, MTI and volumetric values 
(corrected for intracranial volumes) per group, paired T-testing per group was used. 
Alpha was set to 0.05 to be significant. Secondly, to account for multiple testing (15 
regions) a Bonferroni correction was applied, resulting in an alpha < 0.0033 for the 
strongest findings. For correlation analysis between significant longitudinal findings, 
a Pearson correlation was applied to the difference between the 2 time points of 
the clinical and MTI values. 
Results
Group characteristics and clinical measures on both the baseline visit as the 
follow up visit are shown in table 1. A significant longitudinal increase in motor 
disturbances is evident in PreHD-B, HD 1 and HD 2. Global functioning as 
measured by the TFC significantly decreases in 2 years in the HD 2 group as does 
the cognitive measure of Stroop word reading.
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Table 1: Group characteristics for controls, premanifest HD groups A +B and 
Manifest HD groups 1 and 2.
Controls PreHD-A PreHD-B Manifest 1 Manifest 2
N 25 10 11 9 12
Age baseline 48.3 (7.6) 45.5 (5.2) 42.9 (11.2) 47.7 (11.8) 50.9 (9.4)
CAG baseline n.a. 41.3 (1.3) 44.0 (3.1) 43.8 (3.5) 43.2 (1.9)
YTO baseline n.a. 13.8 (3.8) 8.4 (1.6) n.a. n.a.
TMS  
baseline 2.4 (2.4) 2.3 (1.7) 3.0 (1.1) 16.9 (8.8) 26.2 (11.7)
follow up 1.7 (1.4) 6.0 (6.9) 6.3 (2.5) * 23.0 (9.0) * 37.8 (14.3) *
TFC   
baseline 12.9 (0.2) 12.7 (0.7) 12.6 (0.9) 12.0 (1.0) 8.6 (1.2)
follow up 12.8 ( 12.5 (0.9) 12.4 (1.2) 11.2 (2.0) 6.0 (3.3) *
MMSE 
baseline 29.2 (1.2) 29.0 (1.2) 28.4 (1.9) 29.0 (0.9) 26.5 (3.1)
follow up 29.1 (1.2) 29.3 (0.8) 28.6 (1.7) 28.7 (1.1) 27.0 (3.9)
SDMT
baseline 50.1 (9.6) 52.7 (7.4) 46.9 (12.0) 42.0 (8.1) 31.2 (11.1)
follow up 51.5 (10.8) 52.7 (9.5) 48.3 (9.9) 39.6 (10.7) 27.9 (13.3)
Stroop
baseline 99.8 (13.4) 97.1 (10.5) 86.9 (16.3) 88.4 (13.6) 69.4 (21.5)
follow up 102.7 (16.9) 92.5  (7.5) 83.4 (19.3) 89.8 (18.9) 55.6 (22.6) *
PBA-s
baseline 6.4 (8.4) 6.7 (8.7) 7.4 (7.1) 11.7 (11.7) 14.0 (11.8)
follow up 6.6 (9.0) 6.1 (11.9) 7.8 (9.70) 9.7 (11.7) 22.6 (16.3)
Values are Mean (SD). PreHD-A = premanifest HD far from expected disease onset, PreHD-B 
premanifest HD close to expected disease onset, CAG = CAG-repeat length, YTO = expected years 
to disease onset, TMS = total motor score, TFC = total functional capacity, MMSE = mini mental state 
exam, SDMT = symbol digit modality test, Stroop = stroop word reading test, PBA = problem behaviour 
assessment - short version.* = p < 0.005 significant longitudinal change 
All MTI-values for 15 VOI’s are displayed in the supplementary material table 1 for 
the premanifest HD groups and in supplementary material table 2 for the Manifest 
HD groups. In PreHD-A five subcortical grey matter regions show an increase in 
MTI parameters, namely the mean MTR of the right caudate nucleus (p=0.049), 
the MTR peak height of the right putamen(p=0.003), MTR peak height of the left 
pallidum (p=0.032), mean MTR of the right thalamus (p=0.047) and MTR peak 
height of the right amygdala (p=0.050). However, after Bonferroni correction, 
the only statistically significant variation was the MTR peak height of the right 
putamen. In the PreHD-B group the cortical grey matter shows a longitudinal 
reduction in mean MTR (p=0.020) and the left hippocampus an increase in MTR 
histogram peak height (p=0.037). For the HD 1 group the right amygdala mean 
MTR decreases (p=0.036) in the 2 year follow up period. Only the left amygdala 
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mean MTR shows a reduction (p=0.022) in the HD 2 group. None of the results in 
the PreHD-B, HD 1 or HD 2 group are statistically significant after correction for 
multiple comparisons.
The statistical analysis procedure was also applied to a 3 group division instead 
of the 5 group division, encompassing the total premanifest group (PreHD A + B) 
and the total manifest group (HD 1 + 2) and the control group. This was performed 
in order to increase the power of the study, however in essence no additional 
information can be gathered from this analysis. The supplementary material 
contains exact details of the findings. The results also display subcortical MTR 
parameter increases in the premanifest group and a decrease in MTR parameters 
of the amygdala in the manifest HD group. The subdivision of groups is therefore 
more informative as it gives more exact disease stage related changes. 
Correlation analysis of the significant longitudinal findings (without correction 
for multiple comparison) in MTI values with clinical measures resulted in two 
significant findings, namely in the PreHD-B group the MTR peak height of the left 
hippocampus correlated to TFC reduction (R = -.622, p= 0.043) and in the HD 2 
group the reduction of mean MTR correlated to the reduction in SDMT performance 
(R = -.667, p= 0.018). Both findings did not survive Bonferroni correction for 
multiple comparisons.
All volumetric values are shown in the supplementary materials table 3. Significant 
volumetric decline of several VOI’s was seen in premanifest (caudate nucleus and 
putamen) and manifest groups (caudate nucleus, putamen, thalamus, white matter 
and whole brain).
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Discussion
The main finding of this study is the fact that MTI parameters do not change over 
a two year follow up period in manifest HD. The expected decline in structural 
integrity in this group could not be detected with MTI. However an interesting 
finding in the premanifest “far from expected disease onset” was made, namely an 
increase in MTR value in the putamen, which possibly can be interpreted as a form 
of aberrant development or compensatory mechanism. There is no relationship of 
changing MTR parameters to increasing clinical symptoms in any of the groups. 
Clinical progression was evident in premanifest close to disease onset group and 
the manifest HD groups.
 
Previous cross-sectional observations with MTI in HD showed promising results 
for both mean MTR as MTR histogram peak height for these measures to serve 
as a disease monitoring biomarker6;7;17. Mean MTR was found to be lower in 
several brain regions in manifest HD6 or in a combined cohort of premanifest and 
manifest HD7 compared to controls. Also MTR peak height in several regions was 
found to be lower in manifest HD6 and, although there was no group difference, 
the MTR peak height related to subtle motor abnormalities and higher CAG 
repeat length in a premanifest HD cohort17. To date no longitudinal MTI studies 
in HD were available. In fact there is relatively little longitudinal research of MTI 
values available at all. Only in multiple sclerosis, optic neuritis and systemic 
lupus erythematosus reports are available, suggesting a good potential for MTI to 
examine both grey and white matter as lesion evolution26-29. In normal aging Ge et 
al. (2008) described, via a histogram analysis, reduction of MTR values after the 
age of 40 and significant group differences after the age of 50 years30. The groups 
in our study span exactly this age range. We therefore calibrated our MTR values 
of the HD groups to the control values. 
The goal of this study was to examine the potential of MTI to detect loss of 
structural integrity in HD to ultimately serve as an outcome measure in future 
therapeutic trials, as is the overall main goal of the TRACK-HD study10. This current 
study and the recently published 24-month analysis of the main TRACK-HD study 
demonstrate that volumetric MRI measures are sensitive for detecting change over 
a 2 year period31. In our MTI study no statistically strong changes were seen in any 
of the regions. Three regions did show longitudinal reduction, namely the cortical 
grey matter in PreHD-B and the amygdala in HD 1 and 2, however these findings 
did not survive correction for multiple comparison, thus should be interpreted 
with extreme caution. These regions are shown to be affected at these disease 
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stages10;11, however other regions such as the caudate nucleus or putamen or 
pallidum are known to be  more severely affected in terms of atrophy. Noteworthy 
is the fact that MTR histogram peak height was normalised for volume and mean 
MTR is non-dependent on atrophy; only the number of voxels from which this 
mean is calculated could have an influence. The measures used are therefore 
relatively non-influenced by atrophy. We must conclude from our study, based on 
the group comparisons of MTI-parameters, group comparisons of volumes and 
the lack of correlation of MTI to clinical measures, that MTI is inferior to volumetric 
measures to serve as a biomarker to detect longitudinal change in a 2 year follow 
up. It is noteworthy to mention that clinical trials from a practical point of view will 
not last longer than two years, hence a longer follow up period may be of interest 
scientifically, but the impact on biomarker research in HD will be limited.
The interesting finding in this study in PreHD-A is that an increase in MTI values 
was observed. This pattern was seen in 5 subcortical grey matter structures, 
with the finding of increased MTR histogram peak height in the putamen, one 
of the most heavily involved structures in HD, surviving the stringent correction 
for multiple comparisons. The explanation of this increase could be sought in an 
earlier postulated theory by Paulsen et al. They gave two possible explanations 
when their group detected increased cortical volume in premanifest HD. These 
explanations consist of either a predegenerative process, such as swelling of 
tissue, or alternatively it may be a reflection of aberrant brain development or 
maturation32. 
Furthermore, evidence from fMRI studies point towards another possible 
explanation. Two reports exist on increased activation in premanifest HD, which 
is thought to represent cortical recruitment as compensatory strategies, this was 
specifically true for premanifest HD far from expected onset and not in the close 
to onset group33;34. In our view any of these proposed explanations could be true, 
however we should be extremely cautious not to overly interpret the findings as 
the correction for multiple comparisons reduced the number and strength of the 
findings. This finding could however lead to broader examination of MTI and other 
MRI measures in the premanifest far from disease onset group as this potentially 
can lead to better understanding of the neuropathology in HD.
Limitations of our study lay in the fact that not all participants were retained for the 
follow up period. However, those lost to follow up were evenly divided over the 
groups; hence we do not believe this ultimately influenced our results. Furthermore 
the group sizes were relatively small, possibly suggesting the study could be 
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underpowered, however combining the groups did not result in any additional 
findings. On the other hand aggregated groups could be too heterogeneous to yield 
additional significant findings. 
Conclusion
We believe MTI derived measures are not suitable for disease monitoring in HD 
as there is no significant decrease in structural integrity in any of the groups over 
two years and there is no significant relation to clinical measures. The finding of 
increased MTI measures in the premanifest far from disease onset group could 
relate to a pre-degenerative process, compensatory mechanisms or aberrant 
development, but should be interpreted with caution until confirmation of these 
findings in future studies is made.
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The control values displayed a significant change over time in three regions, as 
shown in table 4. In the left thalamus and the left caudate nucleus a significant 
decrease in mean MTR was seen and in the right putamen a significant increase in 
mean MTR was observed. To ensure that our most significant longitudinal finding, 
namely MTR peak height of the right putamen, was not affected by the potential 
influence of calibration, we also examined the difference over time of this value 
without calibration to controls. As expected, the MTR peak height from the right 
putamen in the premanifest far from onset group also displayed a very significant 
(p= 0.005) increase over the 2 year follow up. 
Premanifest versus manifest in three group division
When the two premanifest and two manifest groups were combined there were 
six noteworthy increases: the MTR peak height of the right putamen (p= 0.010), 
the MTR peak height of the left pallidum (p=0.001), MTR peak height of cortical 
grey matter (p=0.024), mean MTR of the left amygdala (p=0.024) and mean MTR 
of the right thalamus (p=0.048). Furthermore a decrease is seen in mean MTR of 
the left caudate nucleus (p=0.030) and in the manifest HD group the left and right 
amygdale show a decrease in mean MTR (left amygdale p=0.042, right amygdale 
p=0.025). However, when the Bonferroni correction for multiple testing was applied, 
only the increase in MTR peak height of the left pallidum remains statistically 
significant.
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Table 1: MTI derived values in 14 different regions on both baseline and 
follow up visit for the premanifest HD A and premanifest HD B group.
Premanifest A  Premanifest B 
Baseline Follow up Baseline Follow up
Mean SD Mean SD p Mean SD Mean SD p
White matter
Peak height 1.144 0.161 1.176 0.223 0.567 1.092 0.258 1.188 0.134 0.172
Mean MTR   0.387 0.013 0.389 0.010 0.249 0.388 0.017 0.388 0.010 0.903
Cortical grey matter
Peak height 0.752 0.107 0.796 0.109 0.091 0.685 0.136 0.727 0.111 0.152
Mean MTR   0.326 0.014 0.329 0.013 0.079 0.325 0.012 0.319 0.013 0.020
Caudate Right
Peak height 0.852 0.133 0.910 0.184 0.320 0.849 0.182 0.838 0.169 0.804
Mean MTR   0.339 0.018 0.346 0.020 0.049 0.333 0.031 0.340 0.025 0.353
Caudate Left 
Peak height 0.974 0.245 1.046 0.085 0.367 0.964 0.199 1.013 0.146 0.480
Mean MTR   0.357 0.021 0.351 0.016 0.308 0.359 0.024 0.346 0.022 0.062
Putamen Right
Peak height 1.132 0.235 1.375 0.206 0.003 1.338 0.354 1.409 0.241 0.396
Mean MTR   0.329 0.015 0.335 0.012 0.160 0.330 0.031 0.334 0.021 0.312
Putamen Left
Peak height 1.291 0.199 1.340 0.181 0.614 1.298 0.314 1.433 0.295 0.091
Mean MTR   0.352 0.013 0.356 0.015 0.119 0.353 0.031 0.356 0.024 0.494
Pallidum Right
Peak height 1.569 0.333 1.740 0.272 0.112 1.617 0.318 1.701 0.285 0.400
Mean MTR   0.381 0.006 0.382 0.007 0.740 0.382 0.021 0.387 0.013 0.300
Pallidum Left
Peak height 1.471 0.285 1.721 0.218 0.032 1.528 0.310 1.709 0.223 0.086
Mean MTR   0.386 0.010 0.386 0.009 0.958 0.383 0.019 0.392 0.013 0.094
Thalamus Right
Peak height 1.013 0.139 1.083 0.159 0.142 1.003 0.204 0.999 0.167 0.946
Mean MTR   0.359 0.015 0.367 0.018 0.047 0.352 0.028 0.359 0.021 0.398
Thalamus left
Peak height 1.166 0.279 1.197 0.098 0.717 1.116 0.222 1.196 0.167 0.332
Mean MTR   0.372 0.018 0.380 0.014 0.090 0.371 0.020 0.375 0.020 0.467
Amygdala Right
Peak height 1.297 0.116 1.405 0.191 0.050 1.259 0.327 1.279 0.240 0.837
Mean MTR   0.357 0.017 0.358 0.011 0.817 0.364 0.027 0.351 0.019 0.164
Amygdala Left
Peak height 1.530 0.190 1.613 0.212 0.236 1.304 0.231 1.486 0.325 0.064
Mean MTR   0.374 0.016 0.370 0.015 0.506 0.377 0.026 0.364 0.018 0.200
Hippocampus Right
Peak height 1.346 0.219 1.298 0.224 0.586 1.164 0.266 1.198 0.288 0.637
Mean MTR   0.360 0.015 0.363 0.009 0.635 0.365 0.021 0.355 0.017 0.124
Hippocampus Left
Peak height 1.010 0.195 1.059 0.170 0.558 0.888 0.188 1.088 0.197 0.037
Mean MTR   0.381 0.022 0.387 0.018 0.347 0.380 0.018 0.373 0.013 0.317
Whole brain
Peak height 0.923 0.123 0.963 0.141 0.198 0.864 0.181 0.936 0.094 0.118
Mean MTR   0.352 0.013 0.355 0.011 0.110 0.353 0.013 0.350 0.010 0.297
MTR = Magnetization Transfer Ratio. Bold =significant finding at p≤0.05
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Table 2: MTI derived values in 14 different regions on both baseline and 
follow up visit for the manifest HD 1 and manifest HD 2 group.
Manifest 1 Manifest 2
Baseline Follow up Baseline Follow up
Mean SD Mean SD p Mean SD Mean SD p
White matter
Peak height 0.747 0.274 0.824 0.243 0.388 0.866 0.263 0.916 0.245 0.560
Mean MTR   0.372 0.025 0.384 0.013 0.121 0.380 0.016 0.379 0.014 0.713
Cortical grey matter
Peak height 0.589 0.174 0.587 0.137 0.961 0.602 0.127 0.632 0.097 0.239
Mean MTR   0.319 0.014 0.316 0.015 0.264 0.311 0.017 0.311 0.013 0.928
Caudate Right
Peak height 0.726 0.234 0.704 0.182 0.762 0.777 0.204 0.703 0.200 0.371
Mean MTR   0.331 0.034 0.344 0.039 0.321 0.323 0.034 0.339 0.032 0.123
Caudate Left 
Peak height 0.784 0.240 0.798 0.156 0.852 0.833 0.244 0.898 0.236 0.311
Mean MTR   0.339 0.045 0.338 0.045 0.930 0.346 0.039 0.346 0.037 0.999
Putamen Right
Peak height 0.877 0.326 1.018 0.287 0.152 0.961 0.282 1.082 0.334 0.221
Mean MTR   0.330 0.029 0.338 0.024 0.276 0.329 0.018 0.323 0.029 0.455
Putamen Left
Peak height 0.941 0.332 1.037 0.178 0.415 1.029 0.295 1.177 0.275 0.106
Mean MTR   0.346 0.026 0.352 0.031 0.720 0.360 0.015 0.353 0.033 0.348
Pallidum Right
Peak height 1.178 0.466 1.325 0.359 0.203 1.307 0.409 1.356 0.394 0.714
Mean MTR   0.396 0.039 0.389 0.018 0.565 0.384 0.021 0.394 0.019 0.146
Pallidum Left
Peak height 1.138 0.366 1.240 0.211 0.321 1.237 0.364 1.370 0.282 0.268
Mean MTR   0.376 0.047 0.396 0.026 0.237 0.399 0.012 0.392 0.023 0.308
Thalamus Right
Peak height 0.825 0.297 0.826 0.208 0.988 0.874 0.234 0.838 0.205 0.667
Mean MTR   0.349 0.035 0.360 0.038 0.396 0.335 0.042 0.358 0.028 0.079
Thalamus left
Peak height 0.884 0.311 0.901 0.183 0.856 0.933 0.285 0.993 0.280 0.477
Mean MTR   0.346 0.054 0.367 0.045 0.230 0.354 0.044 0.373 0.038 0.214
Amygdala Right
Peak height 1.076 0.366 1.100 0.336 0.875 1.131 0.277 1.080 0.325 0.536
Mean MTR   0.361 0.019 0.333 0.029 0.036 0.351 0.024 0.349 0.017 0.686
Amygdala Left
Peak height 1.128 0.344 1.298 0.388 0.102 1.198 0.265 1.121 0.228 0.434
Mean MTR   0.377 0.042 0.345 0.036 0.157 0.369 0.020 0.354 0.015 0.022
Hippocampus Right
Peak height 0.974 0.264 0.976 0.233 0.994 1.097 0.235 0.948 0.249 0.131
Mean MTR   0.372 0.036 0.344 0.022 0.073 0.354 0.027 0.359 0.018 0.576
Hippocampus Left
Peak height 0.717 0.226 0.798 0.181 0.142 0.957 0.256 1.062 0.232 0.350
Mean MTR   0.394 0.045 0.364 0.029 0.150 0.389 0.017 0.379 0.020 0.284
Whole brain
Peak height 0.661 0.217 0.696 0.184 0.579 0.719 0.174 0.762 0.153 0.428
Mean MTR   0.343 0.016 0.347 0.014 0.098 0.342 0.016 0.343 0.012 0.728
MTR = Magnetization Transfer Ratio. Bold =significant finding at p≤0.05
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Table 4: control values of MTR parameters
Control group (n = 25) Mean SD
White matter
MTR peak height Baseline 1.109 0.220Follow up 1.125 0.231
Mean MTR Baseline 0.391 0.012Follow up 0.394 0.012
Cortical grey matter
MTR peak height Baseline 0.769 0.119Follow up 0.735 0.132




MTR peak height Baseline 0.799 0.192Follow up 0.830 0.224
Mean MTR Baseline 0.349 0.026Follow up 0.343 0.025
left
MTR peak height Baseline 0.892 0.188Follow up 0.831 0.198
Mean MTR Baseline 0.369 0.018Follow up 0.354 0.018
Putamen
right
MTR peak height Baseline 1.257 0.372Follow up 1.240 0.271
Mean MTR Baseline 0.340 0.019Follow up 0.351 0.017
left
MTR peak height Baseline 1.337 0.268Follow up 1.266 0.265
Mean MTR Baseline 0.360 0.015Follow up 0.357 0.016
Pallidum
right
MTR peak height Baseline 1.494 0.343Follow up 1.435 0.230
Mean MTR Baseline 0.382 0.015Follow up 0.388 0.014
left
MTR peak height Baseline 1.601 0.301Follow up 1.490 0.268
Mean MTR Baseline 0.386 0.014Follow up 0.388 0.014
Thalamus
right
MTR peak height Baseline 0.988 0.261Follow up 0.936 0.236
Mean MTR Baseline 0.369 0.021Follow up 0.350 0.021
left
MTR peak height Baseline 1.067 0.226Follow up 1.003 0.251
Mean MTR Baseline 0.383 0.020Follow up 0.368 0.016
Amygdala
right
MTR peak height Baseline 1.329 0.295Follow up 1.287 0.289
Mean MTR Baseline 0.360 0.020Follow up 0.363 0.025
left
MTR peak height Baseline 1.475 0.307Follow up 1.328 0.369
Mean MTR Baseline 0.370 0.021Follow up 0.370 0.026
Hippocampus
right
MTR peak height Baseline 1.240 0.309Follow up 1.194 0.273
Mean MTR Baseline 0.366 0.019Follow up 0.371 0.020
left
MTR peak height Baseline 0.981 0.247Follow up 0.929 0.222
Mean MTR Baseline 0.386 0.015Follow up 0.391 0.017
Whole brain
MTR peak height Baseline 0.917 0.152Follow up 0.906 0.156
Mean MTR Baseline 0.356 0.011Follow up 0.359 0.012
MTR = Magnetization Transfer Ratio. Bold = significant finding after bonferroni correction (p<0.0033)
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Previous cross-sectional magnetic resonance spectroscopy (MRS) studies 
in Huntington’s disease (HD) have demonstrated differences in metabolite 
concentrations compared to controls in several regions of interest, especially the 
putamen and caudate nucleus. It has been suggested that metabolite changes 
could be used as biomarker in future therapeutic trials. The aim of the present 
study was to assess metabolite changes in both premanifest and early HD over a 
two year follow up period using MRS at 7 Tesla.
Methods
In 13 HD gene carriers (10 premanifest and 3 manifest HD) proton MRS was 
performed at baseline and after 24 months. At follow up, four of the premanifest HD 
gene carriers had progressed into manifest HD, as assessed by clinical measures. 
7T MR proton spectroscopy was performed in three regions of interest; the caudate 
nucleus, putamen and prefrontal cortex. Six metabolites were quantified for each 
region at each time point. Statistical analysis was performed using paired t-tests.
Results
In the caudate nucleus a decrease in creatine (p=0.032) and myo-inositol 
(p=0.006) concentrations was observed. A significant decrease in the putamen was 
seen in the total N-acetylaspartate (tNAA) (p=0.022) and choline concentrations 
(p=0.007). Premanifest HD converters showed higher rates of tNAA decrease in 
the putamen (p<0.003) than non-converting premanifest HD.
Conclusion
Over a period of 2 years we have demonstrated metabolite changes in the 
caudate nucleus and putamen of HD gene carriers around disease onset. 
This demonstrates the potential of MRS for providing a biomarker of disease 
progression and for evaluating future therapeutic interventions.
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Introduction
Huntington’s disease (HD) is a devastating neurological disorder causing 
widespread neuronal damage throughout the brain1-3. Atrophy of the striatum is 
regarded as the hallmark of the pathologic findings in HD4 and is consistently 
reported as the earliest brain structure affected, well before clinical symptoms 
arise1-3;5. Almost all other brain regions show structural changes at later stages of 
the disease, which can be examined in vivo with MRI2 and post-mortem4. 
The pathophysiological mechanism leading to neuronal damage still remains 
unclear. The genetic defect is located at chromosome 4 in the Htt-gene, leading 
to a mutant huntingtin protein6. Several pathophysiological hypotheses have been 
postulated. First, direct toxic effects of the aggregated and misfolded huntingtin 
protein could lead to neuronal damage. Second, transcriptional dysregulation of 
multiple genes is reported with associated functions in neurotransmitter receptors, 
enzymes and proteins involved in neuron structure, stress responses and axonal 
transport. Furthermore, there is evidence for impaired energy metabolism due to 
mitochondrial disturbances and disrupted dynamic intracellular processes, such as 
trafficking of intracellular vesicles and synaptic disruptions. Finally, the excitotoxicity 
hypothesis has gained a lot of support, which describes an increased sensitivity to 
neurotransmitter mediated stimulation, causing overstimulation and cell death7-9. 
Magnetic resonance spectroscopy (MRS) can be used in HD research either to 
explore pathophysiological mechanisms of the disease and/or in the search for 
a HD biomarker. Both objectives are closely linked as a robust biomarker should 
have a basis in the pathologic mechanisms of the disease. In HD, there is a need 
for objective biomarkers both for disease monitoring purposes and for evaluation 
of future therapeutic compounds. Novel compounds targeting specific pathogenic 
pathways, such as disturbed energy metabolism and those related to excitotoxicity 
theory, can potentially be monitored by means of MRS.
Previous studies have consistently demonstrated reduced N-acetylaspartate (NAA) 
and creatine levels in the caudate nucleus and/or putamen in manifest HD10-12. 
Whether these reductions in metabolite concentrations start in the premanifest 
phase of the disease or at a later disease stage remains a matter of debate. Lower 
concentrations of NAA and creatine in premanifest HD have been demonstrated12, 
although not all studies agree on this finding10;13. In addition to NAA and creatine, 
changes in choline14, glutamate11;15, lactate16 and myo-inositol10 concentration in 
HD have been reported. Choline was found to be reduced in the frontal lobe and 
was related to cognitive deficits14. Glutamate levels have been reported to be 
either increased15 or decreased11 in the striatum in manifest HD. This discrepancy 
could possibly be explained by the use of a glutamate-to-creatine ratio in one 
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publication15, against a glutamate concentration calculation using water as a 
concentration standard in the other11. Increased lactate in the occipital cortex and 
basal ganglia has been reported, suggestive of impaired energy metabolism16. 
Finally, a myo-inositol increase in the putamen has recently been reported in a 
large cohort from the TRACK-HD study10.
All of the above described studies have been cross-sectional in design. In terms of 
identifying potential biomarkers, following changes in metabolite concentrations in 
longitudinal studies is imperative. Our study population consists of predominantly 
premanifest HD participants, which show a high conversion rate, meaning 
progression from the premanifest to manifest HD. This specific study group is of 
particular interest given the fact that if any potential therapeutic compound should 
prove effective, it is in this premanifest stage of the disease, when neuronal loss 
is still limited, that one would start with interventions. Therefore, the aims of our 
study were to assess metabolite changes in both premanifest and early HD over 
a two year follow up period and how potential changes relate to clinical outcome 
measures. The current study consists of the follow up data of previously reported 
7T MRS results in manifest and premanifest HD11. 
Materials and methods
Subjects 
Recruitment of participants was performed as described previously11. In short, 
participants were recruited from the outpatient neurology clinic of the Leiden 
University Medical Centre. The presence of a positive genetic test with a CAG 
repeat ≥ 39 and the absence of significant comorbidity were mandatory inclusion 
criteria for both participant groups. The premanifest HD group was defined by the 
absence of motor disturbances on the Unified Huntington’s Disease Rating Scale 
’99 (UHDRS), with a total motor score (TMS) < 5. Early manifest HD was defined 
as a TMS of ≥ 5, a Total Functional Capacity (TFC) ≥ 7 and a diagnostic confidence 
level of 4 on the UHDRS. In total thirteen gene carriers were available for a follow 
up scan after two years. The study was approved by the local Medical Ethical 
Committee of the Leiden University Medical Centre. All participants provided 
written informed consent.
Clinical measures
At both time points the same set of clinical measures was performed. This 
included the UHDRS motor scale (score 0-124) and the TFC, a global scale of 
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impairment in daily life activities, score 0-13. In addition, a short cognitive battery 
was administered, consisting of the Mini Mental State Exam (MMSE), Stroop word 
reading card (Stroop), the Symbol Digit Modality Test (SDMT) and the Trail Making 
Test part B (TMT-B), Behavioural disturbances were evaluated with the Beck 
Depression Inventory 2nd version (BDI-II) and the Problem Behaviour Assessment 
short version (PBA-s). Predicted years to onset were calculated from current age 
and CAG repeat length using the formula by Langbehn et al.(2004)17.
MR data acquisition: 
The MR protocol performed at the baseline time point has been described 
previously: it consisted of a T1-weighted MRI and an MRS sequence performed 
on a Philips 7 Tesla Achieva whole body scanner (Philips Healthcare, Best, The 
Netherlands) with a NOVA Medical quadrature transmit coil and 16 channel 
receive coil array. A three-dimensional, high resolution, T1-weighted gradient 
echo (GRE) scan was acquired (TR/TE = 11/5.4 ms, voxel size 0.44 x 0.44 x 0.84 
mm, total scan time 1:46 mins) for accurate planning. Localized proton spectra 
were acquired using a stimulated echo acquisition mode (STEAM) sequence with 
the following scan parameters: TR/TE/TM = 2000/19/25 ms, BW 4 kHz, 2048 
complex data points and 128 signal averages. Water suppression was performed 
using a frequency-selective RF pulse and gradient spoiling, six saturation bands 
were additionally applied to suppress signal from surrounding tissue. All scans 
included a reference scan without water suppression for quantification. The voxel 
was placed within the region of interest with the maximum volume containing only 
tissue from the intended structure, minimizing the contribution from surrounding 
tissue, and also partial volume effects. Regions of interest consisted of the caudate 
nucleus, putamen, and the prefrontal white and cortical grey matter. For the 
prefrontal voxel, positioning included approximately 50% white and 50% cortical 
grey matter.
In the follow up studies minor changes were made to improve the signal to noise 
ratio (SNR), without changing the basic imaging and spectroscopy sequences 
which remained identical; volume-selective rather than global power optimization 
was implemented18, the first- and second-order shims were adjusted using a 
B0 map19 rather than a pencil-beam shimming routine, and water suppression 
was achieved using variable-power RF pulses with optimized relaxation delays 
(VAPOR)20;21 rather than frequency selective excitation and spoiling. 
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MRS post-processing
MRS data were analyzed with LCModel22;23 according to the procedure described 
previously11. The unsuppressed water was used as an internal reference to 
calculate the concentrations of the metabolites of interest: choline, creatine, 
glutamine + glutamate (Glx), total NAA (N-acetylaspartateglutamate + NAA), 
myo-inositol and lactate. Data processing was identical for both time points, with 
a Cramer-Rao Lower Bound (CRLB) of 20% or less as calculated by LCmodel 
required for all spectra as inclusion criteria for all metabolites with the exception 
of lactate for which we followed the guidelines of Tkac et al.(2009)24. For lactate 
CRLB above 100% were excluded from further analysis. If lactate was not 
quantified with a CRLB <100% in at least 50% of analyzed spectra, the analysis of 
lactate was not performed. For inclusion in the statistical analysis the participant 
had to have spectra of sufficient quality at both time points. After this quality check, 
longitudinal data of 9 participants was included for the caudate nucleus, 7 data sets 
for the putamen and 9 for the prefrontal cortex.
Statistics
All statistical analysis was performed with SPSS for Windows (version 17.0, SPSS 
Inc, Chicago, IL, USA). Paired t-tests were applied to assess differences between 
the baseline visit and follow up for clinical variables as well as for metabolite 
concentrations. The differences in clinical measures and metabolite concentrations 
between the two time points were calculated. Pearson’s correlation was used to 
explore the relationship between changes in metabolite concentrations and clinical 
measures. This correlation analysis was only performed for those metabolites that 
demonstrated statistically significant longitudinal change. Finally, paired t-tests 
were used to examine two separate subgroups; premanifest gene carriers that 
progressed to manifest HD as opposed to those premanifest HD participants that 
did not undergo this conversion. Again this procedure was only performed for those 
metabolites demonstrating significant longitudinal changes.
Results 
Demographics and clinical measures
The gene carrier group consisted of 10 premanifest and three early manifest 
participants. During the two year follow up period four premanifest participants 
converted to manifest HD as defined by their UHDRS TMS. At baseline the mean 
age of the group was 43.5 years with a standard deviation (SD) of 10.6 years 
and the mean CAG-repeat length was 44.0 (SD 3.2). The group consisted of 5 
males and 8 females. The premanifest HD group was mean 7.8 years (SD 4.3) to 
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predicted years to onset. The clinical characteristics at baseline visit and follow up 
are shown in Table 1. Over the 24 month period a significant decrease in the BDI-II 
and Stroop performance was observed. 
Table 1: Clinical measures at baseline and follow up of 13 gene carriers
































Follow up 28.85 1.68
Total gene carriers N = 13
Total premanifest at baseline 
(includes 4 converters during follow-up) N = 10
Total manifest at baseline N = 3
TMS = total motor score, TFC = total functional capacity, PBA-s= problem behaviour assessment 
short version, BDI-II: becks depression inventory, second version, TMT-B= trail making test, part B, 
SDMT=symbol digit modality test, MMSE=mini mental state exam, SD = standard deviation, n = number 
of participants
Metabolite analysis
All metabolite concentrations at both baseline and follow up are shown in Table 
2. In the caudate nucleus a decrease in creatine (p=0.032) and myo-inositol 
(p=0.006) concentrations was observed. In addition, in the putamen significant 
decreases in total N-acetylaspartate (p=0.022) and choline concentration (p=0.007) 
were observed. No metabolite concentration differences were found in the 
prefrontal region. Figure 1 shows typical examples of spectra from the follow up 
visit. 
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Relationship to clinical measures
Table 3 shows the association between cognitive changes over time and 
(significant) metabolite changes in the putamen and caudate nucleus. A decrease 
in depressive symptoms as measured by the BDI-II was related to a decrease 
in myo-inositol (p=0.020). Furthermore a decrease in cognitive performance as 
measured by the Stroop test was correlated to choline concentration decrease in 
the putamen (p=0.048).
Conversion from premanifest to manifest HD
The premanifest HD group that converted to manifest HD showed longitudinal 
changes in concentrations in both caudate nucleus and putamen for three 
metabolites, namely myo-inositol (p=0.019), choline (p=0.025) and NAA (p=0.003), 
as shown in table 4. The premanifest non-converter group showed a significant 
longitudinal change in creatine in the caudate nucleus (p=0.040). 
Figure 1: Typical 
example spectra 
and LCModel fit 
from 3 regions 
of interest in 
Huntington’s 
disease gene 
carriers from the 
follow up visit of 
3 premanifest 
participants. 
On the left the 
actual voxel in 
the sagital plane. 
Actual planning 
was performed 
in 3 directions. 
ppm=part per 
million
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Table 2: Metabolite concentrations at baseline and follow up in 3 regions of 
interest in Huntington’s disease gene carriers
Caudate nucleus (N=9, 7 PGMC (incl. 2 converters), 2 MHD)





















Follow up 9.76 1.53
Glx Baseline 12.11 4.09 0.824 0.434
Follow up 11.18 2.85
Putamen (N=7, 6 PGMC (incl. 3 converters), 1 MHD)





















Follow up 11.83 2.05
Glx Baseline 13.29 3.13 0.387 0.712
Follow up 12.73 2.41
Frontal (N=9, 7 PGMC (incl. 4 converters), 2 MHD)





















Follow up 11.27 1.75
Glx Baseline 10.52 3.48 -0.005 0.996
Follow up 10.53 1.71
PMGC = premanifest gene carriers, MHD = manifest HD, tNAA=total N-acetylaspartate, 
Glx = Glutamate and Glutamine
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Table 3: Correlation analysis between metabolite concentrations and clinical 
measures in Huntington’s disease gene carriers
TMS TFC PBA-S BDI-II TMT-B SDMT Stroop MMSE
Caudate Nucleus
Creatine
R -.562 -.027 .255 .056 -.320 -.091 -.135 -.297
p 0.116 0.944 0.507 0.887 0.400 0.817 0.730 0.437
Myo-Inositol
R -.228 -.507 -.560 -.749 .329 .464 .404 .274
p 0.555 0.164 0.117 0.020 0.387 0.208 0.281 0.476
Putamen
Choline
R .248 -.195 -.355 -.474 -.031 .236 .759 -.143
p 0.593 0.675 0.435 0.282 0.948 0.611 0.048 0.760
tNAA
R .721 -.489 -.413 -.678 .030 .613 .324 .087
p 0.067 0.265 0.358 0.094 0.949 0.143 0.478 0.853
TMS = total motor score, TFC = Total Functional Capacity, PBA-s= problem behaviour assessment 
short version, BDI-II: becks depression inventory, second version, TMT-B= trail making test, part B, 
SDMT=symbol digit modality test, MMSE=mini mental state exam, tNAA=total N-acetylaspartate
Table 4: Metabolite concentrations in the conversion from premanifest to 
manifest HD versus non-conversion
Baseline Follow up p-value
Caudate nucleus N Mean SD Mean SD
Creatine 
non converters 5 11.31 2.23 9.28 1.62 0.040
converters 2 14.11 2.03 9.23 0.52 0.137
Myo-inositol
non converters 5 6.83 1.69 4.98 1.89 0.108
converters 2 8.01 1.81 4.56 1.66 0.019
Putamen
Choline
non converters 3 3.19 0.28 2.86 0.19 0.353
converters 3 3.57 0.22 2.67 0.11 0.025
tNAA
non converters 3 14.05 1.13 13.79 1.01 0.457
converters 3 15.83 0.26 10.81 0.42 0.003
SD = standard deviation, tNAA=total N-acetylaspartate
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Discussion
The main findings of this study show that over a period of two years, significant 
metabolite changes were observed in the progression of HD. More specifically, 
these changes occurred in a predominantly premanifest gene carrier group 
in which four participants converted from premanifest to manifest HD. The 
premanifest HD participants who converted to manifest HD seem to show a more 
rapid decline in NAA in the putamen than those who did not convert.
This longitudinal study expands the knowledge on metabolite changes in HD by 
demonstrating changes in creatine concentration in the caudate nucleus and total 
NAA concentration in the putamen. This reduction occurs in a mixed premanifest 
and early manifest HD group (peri-manifest). In participants converting from
premanifest to manifest HD, higher rates of decrease were particularly observed 
in the total NAA of the putamen. In our previous cross-sectional study, NAA and 
creatine were significantly decreased in both the putamen and caudate nucleus in 
manifest HD, but not in the premanifest group11. However, it was suggested that 
this decrease in concentration might already be visible in the premanifest group, 
but due to large intersubject variations in metabolite concentrations in combination 
with a small sample size, this finding did not reach statistical significance. The 
results of other cross-sectional results are in line with our longitudinal study10;12; 
one study reported decreases in NAA and creatine concentrations in the putamen 
in premanifest HD12, whereas in another study lower total NAA and creatine 
in the putamen in manifest HD as well as a non-significant decrease in these 
metabolites in premanifest HD were reported10. In contrast to these findings, one 
study reported no altered metabolite concentration in premanifest HD13, however 
relative metabolite concentrations as opposed to absolute ones referenced to water 
were used. In this respect, the use of metabolite ratio’s should be approached 
with caution, since in HD it it has been demonstrated, cross-sectionally10-12 and 
longitudinally, that both NAA and creatine concentrations change. Summing all 
the data, it seems that creatine in the caudate nucleus and especially NAA in the 
putamen are metabolites that show great potential for use as a biomarker.
Our study demonstrated a decrease in choline in the putamen over the two year 
follow up. One other study also reported decreased choline concentrations in the 
frontal region in premanifest HD14. A possible explanation for a reduced choline 
concentration in the frontal lobe is that membrane turnover slows down prior to 
neuronal death14. 
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Myo-inositol concentration in the caudate nucleus was found to decrease over 
time in our study population. Abnormalities in myo-inositol concentrations have 
only been found by one other study reporting an increase rather than a decrease10. 
However, this increase in myo-inositol concentration was found only in the manifest 
stage of the disease as compared to controls with a cross-sectional design. It 
might be that the changes in the concentration of myo-inositol are non-linear and 
dependent on disease stage. It is possible that myo-inositol initially decreases in 
premanifest stages before increasing in manifest HD. However, this hypothesis 
must be investigated in larger longitudinal trials including multiple disease stages 
such as the TRACK-HD study3;10.
Two changes in clinical measures were found to relate with lower metabolite 
concentrations. First, the decrease in depressive symptoms as measured by the 
BDI-II was significantly related to myo-inositol concentration decreases in the 
caudate nucleus. However, it must be noted that the clinical impact of this decrease 
in depressive symptoms is relatively small. The higher baseline BDI-II score could 
be explained by the fact that, before disease onset, anxiety to receive an imminent 
and expected diagnosis adds to psychological stress25. Reduced symptom 
awareness after disease onset may explain the lower scores during follow up26. 
Still, the relationship of BDI-II scores with myo-inositol, which is thought to be a 
glial marker, is not straightforward and these two changes could occur in parallel 
and be unrelated. The second relationship between changes in clinical measures 
and changes in metabolite concentrations is the simultaneous reduction in choline 
and Stroop performance. A similar neuropsychological disturbance relating to 
frontal choline concentrations has previously been reported14. As choline could 
possibly represent a pathogenic process related to neuronal loss or dysfunction in 
the putamen, the relationship to decline in executive functioning as measured by 
the Stroop seems plausible. 
A limitation to our study is the relatively small sample size, which could obscure 
subtle changes. However, even with the relative small numbers statistically 
significant results are obtained for different metabolites in various regions of 
the brain, emphasizing the robustness of these findings and suggesting the 
high potential of MRS as a biomarker in HD. The sample size for the analysis 
of specifically premanifest converters is even smaller, hence findings should 
be treated with caution. However, again the differences observed between the 
premanifest group that converted to manifest HD versus the non-converter group 
are in line with other cross-sectional results and as expected, all metabolites show 
a higher rate of decrease in the progressive premanifest group.
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In conclusion, we have demonstrated several metabolite changes in the putamen 
and caudate nucleus close to disease onset in HD over a two year period. 
This demonstrates the potential of MRS for providing a biomarker of disease 
progression and could be useful in evaluating future therapeutic interventions. 
Specifically the NAA in the putamen seems the best candidate biomarker.
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The aim of this thesis was to find potential MRI biomarkers for Huntington’s disease 
(HD). A hypothetical model of disease processes, MRI abnormalities and clinical 
signs is shown in Figure 1. These hypothetical s-shaped curves are commonly 
used to illustrate pathological change, whereby the pathofysiologic processes 
starts relatively slowly, subsequently shows a faster increase at a certain point in 
the pathologic cascade, and slows down towards the end. This model has been 
used in other neurodegenerative diseases such as Alzheimer’s disease1 and 
we now applied this model to HD. MRI abnormalities in HD emerge more than a 
decade before symptom onset2;3. However, the line depicting MRI abnormalities 
is an oversimplification in this model as many different techniques are used with 
different sensitivity. In this thesis volumetric MRI, magnetization transfer imaging 
(MTI), diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS) 
were investigated in different disease stages of HD.
Figure 1: Hypothetical Huntington’s disease model. Premanifest A = premanifest gene carriers far 
from expected disease onset, Premanifest B = premanifest gene carriers close to expected disease 
onset, HD 1 = Huntington’s disease stage 1, HD 2 = Huntington’s disease stage 2, HD 3 = Huntington’s 
disease stage 3, HD 4 = Huntington’s disease stage 4
MRI parameter changes per disease stage
Volumetric analysis of subcortical grey matter structures in HD have shown striatal 
volume decreases in premanifest and manifest stages of HD2-4. The volumetric 
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study in this thesis extended this knowledge to six other subcortical grey matter 
structures and demonstrated more widespread involvement of the brain and 
in particular the basal ganglia (Chapter 3). Furthermore, an assessment was 
developed regarding the rate of atrophy of subcortical structures in respect to 
whole brain atrophy, to determine the relative speed of volume loss. This provided 
insight into patterns and rate of atrophy. Besides the caudate nucleus and 
putamen, the pallidum and accumbens nucleus also demonstrated strong volume 
reductions in the premanifest stage of the disease. All structures at some point 
showed atrophy, however, when compared to whole brain atrophy the amygdala 
and brainstem were relatively spared in the early stage of manifest disease. 
Hippocampus atrophy only exceeded the whole brain atrophy rate at later disease 
stages. 
To further enhance our knowledge about volume changes we applied a surface 
based technique, whereby localized loss of volume can be detected (Chapter 
4). This technique visualizes 3D boundary displacements of specific regions in 
subcortical structures5. With this application we showed that specifically the corpus 
of the caudate nucleus is affected. The putamen, on the other hand, shows more 
uniformly distributed displacements. These regions of displacements have specific 
cortical projections and therefore, for striatal and all other subcortical structures, we 
can extrapolate these findings to functional cortical regions and clinical symptoms. 
 
Structural integrity of brain regions was assessed using MTI (Chapter 5). This 
technique quantifies structural brain disturbances dissimilar to conventional 
volumetric MRI. When neuronal loss is present, it can be assumed that structural 
integrity of those regions is reduced, hence MTI parameters could potentially 
be a sensitive biomarker. This analysis provided the insight that in the manifest 
stage loss of structural integrity is present. In premanifest HD, although atrophy 
is present at this stage, no structural integrity loss was detected using MTI. MTI 
performed longitudinally did not show any significant reduced structural integrity 
in a 2 year follow up in either premanifest or manifest HD (Chapter 8). This 
greatly diminished the potential of MTI as a biomarker. Despite this disappointing 
result, an unexpected finding was made when the premanifest group far from 
disease onset exhibited increased MTR peak height in the putamen (Chapter 8). 
A novel finding which could lead to a new insight in compensatory mechanisms in 
neurodegenerative processes in HD. However confirmation of this novel finding is 
needed.
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When neuronal degradation is present, it is not unlikely that also their axons will be 
affected. The structural integrity of white matter pathways is therefore of interest, 
providing new targets for sensitive MRI measures. DTI can be used to visualize 
white matter pathways and quantify integrity parameters of these fiber bundles. DTI 
analysis showed multiple white matter pathways being affected in manifest HD, 
but also specifically showed that the white matter projecting from the sensorimotor 
cortex was affected in premanifest HD (Chapter 6).
Tapping into more dynamic cell processes as well as structural integrity, MRS 
provided evidence that both energy metabolism and cellular integrity are impaired 
in manifest HD (Chapter 7). Moreover, longitudinal analysis of metabolite changes 
revealed that these changes occur in the transition phase from premanifest to 
manifest HD (Chapter 9). 
Clinical features 
The genetic defect is present from the embryonic stage6, but when does 
the pathofysiological cascade of events start and lead to neuronal loss and 
subsequently functional loss, manifesting in clinical signs? And what period must 
be considered premanifest HD? In this thesis premanifest is best described as 
pre-motor manifest as the clinical inclusion criteria only describes the motor 
score from the UHDRS, which is a practical tool with good interrater reliability7. 
For the interpretation of all HD research, it is good to bear in mind that we label 
a person premanifest only by agreement about cut-off points in this clinical scale, 
mainly describing motor features. Cognitive or psychiatric impairments are harder 
to objectify. Cognition, for instance, is influenced by factors such as education. 
The psychiatric disturbances are difficult to link directly to HD pathology. This is 
especially relevant during the premanifest stage when the predictive genetic test 
alone causes significant stress8. 
Relating MRI disturbances to clinical measures is important but not an easy feat. 
It is difficult to select the appropriate participant group. If we want to encompass 
the whole course of HD, including the transition period, only one group, namely 
gene carriers (both premanifest and manifest HD), should be examined. However, 
the downside to this approach is that it assumes, during the total disease course, 
a more or less linear relationship between clinical measures of disease and MRI 
parameters. This is probably not the case. Performing correlations per disease 
stage group could help to overcome this problem. The advantage is that possible 
linearity problems would be less evident within these more homogeneous groups. 
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However the disadvantage of this approach is that the cut-off points are rigid, 
but the scales on which these cut off points are based can be quite variable. 
The second reason why relating MRI parameters to clinical measures is not 
straightforward is that it is hard to prove a causal relationship between these MRI 
disturbances and the observed symptoms. Conclusions based on correlations 
can also reflect an epiphenomenon. For example, a high UHDRS motor score 
can be observed in manifest HD at the same time as a reduced hippocampus 
volume. Correlation analysis could be significant, however hippocampal volume 
may not be responsible for motor score. Thus, the correlation between these two 
simultaneously occurring changes does not reflect causality. In this example, it is 
more plausible that motor disturbances occur as a result of structural changes in 
the motor performance networks such as volume reduction of the basal ganglia 
or reductions in integrity of motor cortex projections. The hippocampus is not 
part of the motor performance networks and its volumetric decline may result in 
other symptoms than motor disturbances. Thus, one should always be wary of 
epiphenomological results when interpreting relationships of clinical disturbances to 
MRI changes.
Despite the above-described difficulties in relating MRI measures to clinical 
measures, in recent literature the existence of a relationship seems hardly 
disputed. In this thesis volumetric measures were correlated to main features of 
the UHDRS, namely total motor score and TFC (Chapter 3). Volume reductions of 
the accumbens nucleus, putamen and pallidum were most strongly related to the 
motor disturbances in manifest HD, and surprisingly, there was no relationship of 
the caudate nucleus to this clinical measure. The putamen and hippocampus were 
related to global functioning measured by the TFC, however TFC is only applicable 
in the manifest stages of the disease. The putamen is the most important structure 
for both measures. 
MTI abnormalities have a correlation to clinical measures (Chapter 5). However, 
there were no significant longitudinal changes in MTI parameters where clinical 
deterioration was evident (Chapter 8). Further assessment of structural integrity 
using DTI, showed a relationship with motor and oculomotor measures to integrity 
loss of white matter fiber bundles of the sensorimotor cortex, prefrontal cortex, 
thalamus and corpus callosum. Interestingly, again no relationship was found 
between disturbances of the fiber bundles from the caudate nucleus and clinical 
measures of disease. Cognitive decline was related to white matter pathway 
disturbances in the corpus callosum, sensorimotor cortex and prefrontal cortex 
white matter pathways (Chapter 6). 
Using MRS a relationship of the neuronal marker NAA in the putamen was 
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found with UHDRS total motor score and TFC (Chapter 7). This is in line with 
the volumetric correlations described above. Furthermore, the caudate nucleus 
NAA concentration did not relate to UHDRS total motor score, again similarly to 
the volumetric correlations. The NAA reductions in the caudate nucleus did relate 
to psychiatric disturbances and TFC. Glutamate, a neurotransmitter possibly 
implicated in the pathofysiological pathway of excitotoxicity, showed a correlation 
to cognitive decline. Changes in metabolites from premanifest to manifest HD 
progression showed only modest correlations to changes in clinical features 
(Chapter 9); however, this particular analysis was performed in a predominantly 
premanifest HD group where clinical features are only subtle.
Considering all these correlations a pattern emerges; clinical motor measures are 
related to disruptions of multiple parts of motor networks, such as putamen and 
white matter pathways, but not to the caudate nucleus. However, the caudate 
nucleus is involved in global and specific cognitive functions and psychiatric 
disturbances. This highlights the fact that examining the individual parts of the 
striatum is necessary. Conversely, we should not think of any structure alone 
as being responsible for a single task or clinical feature. All these functions are 
integrated in complex networks. These correlations only tell us something about 
the relative contribution of each of these structures to such networks at a certain 
point in time. 
Conclusion
Different MRI techniques have different sensitivities for detecting pathogenic 
changes in HD. From this thesis the temporal relationship of the examined 
techniques in different disease stages can be extrapolated. These temporal 
relationships are displayed in figure 2. Volumetric changes, especially of the 
caudate nucleus and putamen, show early and rapid volume reductions. 
Longitudinal evaluation of volumetric MRI is available from the main TRACK-
HD paper9. DTI displays early disturbances of white matter pathways of the 
sensorimotor cortex. The longitudinal evaluation is not discussed in this thesis, and 
is thus depicted as a dotted line. However, evidence from other cross-sectional10;11 
and longitudinal12 reports, suggestive of the high potential of DTI as a biomarker, 
are incorporated into this hypothetical curve. MRS parameters change close to 
disease onset, especially in the transition period. MTI parameters are significantly 
reduced in manifest HD, however the rate of change is relatively slow and is thus 
depicted below the clinical symptoms line. Note that the MTI line in premanifest far 
from expected disease onset is modestly below the x-axis, depicting the possible 
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increased MTR peak height of the putamen. For all techniques, this thesis only 
examined premanifest and early HD stages (HD 1 and 2) and thus the lines are 
dotted beyond this point. This hypothetical model is the interpretation of all the 
combined research in this thesis. It is not presented as proven fact, but rather 
provides a framework for future research into the MRI parameter changes in 
premanifest and early HD.
Figure 2: temporal relationships of volumetric MRI, DTI, MTI and MRS. Premanifest A = premanifest 
gene carriers far from expected disease onset, Premanifest B = premanifest gene carriers close to 
expected disease onset, HD 1 = Huntington’s disease stage 1, HD 2 = Huntington’s disease stage 2. 
DTI = diffusion tensor imaging, MRS = magnetic resonance spectroscopy, MTI = magnetization transfer 
imaging
Choosing the correct biomarker for evaluating therapeutic effects is dependent 
on the disease stage and therapeutic compound. To evaluate the premanifest 
stages of the disease, volumetric MRI of putamen, caudate nucleus, accumbens 
nucleus and pallidum and DTI of the white matter pathway of the sensorimotor 
cortex are most suitable. When the transition period is the desired timeframe for 
evaluation, MRS can also be useful, especially if the compound in question has 
a direct potential influence on pathogenic pathways which in turn have an impact 
on specific metabolites such as creatine or NAA. In early manifest HD volumetric 
MRI, DTI and MRS would be appropriate. With regards to volumetric biomarkers, 
the most appropriate structures may be different than in premanifest HD as 
subcortical gray matter structures show a differential atrophy pattern as the disease 
progresses.
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Future perspectives
The future for MRI biomarkers for HD must continue in the direction of multimodal 
imaging. In this thesis individual MRI parameters were evaluated for their value 
as biomarkers. At a group level several measures were shown to be valuable; 
however, overlap in these measures between disease stages still exists. Thus, 
further improvement of the sensitivity of these MRI biomarkers is desired to 
accurately distinguish between disease groups. At an individual level it remains 
difficult to evaluate disease progression as the heterogenic clinical profile of HD is 
not captured by a single MRI parameter. Composite MRI-based biomarkers, based 
on a combination of markers with proven sensitivity for HD pathology, could be 
beneficial for biomarker research and have clinical applications. A composite MRI 
biomarker has the potential to distinguish between disease groups more accurately 
than a single biomarker and in this way improve the evaluation of therapeutic 
compounds. It is not unlikely that a new compound could have an effect on one 
MRI parameter, but not on another. For example, when a neuroprotective agent 
would have a positive influence on functional MRI, but not on volumetric MRI, a 
possibly valuable effect of such a compound could be missed. Furthermore, it could 
lead to an improved understanding of the structural-functional relationship during 
the disease course. On an individual level it could lead to a better prediction of 
disease onset than genetic models currently allow. The first reports on multimodal 
imaging are now emerging in both HD13;14 and Alzheimer’s disease15, showing the 
potential of this approach. These reports also show that a multimodal approach 
does not have to be limited to MRI parameters, but can also incorporate other 
imaging techniques such as positron emission tomography (PET).
Taking the multimodal imaging approach a step further, it is even worth considering 
constructing a model summing or averaging all these variables into a so-called 
‘HD-quotient’ of MRI parameters. However the sensitivity and utility of such a 
quotient is highly speculative. Large longitudinal multicentre trials, such as TRACK-
HD2 and PREDICT-HD16 are ideal platforms to apply multimodal image sequences. 
The challenge lies in combining all current and future data generated by these 
studies. 
As a final remark, it must be noted that eventually a clinical endpoint is always 
needed to confirm a therapeutic effect. However, in the absence of appropriate 
clinical endpoints, the use of surrogate endpoints in the form of MRI parameters is 
invaluable to HD research.
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The aim of this thesis was to find potential MRI biomarkers for Huntington’s disease 
(HD). Therefore, after an overview of the current literature on MRI biomarkers 
(Chapter 2) volumetric MRI, magnetization transfer imaging (MTI), diffusion tensor 
imaging (DTI) and magnetic resonance spectroscopy (MRS) were applied in 
patients in different disease stages of HD. 
Volumetric analysis of subcortical grey matter structures demonstrated widespread 
involvement of the brain in general and the basal ganglia in particular. The rate of 
atrophy of subcortical structures as compared to whole brain atrophy was used to 
determine the relative speed of volume loss. Our data demonstrated that besides 
the caudate nucleus and putamen, also the pallidum and accumbens nucleus 
demonstrate strong volume reductions in the premanifest stage of the disease. 
Furthermore, we observed that all structures at some point show atrophy, but 
when compared to whole brain atrophy, the amygdala and brainstem are relatively 
spared in the early stage of manifest disease. Hippocampus atrophy only exceeds 
the whole brain atrophy rate at later disease stages. Volumetric measures were 
correlated to main features of the Unified Huntington’s disease Rating Scale 
(UHDRS), namely total motor score (TMS) and total functional capacity (TFC). 
Volume reductions of the accumbens nucleus, putamen and pallidum are most 
strongly related to the motor disturbances in manifest HD, and surprisingly, the 
impact of the caudate nucleus is minimal. The putamen and hippocampus are 
related to global functioning measured by TFC; however, TFC is only applicable 
in manifest stages of the disease. The putamen is for both measures the most 
important structure (Chapter 3).
Using a technique that visualizes 3D displacements of boundaries of subcortical 
structures (shape analysis), we showed that many subcortical regions are not 
uniformly reduced in volume, but show localized volume loss. In premanifest 
HD small areas of displacement in putamen, pallidum, accumbens and caudate 
nucleus were shown. Analysis of shape in manifest HD showed widespread shape 
differences, most prominently in the caudal part of the accumbens nucleus, body 
of the caudate nucleus, putamen and dorsal part of the pallidum. These specific 
regions all have their specific cortical projections and therefore we can use these 
findings and extrapolate them to functional cortical regions and clinical symptoms 
(Chapter 4).
Assessment of structural integrity of brain regions was subsequently performed 
using MTI. This technique, based on the exchange of magnetization between 
a pool of protons bound to macromolecular structures and a pool of free water 
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protons, allows for quantifying structural brain changes in a sensitive way. This 
analysis demonstrated that in the manifest but not premanifest stages loss of 
structural integrity is present (Chapter 5). MTI performed longitudinally did not 
show any significant reduced structural integrity in a 2-year follow up period, 
lowering the potential of MTI as a biomarker. Despite this disappointing result, 
an unexpected finding was that the premanifest group who was far from disease 
onset, exhibited increased MTR peak height in the putamen. A novel finding which 
could lead to new insight in compensatory mechanisms in neurodegenerative 
processes in HD. However these findings should be confirmed first. (Chapter 8)
 
Diffusion Tensor Imaging can be used to visualize white matter pathways and 
quantify integrity of these fiber bundles. DTI showed multiple white matter 
pathways being affected in manifest HD, but also specifically showed that the 
white matter projecting on the sensorimotorcortex was affected in premanifest HD. 
DTI disturbances showed a relationship of motor and oculomotor measures to 
white matter fibre bundles of the sensorimotor cortex, prefrontal cortex, thalamus 
and corpus callosum. Cognitive decline was related to disturbances in the corpus 
callosum, sensorimotor cortex and prefrontal cortex white matter pathways 
(Chapter 6).
Magnetic Resonance Spectroscopy (MRS) provided evidence that both creatine 
and N-acetylaspartate (NAA) concentrations are reduced in manifest HD in caudate 
nucleus and putamen. NAA in the putamen was found to correlate to UHDRS and 
TFC (Chapter 7). Moreover longitudinal analysis of metabolite changes revealed 
that multiple metabolite concentrations changes occur around the time of disease 
onset, such as NAA, creatine, choline and myo-inositol decreases. Among these 
NAA seems the most promising candidate for a biomarker (Chapter 9). 
Final concluding remarks and future perspectives are portrayed (Chapter 10). 
Choosing the optimal biomarker for evaluating therapeutic effects is dependent on 
the disease stage and therapeutic compound. To evaluate the premanifest stages 
of the disease volumetric MRI and DTI are most suitable. When the transition 
period is the desired timeframe for evaluation, also MRS can be very useful, 
especially if the compound in question has a direct potential influence on certain 
pathogenic pathways which in turn have an impact on specific metabolites. Future 
research should focus on combining multiple imaging techniques; “multimodal 
imaging”. A composite MRI biomarker has the potential to distinguish between 
disease groups more accurately than a single biomarker and in this way improve 
the evaluation of therapeutic compounds.
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In dit manuscript was het doel gesteld om potentiële MRI biomarkers te vinden 
voor de ziekte van Huntington. Na een overzicht van alle huidige literatuur over 
MRI biomarkers (hoofdstuk 2), worden achtereenvolgens de technieken van 
conventionele (volumetrische) MRI, magnetization transfer imaging (MTI), diffusion 
tensor imaging (DTI) en magnetic resonance spectroscopy (MRS) toegepast in 
verschillende stadia van de ziekte van Huntington.
Volume analyse van subcorticale grijze stof structuren liet zien dat de gehele 
hersenen zijn aangedaan, maar in het bijzonder de basale ganglia. De relatieve 
hoeveelheid volumeverlies per structuur werd bepaald aan de hand van een ratio 
van volumeverlies ten opzichte van volumeverlies van het gehele brein. Naast de 
bekende atrofie van de nucleus caudatus en putamen werd ook gevonden dat de 
nucleus accumbens en het pallidum sterk volumeverlies tonen in de premanifeste 
fase van de ziekte. Verder werd het duidelijk dat alle onderzochte structuren op 
een gegeven moment in de ziekte enig volumeverlies tonen, maar wanneer we dit 
relateren aan het volumeverlies van het gehele brein, bleek dat de amygdala en de 
hersenstam relatief gespaard werden in de vroege manifeste fase. Hippocampus 
atrofie overtrof de snelheid van atrofie van het gehele brein pas in latere 
ziektestadia. Volume metingen werden gecorreleerd aan de hoofdonderdelen van 
de ‘unified Huntington’s disease rating scale’ (UHDRS); namelijk de totale motor 
score (TMS) en de totale functionele capaciteit (TFC). Volume veranderingen van 
de nucleus accumbens, het putamen en het pallidum bleken het sterkst gerelateerd 
aan de motoriek afwijkingen bij de ziekte van Huntington, en de invloed van de 
nucleus caudatus was minimaal. Volume veranderingen van het putamen en de 
hippocampus waren gerelateerd aan het globale functioneren zoals gemeten met 
de TFC, echter, TFC is alleen van toepassing in de manifeste fase van de ziekte. 
Het volume van het putamen had de meeste invloed op de uitkomst van zowel 
TMS als TFC (hoofdstuk 3).
Door gebruik te maken van een techniek die 3D verplaatsingen van de 
oppervlakte van subcorticale grijze stof structuren visualiseert (‘shape’ analyse), 
konden we aantonen dat veel van deze structuren niet uniform aangedaan zijn, 
maar juist een meer gelokaliseerd volumeverlies tonen. Kleine gebieden van 
oppervlakteverplaatsingen werden gezien in het putamen, pallidum, nucleus 
accumbens en nucleus caudatus in premanifeste gendragers. In manifeste 
Huntington werden meer wijdverspreide gebieden gezien in alle structuren, 
maar het meest opvallend in het caudale gedeelte van de nucleus accumbens, 
het corpus van de nucleus caudatus, het putamen en het dorsale gedeelte van 
het pallidum. Deze specifieke regio’s hebben hun eigen specifieke verbindingen 
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naar de cortex en daaruit afgeleid kunnen we deze bevindingen extrapoleren naar 
functionele corticale regio’s en klinische symptomen (hoofdstuk 4).
De structurele integriteit van verschillende hersenstructuren werd geanalyseerd 
door gebruik te maken van MTI. Deze techniek is gebaseerd op de uitwisseling 
van magnetisatie van protonen. Deze uitwisseling vindt plaats tussen protonen 
gebonden aan macromoleculen en protonen gebonden aan water. Deze 
techniek is mogelijk zeer sensitief voor het detecteren en kwantificeren van 
hersenveranderingen. De analyse toonde aan dat in de manifeste fase van de ziekte 
de structurele integriteit van het brein duidelijk verminderd is, maar dat dit nog niet 
aanwezig is in de premanifeste fase (hoofdstuk 5). Een longitudinale analyse van 
deze methode liet geen afname van de structurele integriteit zien in een periode van 
2 jaar. Dit verlaagt het biomarker potentieel van deze methode aanzienlijk. Ondanks 
dit tegenvallende resultaat, was er een onverwachte bevinding, namelijk een 
verhoogde MTR piekhoogte in het putamen in de premanifeste Huntington groep 
die ver van het verwachte ziektebegin was. Dit is een nieuwe bevinding die mogelijk 
kan leiden tot nieuwe inzichten in compensatiemechanismen in neurodegeneratieve 
processen bij de ziekte van Huntington. Echter deze nieuwe bevindingen moeten 
eerst bevestigd worden door verder onderzoek (hoofdstuk 8). 
DTI kan worden gebruikt voor het visualiseren van witte stof banen en het 
kwantificeren van de integriteit van deze axonbundels. In manifeste HD liet DTI 
zien dat multipele witte stof banen aangedaan zijn in deze fase van de ziekte, in 
premanifeste Huntington waren specifiek de witte stof banen aangedaan die naar 
de sensorimotorcortex gaan. De integriteitsveranderingen in witte stof banen van 
de sensorimotor cortex, de prefrontale cortex, de thalamus en het corpus callosum 
lieten een relatie zien met (oog)motoriek afwijkingen. Cognitieve achteruitgang was 
gerelateerd aan afwijkingen in de witte stof banen naar de sensorimotor cortex, de 
prefrontale cortex en het corpus callosum (hoofdstuk 6).
Gebruik makend van de techniek MRS werd aangetoond dat zowel creatine als 
N-acetylaspartate (NAA) concentraties verlaagd waren in de nucleus caudatus en 
het putamen. NAA concentratie in het putamen was gerelateerd aan de UHDRS 
motor score en de TFC (hoofdstuk 7). Een longitudinale analyse van metabolieten 
liet zien dat meerdere metabolieten veranderen rondom de tijd van ziektebegin. 
Deze metabolieten betroffen NAA, creatine, choline and myo-inositol. Van deze 
metabolieten liet vooral NAA het grootste potentieel als een biomarker zien 
(hoofdstuk 9). 
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Conclusies en toekomstige perspectieven worden besproken (hoofdstuk 10): 
De keuze voor de optimale MRI biomarker is afhankelijk van het te onderzoeken 
ziektestadium en het type medicament. Voor het evalueren van de premanifeste 
fase is volumetrische MRI analyse en DTI het meest geschikt. Wanneer ook de 
overgangsfase naar manifeste Huntington de gewenste tijdsperiode is, is ook 
MRS zeer bijdragend, zeker als het potentiële medicament invloed uitoefent op 
bepaalde pathogene processen die te maken hebben met specifieke metabolieten. 
Toekomstig onderzoek zou zich moeten richten op het combineren van 
meerdere beeldvormingtechnieken, het zogenoemde ‘multimodal imaging’. Een 
geïntegreerde MRI biomarker heeft het potentieel om verschillende ziektestadia 
beter te onderscheiden dan een enkele biomarker en kan op deze manier het 
evalueren van toekomstige therapieën verbeteren. 
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